Engineering mesenchymal stromal cell constructs to enhance immunomodulation by Zimmermann, Joshua A.
 
 
ENGINEERING MESENCHYMAL STROMAL CELL CONSTRUCTS  


























In Partial Fulfillment 
Of the Requirements for the Degree 
















Copyright © Joshua A. Zimmermann 2016 
 
 
ENGINEERING MESENCHYMAL STROMAL CELL CONSTRUCTS  



























Dr. Todd McDevitt, Advisor 





Dr. Andrés García 
Department of Mechanical Engineering 
Georgia Institute of Technology 
 
 
Dr. Ed Mocarksi 





Dr. Krishnendu Roy 
Department of Biomedical Engineering 
Georgia Institute of Technology 
 
 
Dr. Susan Thomas 
Department of Mechanical Engineering 















I would like to start by thanking my advisor, Dr. Todd McDevitt, for his constant support 
and encouragement through graduate school. Todd was a great mentor who allowed me 
to develop my own project and taught me how to think critically, which has made a 
significant impact on my development as a scientist and an engineer. I would also like to 
thank my committee members, Dr. Ian Copland, Dr. Andrés García, Dr. Edward 
Mocarski, Dr. Krishnendu Roy, and Dr. Susan Thomas, for their insight into my project 
and all the helpful suggestions they provided over the years. The numerous members of 
the McDevitt have also provided so much help, advice, and support over the years. I want 
to particularly thank Dr. Melissa Kinney and Dr. Tracy Hookway for being fantastic 
leaders and role models of the group over the years. I also want to thank Dr. Jenna 
Wilson and Marian Hettiaratchi for always being there to discuss science in the lab and 
for being such great friends outside of lab. I want to also want to thank the other graduate 
students from my year, Torri Rinker, Denise Sullivan, Reggie Tran, and Ariel Kniss-
James for being great friends throughout graduate school. Finally, I want to thank my 
parents, Frank and Nancy, and my brothers, Zack and Jacob, for all their love and support 




TABLE OF CONTENTS 
 
Page 
ACKNOWLEDGEMENTS                iii 
LIST OF TABLES               viii 
LIST OF FIGURES                 ix 
LIST OF SYMBOLS AND ABBREVIATIONS            xii 
SUMMARY                xiv  
CHAPTER 
1 INTRODUCTION                  1 
2 BACKGROUND                  5 
2.1 Mesenchymal Stem/Stromal Cells               5 
2.2 MSC Immunomodulation              10 
2.2.1 MSCs and Monocytes and Macrophages           13 
2.2.2 MSCs and Natural Killer Cells             15 
2.2.3 MSCs and Dendritic Cells             16 
2.2.4 MSCS and T-cells              18 
 
2.3 Three-Dimensional Culture of MSCs             22 
3 AGGREGATION AND CYTOKINE PRE-CONDITIONING TO 
ENHANCE MESENCHYMAL STROMAL CELL IMMUNO- 
MODULATORY ACTIVITY              28 
 
3.1 Introduction                28 
3.2 Materials and Methods               31 
3.2.1 Cell Culture and Expansion             31 
3.2.2 Spheroid Formation and Culture            32 
3.2.3 Cell Viability and Histological Analysis           33 
3.2.4 Cell Number and Immunomodulatory Factor Quantification         33 
3.2.5 THP-1 Co-Culture Assay and Analysis            34 
v 
 
3.2.6 IDO Detection and Peripheral Blood Mononuclear Cell  
Co-culture                35 
3.2.7 Statistical Analysis and Hierarchical Clustering          36 
 
3.3 Results                 38 
3.3.1 Impact of Spheroid Culture on MSC Phenotype          38 
3.3.2 Spheroid Culture Increases Immunomodulatory Factor 
Secretion                39 
3.3.3 Cytokine Conditioning of MSCs is Dependent on Culture 
Medium                42 
3.3.4 Pre-Conditioning MSC Spheroids to Enhance 
Immunomodulation              49 
3.3.5 Effects of Aggregation on MSC Suppression of T-cell 
Proliferation               50 
 
3.4 Discussion                57 
3.5 Conclusions                65 
4 OSTEOPROTEGERIN IS DIFFERENTIALLY EXPRESSED  
BETWEEN ADHERENT AND SPHEROID CULTURES OF 
MESENCHYMAL STROMAL CELLS             67 
 
4.1 Introduction                67 
4.2 Materials and Methods               70 
4.2.1 MSC Expansion and Culture             70 
4.2.2 Antibody Cytokine Array and Analysis           71 
4.2.3 Peripheral Blood Mononuclear Cell Co-Culture Assays         73 
4.2.4 Osteoclast Differentiation and Analysis           73 
4.2.5 Evaluation of β-catenin Localization in MSC Cultures          75 
4.2.6 Statistical Analysis              75 
 
4.3 Results                 77 
4.3.1 Osteoprotegerin is Downregulated Upon Aggregation of  
MSCs                77 
4.3.2 OPG Is Not Responsible for Difference in Immunomodulatory  
Activity between Adherent and Spheroid MSCs           80 
4.3.3 Adherent and Spheroid MSC Paracrine Factors Differentially 
Regulate Osteoclast-Precursor Differentiation           82 
4.3.4 Differential Expression of OPG Mediates Osteoclast-Precursor 
Response to MSC Paracrine Factors            86 
4.3.5 Increased β–Catenin Localization at the Cell Membrane in  
vi 
 
Spheroid Cultures              87 
 
4.4 Discussion                89 
4.5 Conclusions                93 
5 ENGINEERING 3D MSC/MICROPARTICLE CONSTRUCTS TO 
ENHANCE IMMUNOMODULATION             95 
 
5.1 Introduction                95 
5.2 Materials and Methods               98 
5.2.1 Heparin Microparticle Synthesis            98 
5.2.2 Heparin Microparticle Characterization           99 
5.2.3 MSC Expansion and Culture           100 
5.2.4 IFN-γ Loaded Microparticle Bioactivity         101 
5.2.5 MSC Spheroid Formation           102 
5.2.6 Analysis of MSC Immunomodulatory Factor Expression       104 
5.2.7 Peripheral Blood Mononuclear Cell Co-Cultures        105 
5.2.8 Statistical Analysis            107 
 
5.3 Results               107 
5.3.1 Biotinylated IFN-γ Binds To Streptavidin-Coated Microparticles  
But Does Not Remain Bioactive Over Time         107 
5.3.2 IFN-γ Binds To Heparin Microparticles And Remains Bioactive 
Over One Week Of Culture           110 
5.3.3 IFN-γ Loaded Microparticles Induce Sustained  
Immunomodulatory Factor Expression          113 
5.3.4 IFN-γ Loaded Microparticles Enhance MSC Suppression of  
T-Cell Activation and Proliferation          118 
5.3.5 Microparticle Induced Suppression of T-Cell Activation and 
Proliferation Is Dependent on Induction of MSC IDO  
Expression and Aided by Induction of M2-Like Monocytes       121 
5.3.6 Microparticle Delivery of IFN-γ Within MSC Spheroids Sustains 
Immunomodulatory Activity Compared to Soluble Pre-Treated 
MSCs              125 
 
5.4 Discussion              128 
5.5 Conclusions              133 
6 FUTURE CONSIDERATIONS            134 
6.1 Non-Biased Screening Approaches to Evaluate Changes in MSC  
vii 
 
Secretome              135 
 
6.2 Animal Models for Evaluating MSC Construct Immunomodulation       137 
6.3 Conclusions              144 
APPENDIX A               146 
A.1 Introduction              146 
A.2 Materials and Methods             146 
A.2.1 TNBS-Induced Colitis Model           146 
A.2.2 DSS-Induced Colitis Model           147 
 
A.3 Results               148 
A.3.1 TNBS-Induced Colitis Model           148 
A.3.2 DSS-Induced Colitis Model           150 
 
A.4 Conclusions              153 




LIST OF TABLES  
 
Page 
Table 4.1: Protein species on cytokine antibody arrays            72   
ix 
 
LIST OF FIGURES 
 
Page 
Figure 3.1: MSC spheroid formation and suspension culture. 
Figure 3.2: Histological analysis of MSC spheroids of varied size and culture 
medium. 
 
Figure 3.3: Immunomodulatory factor expression of MSCs. 
Figure 3.4: IFN-γ and TNF-α conditioning of 500-cell MSC spheroids. 
Figure 3.5:  Histological analysis of MSC spheroids treated with IFN-γ and 
TNF-α. 
 
Figure 3.6: Cell viability analysis of MSC spheroids treated with IFN-γ and 
TNF-α. 
 
Figure 3.7: Immunomodulatory factor expression of IFN-γ and TNF-α 
conditioned MSC monolayer and spheroid cultures. 
 
Figure 3.8: MSC suppression of THP-1 TNF-α secretion. 
Figure 3.9: IDO expression in IFN-γ stimulated adherent and spheroid MSCs. 
 
Figure 3.10: Suppression of T-cell proliferation and activation by Texas A&M 
and RoosterBio MSCs. 
 
Figure 3.11: A greater dose of MSCs is needed to suppress T-cell proliferation 
when MSCs are aggregated. 
 
Figure 3.12:  Transwell co-culture reduces the ability of both adherent and 
spheroid MSCs to suppress T-cell proliferation. 
 
Figure 3.13:  Heatmap visualization of MSC growth, cytokine secretion, and 
activated mΦ suppression. 
 
Figure 4.1: Cytokine array analysis of adherent and spheroid MSC paracrine 
factors reveals differential expression of OPG. 
 












































Figure 4.3: OPG does not play a role in MSC suppression of T-cell 
proliferation and activation in PBMC co-cultures. 
 
Figure 4.4: Adherent MSCs suppress whereas spheroid MSCs enhance 
osteoclast differentiation. 
 
Figure 4.5: MSC spheroids promote osteoclast differentiation and resorption 
activity. 
 
Figure 4.6: OPG inhibits osteoclastogenesis in MSC spheroid conditioned 
medium. 
 
Figure 4.7: β-catenin is localized to the cell membrane in MSC spheroids. 
 
Figure 5.1: Microparticle delivery of IFN-y within MSC spheroids. 
 
Figure 5.2: Streptavidin coated microparticles bind but do not maintain 
bioactivity of biotinylated IFN-γ. 
 
Figure 5.3: Heparin microparticles bind and present bioactive IFN-γ and 
incorporate stably within MSC aggregates. 
 
Figure 5.4: Heparin microparticles incorporate stably within MSC aggregates. 
 
Figure 5.5: IFN-γ loaded heparin microparticles induce sustained IDO 
expression. 
 
Figure 5.6: MSC IDO expression is greater when IFN-γ is delivered on 
microparticles than solubly. 
 
Figure 5.7: Delivery of IFN-γ on microparticles stimulates IDO throughout 
MSC spheroids. 
 
Figure 5.8: Microparticle delivery of IFN-γ enhances MSC spheroid 
suppression of T-cell activation and proliferation. 
 
Figure 5.9: Increased suppression of T-cells by microparticle delivery of IFN-γ 
is dependent on induction of IDO expression. 
 
Figure 5.10: Microparticle delivery of IFN-γ increases MSC spheroid 
polarization of monocytes to anti-inflammatory phenotype. 
 
Figure 5.11: Microparticle delivery of IFN-γ enhances MSC suppression of T-


















































Figure A.1: Validation of TNBS-induced colitis model 
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Mesenchymal stem/stromal cells (MSCs) are potent modulators of inflammatory and 
immune responses due to their ability to secrete soluble paracrine factors that regulate 
both innate and adaptive immunity and repolarize cells from pro-inflammatory to anti-
inflammatory or pro-resolving phenotypes. Since the initial discovery that MSCs 
suppress T-cell proliferation and activation in vitro, MSCs have been demonstrated to 
regulate numerous leukocyte populations including T-cells, macrophages, dendritic cells, 
and natural killer cells. This ability of MSCs to modulate multiple components that 
contribute to the complexity of an immune response further motivated the use of MSCs to 
treat diseases such as graft-versus host disease, inflammatory bowel disease, and 
autoimmune disorders. In order to modulate immune response, multiple paracrine and 
immunomodulatory factors are expressed by MSCs that mediate suppression of immune 
cells and the coordinated action of the immunomodulatory secretome of MSCs is 
necessary to regulate complex immune responses. Importantly, these immunomodulatory 
factors are not constitutively expressed by resting MSCs and their expression is strongly 
induced by exposure of MSCs to inflammatory cytokines. Thus, MSC 
immunomodulation is highly dependent on the local inflammatory milieu to activate 
immunomodulatory factor expression. Due to the dependency of MSC 
immunomodulation on the local cytokine milieu, the efficacy of MSC-based cellular 
therapies is highly dependent on the in vivo environment they are exposed to after 
injection. The environment may be highly variable based on the individual and disease 
being treated, the stage of inflammation, and the site of MSC transplantation. For 
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example, high concentrations of inflammatory cytokines that often accompany acute 
inflammatory responses stimulate MSC immunomodulation. However, the low levels of 
cytokines observed in chronic inflammation may not be sufficient to induce MSC 
immunomodulatory activity, thereby limiting the ability of MSCs to regulate 
inflammation of certain disease states. Furthermore, MSCs are typically infused 
intravenously and the majority of cells are entrapped within the capillary beds of the lung 
tissue, distant from sites of inflammation. Entrapped MSCs are then rapidly cleared from 
the body within several days, limiting their residency time and effective window for 
immunomodulatory activity. Therefore, the objective of this dissertation was to develop 
strategies to enhance intrinsic MSC immunomodulatory activity to improve cellular 
therapies for the treatment of inflammatory and immune diseases. Three-dimensional 
MSC constructs offer a promising approach to control the microenvironment and thereby 
the immunomodulatory activity of MSCs while also enhancing acute cell survival and 
persistence after transplantation in vivo. Furthermore, engineering the physical and 
chemical elements of the MSC construct microenvironment through biomaterial-based 
approaches serves as a novel route to regulate the temporal presentation of inflammatory 
factors in order to sustain immunomodulatory activity in vivo. Altogether, this strategy 
offers a novel translatable means of controlling MSC paracrine activity post-
transplantation and therefore, improve the efficacy of MSC-based treatment strategies for 









The initial discovery that mesenchymal stem/stromal cells (MSCs) potently inhibit T-cell 
proliferation and activation upon T-cell receptor (TCR) stimulation in vitro motivated the 
use of MSCs as a potential therapeutic agent in inflammatory and immune diseases 
dominated by a pathogenic T-cell response and spurred research to better understand the 
interactions of MSCs and the immune system. Since then, MSCs have been demonstrated 
to regulate numerous leukocyte populations of both innate and adaptive immune systems, 
including T-cells, B-cells, macrophages, dendritic cells, and natural killer (NK) cells. 
Through the expression of numerous immunomodulatory factors in response to the 
inflammatory cytokine milieu, MSCs can modulate multiple signaling pathways and cell 
types that contribute to the complex pathogenesis of inflammatory and immune diseases 
that is currently unachievable with available drug treatment regimens. While the 
immunological mechanisms of MSCs are still actively under investigation, the 
demonstration of immunomodulatory effects in animal models has encouraged the 
investigation of MSCs as cell therapies in clinical trials for treatment of graft-versus host 
disease, inflammatory bowel diseases, and autoimmune disorders. However, positive 
therapeutic outcomes of MSC therapies in these clinical trials have not been consistently 
achieved; the variable responses have been attributed to donor-dependent variability of 
MSCs, environmental host factors, and limited cell survival and retention resulting from 
standard systemic intravenous delivery methods. More importantly, MSC 
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immunomodulation is critically dependent on the cellular microenvironment and the 
composition and concentration of the inflammatory cytokine milieu. High concentrations 
of inflammatory cytokines, such as interferon gamma (IFN-γ), which often accompany 
acute inflammatory responses, stimulate MSC expression of immunomodulatory factors. 
However, the low levels of cytokines observed in chronic inflammation may not be 
sufficient to induce MSC immunomodulation, limiting the ability of MSCs to regulate 
inflammation in these disease states. To address these critical challenges impeding the 
translation of MSC-based therapies, three-dimensional MSC constructs offer a promising 
approach to control the microenvironment and thereby the immunomodulatory activity of 
MSCs while also enhancing acute cell survival and persistence after transplantation in vivo. 
Furthermore, engineering the physical and chemical elements of the MSC construct 
microenvironment through biomaterial-based approaches serves as a novel route to 
regulate the temporal presentation of inflammatory factors in order to sustain 
immunomodulatory activity in vivo. 
 
The long term goal that motivated the work of this dissertation was to develop strategies 
to enhance intrinsic MSC immunomodulatory activity to improve cellular therapies for the 
treatment of inflammatory and immune diseases. The primary objective of this work was 
to characterize the immunomodulatory secretome of MSCs in response to aggregation and 
inflammatory cytokines, in order to engineer transplantable stem cell constructs to enhance 
the extent and temporal kinetics of MSC immunomodulatory paracrine secretion to. The 
central hypothesis was that biomaterial-based presentation of MSC immunomodulation 
stimuli within 3D spheroids will result in the sustained and increased secretion of 
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immunomodulatory activity. The rationale for this work is that local presentation of 
inflammatory cytokines directly within the MSC 3D microenvironment may provide an 
additional level of control to promote persistent paracrine factor expression by regulating 
the spatial and temporal presentation of cytokines to transplanted MSC constructs. The 
central hypothesis was tested by the following specific aims: 
 
Specific Aim 1: Determine the effects of aggregation and cytokine stimulation on 
MSC immunomodulation. The working hypothesis of this aim was that the MSC 
secretome can be manipulated by altering environmental conditions, such as three-
dimensional aggregation and cytokine treatment, to enhance inherent immunomodulatory 
activity. The impact of the culture format (2D monolayer or 3D spheroids) and biochemical 
environment (culture media and cytokine milieu) on MSC immunomodulation was 
assessed by quantification of MSC paracrine factors and suppression of activated 
macrophages and T-cells in peripheral blood mononuclear cell (PBMCs) co-cultures. 
Furthermore, we more broadly assessed the effects of aggregation on the MSC secretome. 
From this analysis, we identified a highly differentially expressed secreted soluble factor, 
osteoprotegerin, and determined its functional role in suppressing T-cell proliferation and 
osteoclast differentiation.  
 
Specific Aim 2: Engineer MSC/microparticle constructs to enhance 
immunomodulatory activity. The working hypothesis of this aim was that the 
presentation of biochemical stimuli of MSC immunomodulation within MSC spheroids 
can serve as a method of enhancing and sustaining inherent MSC immunomodulatory 
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activity that is applicable to cellular therapies for inflammatory diseases. The interaction 
between heparin microparticles and IFN-γ was investigated in order to deliver 
inflammatory cytokines directly within the spheroidal MSC microenvironment. The effects 
of microparticle incorporation within MSC aggregates on enhancing and sustaining 
immunomodulatory activity was evaluated by assessing paracrine factor secretion and 
suppression of activated macrophage and T-cells in PBMC co-cultures in vitro.  
 
This project is innovative because it examines the ability to engineer the physical and 
biochemical elements of transplantable MSC constructs in order to direct MSC paracrine 
factor secretion and enhance immunomodulation. Through the completion of this project, 
we have demonstrated the ability to precisely engineer the environment of transplantable 
MSC multicellular aggregates in order to induce sustained immunomodulatory activity. 
This work establishes a novel and translatable approach that can be used to improve current 
MSC-based therapies for inflammatory and immune disorders and potentially expand the 
use of MSCs to disease states where current MSC strategies are ineffective. Finally, the 
results of this project have yielded novel scientific insights into the mechanisms governing 








2.1 Mesenchymal Stem/Stromal Cells 
The origins of mesenchymal stem/stromal cell (MSC) research dates back to the 1960s 
with the identification of "colony-forming fibroblasts" within the bone marrow stroma that 
were capable of forming new bone after transplantation to an ectopic site [1, 2]. These cells 
were later termed "mesenchymal stem cells" and were described as a proliferative, plastic 
adherent cell population with a potential for differentiation to the cells of skeletal tissue, in 
particular osteoblasts, adipocytes, and chondrocytes [3, 4]. Since these initial discoveries, 
cell populations that exhibit similar phenotypes and differentiation potential have been 
isolated from numerous tissues in addition to bone marrow, most notably in adipose [5], 
umbilical cord [6]. Due to the use of "mesenchymal stem cell" to describe cell populations 
derived from different tissue sources using different isolation and expansion methods, the 
International Society for Cellular Therapy designated minimal criteria for defining human 
"multipotent mesenchymal stromal cells" in an attempt to standardize MSC research. These 
criteria include: 1) adherence to tissue culture plastic, 2) surface antigen expression profile, 
and 3) tri-lineage differentiation potential to osteogenic, adipogenic, and chondrogenic 
lineages [7]. Specifically, in vitro culture expanded MSCs should express the surface 
markers CD105, CD73, CD90 and be negative for the endothelial and hematopoietic cell 
markers CD34, CD45, CD14, CD11b, CD79α, CD19, and HLA-DR. Furthermore, culture 
expanded MSC cultures are a heterogeneous population and individual cells do not all have 
the same multilineage potential [8, 9]. Therefore, the use of “stromal cell” instead of “stem 
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cell” more accurately describes MSCs as the stem cell properties (i.e. in vivo self-renewal 
and clonal multipotency) of most MSC preparations are untested. 
 
Despite the heterogeneous nature of MSC preparations, rare self-renewing progenitor cells 
capable of differentiating into cells of skeletal tissue have been identified among human 
bone marrow MSCs [10]. However, one of the challenges of studying this stem cell 
population is that no unique phenotypic marker of bone marrow mesenchymal stem cell 
exists. The surface markers CD73, CD90, and CD105 are not specific to MSCs and are 
commonly expressed by stromal cells and fibroblasts of various tissues [11]. Furthermore, 
only CD105 has been shown to be expressed on uncultured human MSCs capable of 
generating CFU-F and both CD73 and CD90 expression are acquired during in vitro culture 
expansion [12]. CD44, which is highly expressed on culture expanded MSCs, actually 
selects for the bone marrow fraction with little CFU-F activity while the CD44- fraction 
contains the population with multilineage differentiation potential [13]. Additionally, 
several surface markers of fresh MSCs that have been demonstrated to enrich for CFU-F 
activity are downregulated in cell culture, such as STRO-1 or CD271  [14, 15] expression 
in human MSCs and Nestin expression in mouse MSCs [16]. Despite the lack of individual 
surface markers that precisely mark MSC populations, researchers have taken 
combinatorial approaches to select for cell populations that enrich for CFU-F and stem cell 
activity. Isolation of the CD146+CD45- population from bone marrow yielded a population 
of self-renewing progenitor cells containing all the CFU-F activity and capable of forming 
a heterotopic bone marrow niche in a subcutaneous transplantation model [10]. 
Alternatively, another study demonstrated that the CD271+ fraction of bone marrow 
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contained all the CFU-F activity, although CD271+CD146+ co-expressing cells enriched 
for CFU-F activity compared to CD271+CD146- population [17]. Numerous other markers 
have also been demonstrated to enrich for CFU-F activity or differentiation potential alone 
or in combination with CD271, CD146, CD90, CD73, and CD105 [18]. Despite these 
attempts to better define the heterogeneous MSC population, much work still needs to be 
done to precisely define and standardize phenotypic markers of the stem and progenitor 
cell population amongst MSCs in order to better understand which cells are responsible for 
the biological effects observed in vitro and after injection of MSCs.  
 
The lack of unique markers of MSC populations also makes it difficult to determine the 
extent to which cells from various tissue sources differ in their phenotype and functionality. 
In the case of many of tissues, these MSC-like populations are not stromal cells but reside 
in a perivascular niche, such as in bone marrow [10, 16], fat [19], and skeletal muscle [20]. 
It is hypothesized that MSCs in these tissues may actually be perictyes, a cell population 
that lies on the abluminal side of blood vessels and wrap around endothelial cells [21]. 
Cultured pericytes share a similar morphology to MSCs [22], can differentiate into 
osteoblasts, adipocytes, and chondrocytes [23–25], and express similar surface antigens to 
MSCs [26]. Within the mouse bone marrow, several perivascular stromal cell populations 
exist that display MSC-like characteristics, including CXCL12-abundant reticular (CAR) 
cells and nestin-expressing cells [16, 27]. These bone marrow stromal cell populations play 
a critical role not only in supporting bone tissue repair and homeostasis but in supporting 
hematopoietic stem cell function as well. CAR cells were identified in mice by knocking 
in GFP into the Cxcl12 locus and were found to be co-localized with HSCs within the bone 
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marrow [27]. These CAR cells expressed high levels of CXCL-12, also known as stromal 
derived factor 1 (SDF-1), an important paracrine factor that aids in retaining HSCs in 
hematopoietic organs [28]. Furthermore, investigators identified a subset of CXCL-12 
expressing stromal cells that express GFP under the Nestin promoter [16]. In addition to 
CXCL-12, Nestin-GFP+ cells highly expressed the HSC regulatory paracrine factors 
angiopoietin-1 and stem cell factor (SCF) as well as the adhesion protein VCAM-1. Nestin-
GFP+ cells were located in close proximity to HSCs within the bone marrow and generated 
ectopic bone and bone marrow after transplantation. Additionally, depletion of Nestin-
GFP+ cells from the bone marrow by diphtheria toxin injection in Nes-CreERT2; iDTR mice 
led to loss of HSCs. Another subset of perivascular stromal cells, CXCL-12 expressing 
cells were also identified by the Leptin receptor (LepR) [29]. These LepR+ cells also 
expressed high levels of SCF, highly enriched for CFU-F, produced new osteoblasts and 
adipocytes in adult bone marrow, and could form ossicles that support hematopoiesis. 
Furthermore, conditional deletion of SCF in LepR+ cells led to depletion of HSCs while 
deletion of CXCL-12 in LepR+ cells led to HSC mobilization, demonstrating the 
importance of the paracrine activity of these progenitor cells in the HSC niche. However, 
it remains unclear whether these cell populations, identified in the mouse, are equivalent 
to human CD45-CD146+ cells that are also capable of reconstituting hematopoietic activity 
after ectopic transplantation. While the differences in bone marrow MSCs and MSC-like 
populations from other tissues sources remains unclear, recent evidence suggests that the 
stromal cell population of bone marrow contains perivascular progenitor cell populations 
responsible not only for the maintenance of bone and bone marrow stroma but also 




While the importance of bone-marrow MSC populations in regulating components of the 
hematopoietic system in vivo have recently been demonstrated, no clear link has yet to been 
established between the immunomodulatory paracrine capabilities of culture expanded 
MSCs and their in vivo function. Interestingly, recent studies have begun to examine the 
interaction between MSC populations in the bone marrow and the differentiated progeny 
of HSCs that make up the immune system. In one example, CAR cells and Nestin-GFP+ 
MSCs were found to regulate the egress and retention of monocytes in the bone marrow in 
response to microbial challenge [30]. After systemic injection of a low-dose of 
lipopolysaccharide (LPS), MSCs upregulated expression of CC-chemokine ligand 2 
(CCL2/MCP1) which promoted egress of monocytes from the bone marrow into the blood 
system. In another study, MSCs function was found to be regulated by components of the 
immune system within the bone marrow environment. CD169+ macrophages within the 
bone marrow were found to promote Nestin-GFP+ MSC expression of HSC maintenance 
factors [31]. While the exact mechanism by which CD169+ macrophages promoted MSCs 
paracrine activity were not elucidated, insulin like growth factor 1 (IGF-1), interleukin 1 
(IL-1), interleukin 10 (IL-10), and TNF-α were not responsible. Importantly, this ability of 
MSCs to respond to the local environment and environmental factors (i.e. immune cells, 
cytokines, TLR ligands) is a characteristic also shared by culture expanded MSCs. MSCs 
respond to inflammatory cytokines including IFN-γ, TNF-α, IL-1β, and IL-17 [32–36] as 
well as TLR3 and TLR4 agonists (dsRNA and LPS, respectively) [37, 38] by increasing 
their production of anti-inflammatory paracrine factors. However, it remains unclear if 
MSCs use the same mechanisms in vivo to respond to inflammation and regulate the 
10 
 
immune response. Further understanding of the interactions between MSCs and 
components of the hematopoietic and immune systems, especially during inflammatory 
disease states, may provide further insight into the mechanisms of culture expanded MSC 
immunomodulation.  
 
2.2 MSC Immunomodulation 
The finding that in vitro culture expanded bone-marrow derived MSCs suppress T-cell 
proliferation in vitro [39, 40], has led a rapid increase in the investigation of MSCs as 
potential immunomodulatory agents for the treatment of inflammatory and immune 
diseases. Since these initial discoveries, the ability of MSCs to suppress the activation and 
function of cellular components of both innate and adaptive immunity, including 
neutrophils, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B 
lymphocytes have been extensively investigated [41]. These studies have demonstrated 
that paracrine signaling plays a critical role in MSC immunomodulation and a single 
cytokine, chemokine, or growth factor alone is not responsible for the broad 
immunomodulatory effects on numerous immune cell populations. Furthermore, MSC 
immunosuppression has been found to be dependent on the coordinated modulation of 
myeloid and lymphoid populations simultaneously in order to promote the resolution of 
inflammation. Because of the multifaceted approach used to regulate the complex 
inflammatory milieu, MSCs offer a potent alternative to conventional drug treatment 
regimens. Therefore, MSCs are being explored clinically as a potent alternative approach 
to the treatment of diseases such as graft-versus-host disease [42–45], multiple sclerosis 
[46–49], inflammatory bowel disease [50–53], and systemic lupus erythematosus [54, 55]. 
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Clinically, intravenous (I.V.) delivery of MSCs was initially thought to result in migration 
of MSCs to sites of inflammation and injury by following chemotactic signals and upon 
arrival, impart their immunomodulatory action through secretion of soluble paracrine 
signals without engrafting within the host tissue. However, in actuality, the vast majority 
of I.V. infused MSCs are entrapped within the lung (>60% in lung, 10% in liver, and <5% 
in other tissues) and do not survive for more than a few days [56, 57]. Despite minimal 
homing to inflamed tissue and poor survival post-infusion, a growing list of clinical studies 
have provided evidence that MSC infusion can improve the clinical condition of patients 
[58, 59]. However, lack of standardization of MSC isolation, culture, and delivery to 
patients as well as the variability in the environment between different patients and diseases 
treated by MSCs has limited the ability of researchers to precisely determine the critical 
mechanisms mediating MSC immunomodulation in vivo and disease states in which MSC-
based therapies are most effective. 
 
Over the past ten years, significant progress has been made in understanding the molecular 
mechanisms governing MSC immunomodulation in vitro and in vivo. The production of 
soluble secreted factors such as prostaglandin E2 (PGE2), transforming growth factor beta 
1 (TGF-β1), TNF-α stimulated protein 6 (TSG-6), hepatocyte growth factor (HGF), heme 
oxygenase-1 (HO-1), human leukocyte antigen G5 (HLA-G5), and interleukin-6 (IL-6), as 
well as the intracellular enzyme indoleamine 2,3-dioxygenase (IDO) have all been 
identified as important components of paracrine-mediated MSC immunomodulation of 
both innate and adaptive immunity [60–66]. Furthermore, blocking studies have 
demonstrated that inhibition of individual factors, such as PGE2 [67], IDO [67, 68], TGF-
12 
 
β1 [61], IL-6 [62], HGF [65], and IL-10 [69], can significantly reduce the potency of MSC 
immunomodulation in mixed lymphocyte reactions or in animal models. These studies 
demonstrate that a complex cocktail of paracrine factors are necessary for MSCs to regulate 
immune responses and therefore, delivery of individual factors alone is unlikely to 
recapitulate the immunomodulatory capacity of MSCs. While MSC expression of these 
immunomodulatory paracrine factors suppress inflammatory responses of numerous 
leukocyte populations including macrophages [70], dendritic cells [71, 72], B lymphocytes 
[73, 74], T lymphocytes [75, 76], and natural killer (NK) cells [77], these MSC-secreted 
paracrine factors can also induce anti-inflammatory and tolerogenic phenotypes, including 
M2 macrophages [78, 79], tolerogenic dendritic cells (DC) [80], and regulatory T cells 
(Tregs) [68, 81]. Thus, the potential of MSCs to not only suppress inflammatory responses 
but also induce immune cells towards anti-inflammatory and tolerogenic phenotypes 
suggests MSCs may provide an effective means of establishing endogenous cell 
populations capable of regulating inflammatory responses to prevent or resolve chronic 
inflammation.  
 
In order to elicit immunomodulation, MSCs must be stimulated by signals in the local 
microenvironment in order to secrete immunomodulatory paracrine factors that alter 
immune cell responses [41]. The inflammatory cytokine milieu, including interferon 
gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), and 
interleukin-17 (IL-17) regulates MSC immunomodulatory function by activating MSC 
expression of immunomodulatory factors such as IDO, PGE2, and hepatocyte growth factor 
(HGF) [32–36]. Additionally, ligands for toll-like receptors TLR-3 and TLR-4 can regulate 
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MSC immunomodulation by altering paracrine factor secretion of MSCs [37, 38]. 
However, IFN-γ has been demonstrated to be a key inducer of MSC immunosuppressive 
activity. Wild-type MSCs prevented graft-versus-host disease and delayed-type 
hypersensitivity (DTH) in mice but MSCs lacking the IFN-γ receptor (IFNγR1-/- MSCs) or 
co-delivered with an anti-IFN-γ neutralizing antibody actually enhanced the immune 
response [33]. In human MSCs, IFN-γ priming induces expression of IDO, a key 
component of MSC regulation of adaptive immune responses [67, 82, 83], and the 
International Society for Cellular Therapy has recommended that the expression of IDO in 
response to IFN-γ be a key property to assess the immunomodulatory characteristics of 
MSC populations [84]. Furthermore, both the composition and concentration of the 
inflammatory cytokine milieu are critically important for MSC immunomodulation. Low 
concentrations of IFN-γ upregulate MSC expression of chemokines without induction of 
immunomodulatory factors, such as IDO, resulting in recruitment of lymphocytes without 
suppression of inflammation [85]. Additionally, antigen-pulsed MSCs stimulated with a 
low concentration of IFN-γ can act as antigen-presenting cells and activate antigen-specific 
CD8+ T-cells [86, 87]. Thus, strong inflammatory signals stimulate MSC 
immunosuppression while weak inflammation can actually enhanced the immune response 
[88]. Taken together, these studies demonstrate the importance of inflammatory signals in 
initiating MSC immunomodulatory factor expression.  
 
2.2.1 MSCs and Monocytes and Macrophages 
Monocyte migration into tissues and differentiation into macrophages plays a crucial role 
in the inflammatory response and in subsequent resolution of inflammation and tissue 
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regeneration [89]. Through the secretion of paracrine factors, MSCs can modulate the 
monocyte/macrophage response by recruiting monocytes to sites of inflammation and 
repolarizing macrophages from inflammatory anti-microbial M1 to pro-resolving M2 
phenotypes, thereby supporting resolution of inflammation and wound healing. As 
described above, mouse MSC-like populations in the bone marrow regulate monocyte 
egress from the bone marrow in response to microbial challenges through a CCL2/MCP1 
dependent mechanism [30]. Furthermore, MSCs at sites of inflammation can recruit 
monocytes and macrophages into inflamed tissue by secretion of the chemokines CCL3, 
CXCL2 (MIP2), and CCL12 (MCP5) [90]. Upon recruitment of macrophages, MSCs are 
thought to promote polarization of macrophages to M2-like phenotypes that promote tissue 
repair and enhance clearance of apoptotic cells. In vitro, co-culture of MSCs with 
monocytes induces M2 polarization of macrophages that have high IL-10 expression, low 
TNF-α, IFN-γ, and MHC class II expression, and phagocytic activity [79, 91, 92]. MSC 
regulation of macrophage phenotype has been demonstrated to be dependent on several 
mechanisms including IDO and PGE2 expression [78, 79]. Priming of MSCs by IFN-γ, 
TNF-α, or LPS further enhances MSC induction of M2 macrophages by increasing MSC 
expression of PGE2 and IDO. In vivo, MSCs reprogramming of macrophage phenotype 
was first demonstrated in a sepsis model in which injection of mouse MSCs decreased 
lethality by inducing IL-10 producing M2 macrophages that blocked excessive neutrophil 
infiltration into the peritoneum [70]. Similar results were observed in an endotoxin-induced 
lung injury model, in which local delivery of mouse MSCs decreased the production of M1 
cytokines TNF-α and CXCL2 and increased the production of the M2 cytokine IL-10 by 
alveolar macrophages [93]. Finally, in a zymosan-induced peritonitis model, infused 
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human MSC expression of TSG-6 interfered with TLR2 and downstream NF-κB signaling 
that inhibited M1 polarization of macrophages [94]. Altogether, MSCs can aid in the 
resolution of inflammation through the recruitment of monocytes and polarizing 
macrophages to pro-resolving phenotypes.   
 
2.2.2 MSCs and Natural Killer Cells 
Natural killer (NK) cells also play an important role in innate immunity by eliminating 
virus-infected and stressed cells and secreting pro-inflammatory cytokines such as IFN-γ 
and TNF-α [95]. MSC interactions with NK cells have been found to be dependent on the 
activation state of both the MSCs and NK cells. MSCs inhibit IL-2 and IL-15 induced 
proliferation of freshly isolated, resting NK cells, but have reduced inhibition of 
proliferation on IL-2 activated NK cells [77]. Additionally, MSCs can decrease NK cell 
cytotoxic activity, cytokine production, granzyme B release, and the expression of 
activating receptors NKp30, NKp44, and NKG2D [77, 96]. These effects are mediated 
through cell-cell contact, PGE2, IDO, TGF-β, and soluble HLA-G5 [64, 97]. However, the 
decreased inhibition of activated NK cell proliferation may be due, at least in part, to the 
ability of activated NK cells to lyse autologous and allogeneic MSCs. Expression of the 
ligands for activating NK receptors, ULBPs, CD155, and Nectin-2, were found to be 
responsible for NK cell lysis of MSCs [98]. However, when MSCs are stimulated with 
IFN-γ prior to co-culture, NK-mediated lysis is inhibited [99], which may be in part due to 
upregulation of HLA class I by MSCs [77, 83] and downregulation of ULBP3 [100]. While 
the interaction between MSCs and isolated NK cells in vitro has been investigated, there is 
little information on how MSCs interact with NK cells in vivo. However, it is speculated 
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that resilience of IFN-γ activated MSCs may allow transplanted MSCs to elude NK-
mediated lysis in inflammatory environments and plays a role in the decreased 
immunogenicity of allogeneic MSCs [101]. 
 
2.2.3 MSCs and Dendritic Cells 
Dendritic cells (DCs) serve as a link between the innate and adaptive immune responses 
by both producing cytokines and by acting as potent antigen-presenting cells. Upon 
activation, DCs upregulate MHCs, increase expression of co-stimulatory molecules, and 
migrate to secondary lymphoid tissue in order to prime T-cells for an adaptive immune 
response. Additionally, DCs produce cytokines that direct downstream T cell effector 
function. In both in vitro culture and in vivo animal models, MSCs have been demonstrated 
to interfere with many of these functions of DCs. For example, in vitro MSCs inhibit DC 
endocytosis, decrease expression of MHC and co-stimulatory molecules CD40, CD80, 
CD83, and CD86 during DC maturation, and decrease expression lymph node homing 
chemokine receptor CCR7 [71, 102, 103]. Furthermore, DCs differentiated in the presence 
of MSCs have a reduced ability to stimulate naive T cell proliferation. Infused MSCs also 
inhibit DC function in vivo by suppressing DC maturation, cytokine secretion, and 
migration to lymph nodes. Infusion of MSCs decreased the number of CCR7 and 
CD49dβ1, markers of DC activation, expressing DC in draining lymph nodes and 
decreased antigen priming to ovalbumin-specific CD4+ T-cells [80]. The mediators of 
MSC modulation of DC function include IL-6, which partially contributes to MSC 
inhibition of DC differentiation and downregulation of maturation markers [62]. 
Additionally, contact-dependent Notch signaling has also been demonstrated to be 
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important for MSC-dependent inhibition of DC differentiation and maturation [104] and 
may be mediated through MSC expression of the Notch ligand Jagged-2 [105]. Altogether, 
infused MSCs may significantly impair the development of an adaptive immune response 
by inhibiting DC migration, maturation, and antigen presentation. 
 
Similarly to the effects of MSC on repolarization macrophages from pro-inflammatory to 
anti-inflammatory or pro-resolving phenotypes, MSCs can alter the phenotype of DCs from 
a lymphocyte stimulatory DC into a tolerogenic DC. In vitro, co-cultures of MSCs with 
DCs, increases DC production of IL-10 and TGF-β, decreases production of pro-
inflammatory cytokines IL-12 and TNF-α, and increases phagocytic activity [106, 107]. 
Furthermore, DCs generated in the presence of MSCs in vitro do not activate CD4+ T-cells 
[108] but do promote the generation of antigen-specific Tregs [109]. Both MSC expression 
of PGE2 and Notch ligands, such as Jagged-2, have been implicated in converting mature 
DCs into a regulatory phenotype [110, 111]. Furthermore, MSCs have been found to 
generate tolerogenic DCs through an IL-10 dependent activation of suppressor of cytokine 
signaling-3 (SOCS-3) signaling [106]. However, it is unclear whether these pathways and 
mechanisms are responsible for MSC generation of tolerogenic DCs after infusion in vivo 
that have been shown to inhibit delayed-type hypersensitivity responses [106, 107] and aid 
in heart and skin allograft survival in the presence of low-dose immunosuppression [112]. 
Thus, transplanted MSCs may regulate immune responses, not only by inhibiting DC 
antigen presentation and subsequent activation of T-cells, but also induce tolerogenic DC 
phenotypes that can actively aid in resolving inflammation and induce tolerance to 




2.2.4 MSCs and T-Cells 
T-cells play a critical role in adaptive immunity and become activated in response to 
antigen presented by professional antigen presenting cells [113]. Activation of naïve T-
cells results in proliferation and differentiation to distinct phenotypes with characteristic 
cytokine profiles dependent on the cytokine milieu during activation. MSC suppression of 
activated T-cell proliferation in vitro [39, 40] initially sparked the investigation of MSCs 
as potential immunomodulatory agents. In vitro, MSCs have consistently been reported to 
suppress both CD4+ T-helper (Th) cells and CD8+ cytotoxic T cell proliferation and 
activation [114]. Both mitogen- and antigen-stimulated proliferation of T-cells is inhibited 
by MSCs and results in arrest of T-cells in the G0/G1 phase of the cell cycle [115]. MSC 
suppression of T-cell proliferation has largely been attributed to the expression of IDO 
which inhibits T-cell proliferation through depletion of tryptophan [77, 116]. Additionally, 
metabolites derived from IDO catabolism of tryptophan, including kynurenine, also aid in 
suppression of T-cell proliferation through activation of the stress response kinase GCN2 
[117, 118]. In addition to IDO, other MSC-expressed paracrine factors can aid in 
suppression of T-cell proliferation, including PGE2 [60, 119], HLA-G5 [64], and TGF-β1 
[120].  
 
In addition to the suppression of T-cell proliferation, MSCs are capable of altering the 
balance of CD4+ helper T-cell phenotypes. Numerous studies have demonstrated that 
MSCs can shift the balance of CD4+ T-cells from a pro-inflammatory IFN-γ and TNF-α 
expressing Th1 phenotype to an IL-4, IL-5, IL-10, and IL-3 expressing Th2 phenotype both 
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in vitro [121] and in vivo [122, 123]. Th1 cells are involved in clearance of intracellular 
pathogens and delayed-type hypersensitivity and play an important role in inflammatory 
and autoimmune diseases such as type 1 diabetes mellitus and Crohn’s disease. MSCs have 
been demonstrated to attenuate cutaneous DTH in mice by reducing infiltration of Th1 
cells at the challenge site and promoting apoptosis of activated T-cells in the draining 
lymph nodes [124]. In another example, MSCs reduced disease scores in an TNBS-induced 
experimental colitis model by reducing IFN-γ production by Th1 cells and increasing the 
number of FoxP3+ Tregs [125]. Finally, MSCs have also been shown to suppress Th1-
mediated diabetes mellitus in rats and mice [126, 127]. However, an opposite effect on Th 
populations is observed in the context of Th2 driven pathologies; MSCs promote the Th1 
phenotype and cytokine profile and inhibit Th2 cytokine expression [44, 128]. Th2 
responses are associated with host defense against extracellular parasites and recruitment 
of eosinophils and play an important role in allergic diseases. In an example of MSC 
suppression of Th2 responses, MSC treatment in an ovalbumin-induced airway 
inflammation model reduced the number of infiltrating eosinophils and reduced IL-4 and 
IL-13 production [129]. Additionally, an increase in IL-10 expression and FoxP3+ cells 
was observed, suggesting that MSCs induced Tregs that mediated aided in suppression of 
the Th2 response. Similarly, MSC infusion in human subjects with chronic GvHD was 
reported to reduce IL-4 and IL-10 and increase IL-2 and IFN-γ producing T-cells [44]. 
Finally, MSCs can also inhibit Th17 differentiation [81, 130]. Through expression of IDO 
and PGE2, MSCs suppress expression of the Th17 transcription factor RORγt and 
upregulate expression of the Treg transcription factor Foxp3 [131]. Th17 are characterized 
by their secretion of IL-17A, IL-21, and IL-22 and play a pathogenic role in several 
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diseases including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel 
diseases. Several studies have demonstrated that MSC treatment can improve the disease 
state in experimental autoimmune encephalitis (EAE) models by suppression of IL-17 
production and Th17 activity as well as upregulation of TGF-β and IL-4 in the central 
nervous system [132–134]. Like in MSC suppression of Th1 and Th2 responses, induction 
of Tregs has been associated with amelioration of Th17 inflammation in models of type 1 
diabetes mellitus, collagen-induced arthritis, and EAE [61, 135]. Altogether, these studies 
demonstrate the ability of MSCs to shift the balance of Th phenotypes in multiple disease 
contexts, partially mediated by induction of regulatory T-cells that aid in MSC 
immunomodulation.  
 
Tregs are a subset of CD4+ T-cells that display regulatory or suppressor functions and are 
thought to prevent autoimmunity and aid in resolution of inflammation. Tregs are 
characterized by their expression of CD25 and the transcription factor FoxP3 and can 
regulate the activation of Th cells and other immune cells. Initial studies demonstrated that 
co-culture of MScs with CD4+ T-cells induced a population of CD25+FoxP3+ Tregs that, 
when purified, displayed suppressive activity in a mixed lymphocyte reaction [136, 137]. 
Several mechanisms have been demonstrated to be involved in MSC induction of Treg 
populations. MSC IDO expression, in response to IFN-γ, induce naive CD4+CD25- T-cell 
differentiation into CD4+CD25+FoxP3+ regulatory T-cells (Tregs) [138] and aids in the 
induction of immune tolerance in vivo [139]. MSC expression of TGF-β1 also play a 
critical role in the induction of inducing antigen-specific Treg phenotypes [140, 141]. 
Additionally, MSC expression of PGE2 [136], HLA-G5 [64], HO-1 [66], CCL2 [134], and 
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Fas ligand [142] have all been demonstrated to play a role in MSC induction of Tregs in 
vitro and in vivo. Through these molecular mechanisms, MSC induction of Tregs has been 
strongly associated with protection from or alleviation of alloreactive [143, 144], 
autoimmune [61, 127, 142, 145], and allergic diseases [129, 146]. Therefore, Treg-
mediated induction and maintenance of tolerance to self- or allo-antigens is thought to be 
a critical mechanisms by which MSCs can ultimately be beneficial in treating these 
diseases even when MSCs themselves do not persist in the patient over time.  
 
Finally, in addition to CD4+ T-cells, MSCs can also inhibit CD8+ cytotoxic T-cells (CTLs) 
which are responsible for inducing cell death upon secondary encounter of antigen 
expressed on cells and are responsible for the extensive tissue damage in diseases such as 
graft-versus-host disease. MSC can suppress CTLs directly or indirectly by inhibiting Th 
responses which aid in activation of CTLs. Furthermore, MSCs are resistant to CTL lysis, 
even after pulsing MSCs with a high dose of synthetic peptide at high concentrations, 
despite expressing MHC class I [147]. Furthermore, MSCs did not upregulate CD25 or 
IFN-γ and TNF-α expression in CTLs. Similarly, CTL formation is inhibited in mixed 
lymphocyte cultures when MSCs are added to the culture [148]. However, while MSCs 
can prevent CTL activation during the primary stimulation phase, MSCs are not able to 
suppress already activated CTLs [149]. Interestingly, MSCs have little effect on T-cell 
responses to viruses compared to allo-antigen in vitro [150], suggesting that transplanted 
MSCs may be useful in suppressing pathogenic immune responses without impairing host 




2.3 Three-Dimensional Culture of MSCs 
Self-assembled, scaffoldless, spheroidal aggregates of tightly packed MSCs have been 
proposed in order to improve or maintain MSC properties during ex vivo expansion by 
better recreating the three dimensional nature of the MSC niche[151, 152]. This 3D 
aggregation approach have been commonly applied to other stem cell and cancer cell 
populations to more closely recapitulate the three dimensional structure of tissues (i.e. cell-
cell and cell-matrix interactions) [153]. For example, embryoid body culture has been a 
common technique for culturing pluripotent embryonic stem cells as a model of 
morphogenic events that occur during embryonic development [154]. Tumorspheres are 
another commonly used in vitro model to study cancer biology and potential therapeutics 
in a system that more closely mimics the physical structure of tumors in vivo [155]. 
Furthermore, aggregation of cells has been demonstrated to enhance the maintenance and 
culture of stem cell populations ex vivo. Neural stem cells are typically cultured as 3D 
“neurospheres” which aids in preserving their progenitor cell phenotype [156]. Similarly, 
when applied to the culture of MSCs, aggregation enhanced the intrinsic regenerative 
potential of MSCs by maintaining their differentiation capacity, increasing the secretion of 
angiogenic and immunomodulatory paracrine factors, and improving cell retention and 
survival post-transplantation [157].  
 
Techniques such as hanging drop, forced aggregation, and culture on non-adherent surfaces 
are commonly used to confine MSCs in a high density in order to increase cell-cell contact 
and promote self-assembly [151]. By spatially confining cells, aggregation of MSCs can 
occur through cadherin mediated self-assembly of 3D spheroids. Several studies have 
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demonstrated that ethylenediaminetetraacetic acid (EDTA), a calcium-chelator, inhibits the 
ability of bone marrow and umbilical cord MSC to self-assemble into aggregates [158] by 
interfering with calcium-dependent cadherin binding [159]. Furthermore, MSCs are 
capable of forming spheroids in serum-free media with no supplemental ECM adhesion 
molecules, further suggesting that cadherin molecules are responsible for initial MSC 
aggregation [160, 161]. However, the specific cadherins mediating self-aggregation may 
be dependent on the cell source as well as the aggregation method. Bone marrow derived 
MSCs predominately express N-cadherin and cadherin-11 [162] whereas E-cadherin was 
found to be the primary cadherin mediating aggregation of umbilical cord derived MSCs 
[159]. Differential expression of cadherin expression is thought to mediate the 
ultrastructure of MSC aggregates, with high cadherin expression will be found at the 
interior of the aggregate while low cadherin expressing cells will be found at the exterior 
to minimize the surface free energy. Furthermore, cadherins play an important role in 
interfacing with the cytoskeleton and mediating cytoskeletal tension. As a result of 
aggregation, cells at the interior of the aggregate are rounded in shape due to decreased 
cortical tension from multiple cell-cell connections whereas MSCs at the exterior are 
spread due to the increased tension at the aggregate-medium interface [163–166]. Since 
biophysical changes in the cytoskeletal have been demonstrated to influence MSC 
differentiation and function [167, 168], these physical changes achieved by 3D aggregation 
of MSCs may play a role in the increased regenerative potential of aggregated MSCs. 
 
As the trophic effects of MSCs are a key component of the regenerative potential of MSCs, 
it is unsurprising that the overall paracrine activity of MSCs is increased when MSCs are 
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aggregated into three dimensional spheroids. Secretion of the angiogenic factors VEGF, 
FGF-2, HGF, EGF, SDF-1, and angiogenin have all been found to be increased in MSC 
aggregate culture compared to adherent monolayer cultures [169–171]. Cadherins in 
particular have been found to be critically important in mediating the increased expression 
of angiogenic factors by MSC spheroids. For example, activation of N- and E-cadherin 
through cell-cell interactions regulate VEGF secretion in cord blood and umbilical cord 
derived MSCs, respectively [159, 172]. Furthermore, the immunomodulatory activity of 
MSCs is greater when MSCs are aggregated as spheroids. Secretion of the 
immunomodulatory factors TNF-α stimulated protein 6 (TSG-6) and PGE2 are both 
increased in MSC aggregate cultures compared to adherent monolayer cultures [173, 174]. 
Upregualtion of TSG-6 and PGE2 secretion in response to aggregation was dependent on 
activation of caspase signaling resulting in upregulation of IL-1α and IL-1β expression 
[175]. MSC expression of IL-1s was subsequently responsible for self-activation of NF-κB 
signaling resulting in increased expression of TSG-6 and PGE2. Additionally, inhibition of 
Notch signaling through γ-secretase inhibitors resulted in decreased PGE2 expression, 
suggesting that Notch signaling may also play a role in the increased immunomodulatory 
factor expression by MSC aggregates. The increased secretion of PGE2 by MSC aggregates 
resulted in increased suppression of inflammatory cytokine secretion of LPS activated 
macrophages in vitro and polarized these macrophages to an M2-like phenotype [174]. 
Furthermore, MSC spheroids injected intraperitoneally (I.P.) in a zymosan-induced 
peritonitis mouse model resulted in a decreased inflammatory response (i.e. decreased 
inflammatory cytokines and secreted neutrophil myeloperoxidase in lavage fluid) 
compared to injection of adherent cultures MSCs or no MSC treatment. Additionally, 
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intraluminal injection of MSC spheroids improved disease scores and decreased 
inflammatory cytokine expression in a mouse model of colitis [176]. Altogether, these 
results demonstrate that several signaling pathways (cadherin, caspase, NF-κB, Notch) are 
involved in enhancing paracrine activity of MSCs upon aggregation. 
 
The increased secretion of paracrine factors by aggregated MSCs has also been attributed 
to improved differentiation efficiency of MSCs cultured as spheroids. Culture of MSCs as 
large pellets (typically > 250,000 per aggregate) enhances the osteochondral differentiation 
potential of MSCs that is thought to be a result of the formation of a hypoxic core within 
the pellets [177, 178]. However, enhanced differentiation potential towards osteogenic, 
chondrogenic, and adipogenic fates has been demonstrated in smaller MSC spheroids (< 
200 µm in diameter [179–181]), below the threshold of aggregate size at which oxygen 
gradients are expected to develop [182]. Alternatively, the increased differentiation 
potential of MSC aggregates may be due to the enhanced secretion of growth factors and 
ECM proteins observed in spheroid culture. For example, increased expression of 
fibroblast growth factor 2 (FGF-2) [169] and bone morphogenic protein 2 (BMP-2) [183] 
have been observed in MSC spheroid culture and both of these growth factors regulate 
MSC proliferation and differentiation towards osteochondral fates [184]. Furthermore, 
increased expression of ECM molecules such as fibronectin, collagens, and 
glycosaminoglycan [169, 185, 186] by MSCs cultured as spheroids may further aid in 
promoting differentiation and aid in locally presenting and retaining growth factors to 




 Importantly, differentiation of MSCs in aggregate culture requires the supplementation of 
differentiation cues into the culture medium to direct differentiation, suggesting that 
aggregate cultures alone does not induce spontaneous differentiation of MSCs. Instead of 
inducing differentiation, spheroid culture better maintains the multipotency of MSCs 
compared to adherent culture [187]. MSC spheroids cultured for over two weeks in growth 
medium did not differentiate toward adipogenic or osteogenic lineages but maintained their 
capacity for differentiation when transferred to mediums containing the necessary 
biochemical cues for differentiation [179]. Additionally, clonal aggregates of Nestin+ 
perivascular stromal cells that contain all the CFU-F activity within mouse bone marrow 
self-renew and generate heterotopic bone ossicles with hematopoietic activity after serial 
transplantations [16, 188], indicating that multipotency and hematopoietic activity is 
maintained in spheroid culture. Furthermore, spheroid culture may not only support 
maintenance of MSCs but also induce dedifferentiation of MSCs to an early mesendoderm-
like state [189]. Since formation of a compact mesenchymal blastema and subsequent 
dedifferentiation is necessary for limb regeneration in zebrafish, xenopus, and newts, 
Pennock et al. sought to mimic these conditions by generating 3D spheroids of human 
MSCs. Aggregation of MSCs was found to reverse cell hypertrophy, increase expression 
of reprogramming factors (Oct4, Nanog, and Sox2) and early mesendoderm markers, and 
increase in vivo mesodermal tissue generation. Finally, an autophagic response of MSCs 
cultured as spheroids was observed and promoted cytoplasmic remodeling, mitochondrial 
regression, and a switch from oxidative phosphorylation to anaerobic metabolism 
suggesting a dedifferentiated state. Altogether, aggregation of MSCs improves biological 




Infusion or transplantation of single-cell suspensions of MSCs results in little retention and 
engraftment within desired tissues. For example, when systemically administered, the vast 
majority of cells are entrapped within the capillary beds of lung tissue and cleared from the 
tissue within a few days. Alternatively, transplantation of pre-formed cellular aggregates 
can improve cellular engraftment and viability [190]. In addition to the increased 
expression of angiogenic and ECM proteins that can aid in protecting transplanted cells 
from cytotoxic injury or inflammatory sites,  maintenance of cell-cell interactions and ECM 
components of spheroids prior to implantation prevents anoikis and associated cell loss, 
yielding better engraftment in host tissue [159, 169, 186]. This improved cell-survival of 
MSC aggregates has been attributed to improved regenerative capacity in several wound 
healing models. For example, increased cell survival of MSC aggregates improved bone 
healing in heterotopic and orthotopic sites compared to single-cell MSC suspensions [191]. 
Furthermore, improved retention of MSC aggregates after transplantation of MSCs in 
cardiac and skeletal muscle was observed due to physical entrapment within the tissue due 
to aggregate size [159, 192]. Entrapment of MSC aggregates within cardiac tissue resulted 
in increased retention of cells and increased paracrine activity that ultimately improved 
cardiac function and reduced fibrosis in myocardial infarction in rodent models [185]. 
Altogether, transplantation of 3D MSC aggregates may be a means of improving retention 
and survivability of MSCs at sites of transplantation and thereby increasing the duration 








AGGREGATION AND CYTOKINE PRE-CONDITIONING TO ENHANCE 




Mesenchymal stem/stromal cell (MSC) immunomodulation and paracrine factor secretion 
is highly regulated by the local microenvironment of the cells [41]. In particular, the 
inflammatory cytokine milieu, including interferon gamma (IFN-γ), tumor necrosis factor 
alpha (TNF-α), and interleukin 1 beta (IL-1β), regulates MSC immunomodulatory function 
by activating MSC expression of immunomodulatory factors such as PGE2, IDO, and HGF 
[32–34]. Furthermore, ligands for toll-like receptors TLR3 and TLR4 can regulate MSC 
immunomodulation by altering paracrine factor secretion of MSCs [37, 38]. Interestingly, 
3D aggregation of MSCs also enhances immunomodulatory paracrine factor secretion, 
including PGE2 and TNF-α stimulated gene/protein 6 (TSG-6), which aid in MSC 
suppression of macrophage inflammatory cytokine production [173–175]. While hypoxic 
conditioning due to transport limitations of oxygen within the 3D cellular structure has 
largely been implicated in the increased paracrine secretion observed in MSC spheroid 
cultures [169, 193], it is currently unclear what role 3D aggregation plays in enhancing 
MSC immunomodulation in small cellular aggregates where transport of oxygen is not a 
limitation. Furthermore, while the exact mechanisms and interplay of environmental 
parameters, including 3D aggregation and cytokine stimulation, on the regulation of MSC 
                                                 
1 Modified from: Zimmermann JA, Mcdevitt TC. Pre-conditioning mesenchymal stromal cell spheroids for 
immunomodulatory paracrine factor secretion. Cytotherapy. 2014;16(3):331-345. 
29 
 
immunomodulation are not yet fully understood, variability in the biochemical or physical 
components of the local inflammatory environment may contribute to the success or failure 
of MSC-based therapies. Thus, understanding the specific effects of the local 
microenvironment regulating MSC immunomodulation activity may provide new insights 
into components of the microenvironment that can be utilized to enhance MSC 
immunomodulatory therapies that are broadly applicable to an array of inflammatory and 
immune diseases. 
 
While MSCs have been investigated as cell therapies for the treatment of inflammatory and 
immune diseases, reproducibility of positive patient responses to MSC treatments in 
clinical trials has not been clearly demonstrated between studies with differences in patient 
populations, donor cells, culture conditions, and treatment regimens. The lack of a robust 
therapeutic response in these immune and inflammatory diseases has largely been 
attributed to inconsistent numbers of MSCs at sites of inflammation due to a lack of cell 
engraftment or insufficient cell homing [194, 195]. Additionally, discrepancies between 
studies have been attributed to variability in processing and culture conditions including 
growth medium and passage number, resulting in highly variable starting cell populations 
for transplantation [196]. Since MSC immunomodulatory factor secretion can be induced 
by environmental stimuli, culturing MSCs in a defined environment containing activating 
signals, such as with 3D aggregation or pro-inflammatory cytokine stimulation, may be a 
means of priming cells to increase immunomodulatory activity. MSCs that display 
increased immunomodulatory factor secretion immediately upon transplantation could 
enhance the therapeutic potential of MSCs during the relatively short resident times after 
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transplantation. Therefore, development of pre-conditioning strategies could maximize 
MSC immunomodulatory potential and thereby increase the effectiveness of MSC-based 
cell therapies for inflammatory and immune diseases. 
 
The objective of this study was to systematically determine whether environmental culture 
conditions, such as three dimensional aggregation and pro-inflammatory cytokine 
stimulation, modulate endogenous MSC paracrine factor secretion and pre-condition 
MSCs to enhance their immunomodulatory activity. Human MSCs were cultured either as 
adherent monolayers or 3D spheroids formed via forced-aggregation in microwells with a 
prescribed number of cells per aggregate. Additionally, subsets of MSC cultured in 
monolayer and as spheroids were cultured in medium supplemented with the pro-
inflammatory cytokines IFN-γ and TNF-α. The impact of spheroid culture and pro-
inflammatory cytokine treatment on immunomodulatory paracrine factor secretion and 
pre-conditioning of MSCs was analyzed by morphological and phenotypic analysis as well 
as by evaluating suppression of inflammatory responses through co-culture with activated 
macrophages. Furthermore, the ability of MSC spheroids to suppress T-cell proliferation 
in vitro was evaluated. The results of this study demonstrate that 3D aggregation and pro-
inflammatory cytokine treatment modulate MSC paracrine factor secretion and work 
synergistically to enhance MSC immunomodulation. Additionally, the results provide a 
translatable approach to pre-condition MSCs through 3D aggregation and pro-
inflammatory cytokine pre-treatment to enhance their inherent immunomodulatory 
properties and thereby improve the efficacy of MSC-based treatments of inflammatory 
diseases and immune disorders. 
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3.2 MATERIALS AND METHODS 
3.2.1 Cell Culture and Expansion 
Human bone marrow-derived MSCs were obtained from the Texas A&M College of 
Medicine Institute for Regenerative Medicine and expanded according to established 
protocols [197]. Approximately 1x106 cryopreserved MSCs were seeded onto a 15-cm 
tissue culture dish in 20 mL MSC complete culture medium (CCM, Minimal Essential 
Medium Alpha (MEMα, VWR, Radnor, PA) supplemented with 16.5% fetal bovine serum 
(FBS, Hyclone, Logan, UT), 2mM L-glutamine (Corning cellgro, Manassas, VA), 100 
U/mL penicillin and 100 µg/mL streptomycin (Corning cellgro)). After overnight 
incubation, adherent MSCs were washed with phosphate-buffered saline (PBS, Invitrogen, 
Carlsbad, CA) and detached from the plate using 0.25% trypsin and 1 mM EDTA in Hanks' 
Balanced Salt Solution (Corning cellgro). Dissociated cells were counted using a 
hemocytometer and plated onto 15-cm tissue culture dishes at a density of 60 cells/cm2 in 
20 mL CCM per dish. Media was completely exchanged every 3 days until cells reached 
approximately 70% confluence. Cells were trypsinized, counted, and either re-plated for 
monolayer expansion cultures or used for experiments after passage 4. MSCs from Texas 
A&M College of Medicine Institute for Regenerative Medicine were used for evaluation 
of cell viability and histology, immunomodulatory factor quantification, and THP-1 cell 
co-cultures described below. 
 
Human bone marrow-derived MSCs were also obtained from RoosterBio Inc. (Frederick, 
MD) and expanded according to the manufacturer’s protocols. Briefly, 107 cryopreserved 
MSCs were plated in twelve T225 flasks in 42 mL of RoosterBio High Performance Media 
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and incubated at 37°C for 7 days in a humidified 5% CO2 incubator. Media was exchanged 
after 4 days of culture. Cultures were passaged at 80% confluency by washing with 10 mL 
PBS followed by incubation with 10 mL of TrypLE at 37 oC. An equal volume of 
RoosterBio High Performance Media was added to quench TrypLE activity. Dissociated 
cells were then collected and centrifuged at 200xg. Cells were frozen in CryoStor CS5 cell 
cryopreservation media (STEMCELL Technologies, Vancouver, BC, Canada) prior to 
expansion for experiments. MSCs were expanded for one or two passages from frozen 
stocks by plating 0.5x106 cells in RoosterBio High Performance Media in 15 cm tissue 
culture treated dishes. Media was exchanged every three days and cells were passaged at 
80% confluency. MSCs from RoosterBio Inc. were used in peripheral blood mononuclear 
cell co-cultures described below.  
 
3.2.2 Spheroid Formation and Culture 
Forced-aggregation of single cell suspensions of MSCs was used to generate MSC 
spheroids. Spheroids were formed overnight in 400 µm agarose microwells for a high 
throughput method of generating homogenous cell aggregates [198]. Briefly, 1.2x106, 
3x106, or 6x106 MSCs were added to 6-well microwell inserts containing approximately 
6,000 wells and centrifuged at 200xg for 5 min to force aggregation of spheroids with 
approximately 200, 500, or 1000 cells per aggregate, respectively. After 18h in the 
microwells, spheroids were removed and transferred to suspension culture in 100 mm 
bacteriological grade Petri dishes at equivalent total cell densities (~300,000 cells per plate; 
1500 200-cell spheroids, 600 500-cell spheroids, 300 1000-cell spheroids). Spheroids were 
cultured in suspension on a rotary orbital shaker for up to 4 days at 65 RPM. Additionally, 
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adherent MSC controls were plated in 10-cm tissue culture dishes at a density of ~1300 
cells/cm2. MSC spheroids and adherent controls were cultured in 10 mL of either CCM or 
the serum-free defined MesenCult-XF medium (STEMCELL Technologies, Vancouver, 
Canada). Furthermore, 10 ng/mL IFN-γ, 10 ng/mL TNF-α, or 5 ng/mL of both IFN-γ and 
TNF-α (R&D, Minneapolis, MN) were supplemented on day 1 cultures of 500-cell 
spheroids and adherent controls in both CCM and MesenCult medium. After 4 days of 
culture, MSCs and conditioned media were collected for histological analysis as well as 
cell counts and immunomodulatory factor quantification. 
 
3.2.3 Cell Viability and Histological Analyses 
Cell viability of MSC spheroids treated with IFN-γ and/or TNF-α was analyzed via 
LIVE/DEAD staining (Invitrogen) after 4 days of culture. Samples were incubated in PBS 
containing 1 µM calcein AM and 2 µM ethidium homodimer I for 1 hour at 4º C. Samples 
were washed 3 times in PBS and immediately imaged using confocal microscopy (Zeiss 
LSM700-405, Germany). MSC spheroids were washed twice with PBS and fixed in 10% 
formalin for 20 minutes for histological analyses. After fixation, spheroids were washed 
three times with PBS, paraffin processed, embedded, and sectioned at 5 μm. Histological 
sections were de-paraffinized and stained with either hematoxylin and eosin (H&E), 
Toluidine Blue, Safranin O, or Masson's Trichrome and coverslipped with mounting 
media. A Nikon 80i upright microscope equipped with a SPOT Flex camera (Diagnostic 
Instruments, Sterling Heights, MI) was used to capture brightfield images of samples. 
 
3.2.4 Cell Number and Immunomodulatory Factor Quantification 
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MSCs cultured as monolayers or spheroids with or without inflammatory cytokine 
treatment were cultured for 4 days and evaluated for total cell number and 
immunomodulatory factor secretion. The number of starting cells and after 4 days of 
culture were quantified for each culture condition using a CyQUANT assay (Invitrogen) 
according to the manufacturer's protocol. Collected cells were lysed and total DNA was 
measured and compared to a standard curve of known cell densities to determine cell 
numbers of each sample. PGE2 in conditioned media was quantified using a Prostaglandin 
E2 Parameter Assay Kit (R&D). Human TGFβ1 and IL6 concentrations in conditioned 
media were quantified using DuoSet ELISA kits (R&D). Total secreted PGE2, TGF-β1, 
and IL-6 was determined by subtracting cytokine concentrations in culture media controls 
incubated for 4 days in 100 mm Petri dishes. Total secreted PGE2, TGFβ1, and IL6 were 
normalized to the average cell number over the 4-day culture period for each condition. 
 
3.2.5 THP-1 Co-Culture Assay and Analysis 
The human monocyte THP-1 cell line (ATCC) was expanded in growth media (RPMI-
1640 with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin and 0.05 mM 2-
mercaptoethanol) and differentiated in growth media supplemented with 100 ng/mL 
phorbol-12 myristate 13-acetate (PMA, Sigma Aldrich) to induce macrophage 
differentiation. After 2 days in PMA-supplemented growth media, adherent cells were 
rinsed and cultured in growth media with 100 ng/mL of lipopolysaccharide (LPS) and 40 
ng/mL IFN-γ for 2 days to activate the macrophages. Activated macrophages (8x105) and 
MSCs (1x105) were co-cultured for 16 hours in 0.4 µm pore transwells and 12-well tissue 
culture treated polystyrene plates (Corning), respectively. Adherent monolayer and 
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spheroid MSC cultures were pre-treated with or without 5 ng/mL IFN-γ and 5 ng/mL TNF-
α for 4 days prior to being rinsed in PBS and transferred to 12-well plates. MSCs were 
cultured in the 12-well plates for 6 hours in RPMI-1640 with 10% FBS, 100 U/mL 
penicillin, and 100 µg/mL streptomycin and 0.05 mM 2-mercaptoethanol before addition 
of activated macrophages cultured in the transwells. Non-activated and activated 
macrophages were cultured in transwells without MSCs as controls. Human TNF-α was 
quantified from culture media after 16 hours using a DuoSet ELISA kit (R&D). Secreted 
TNF-α was determined by subtracting the concentration of TNF-α in media-only controls 
incubated for 16 hours in a 12-well plate. 
 
3.2.6 IDO Detection and Peripheral Blood Mononuclear Cell Co-culture Assays  
To evaluate MSC spheroid expression of IDO, RoosterBio MSCs were passaged and either 
plated in 10-cm plates (300,000 cells per plate) or aggregated into 500-cell spheroids. A 
subset of adherent and spheroid MSCs were stimulated with 20 ng/mL IFN-γ for 24 hours. 
After 24 hours, untreated and IFN-γ stimulated adherent and spheroid MSCs were lysed 
and RNA collected for quantitative real-time PCR (qRT-PCR) to measure IDO gene 
expression. RNA was extracted using an E.Z.N.A. Total RNA kit (OMEGA Bio-Tek, 
Norcross, GA) kit and cDNA was subsequently synthesized (300 ng RNA per sample) 
using an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Forward and reverse primers 
for IDO1 (Forward: AGCTTCGAGAAAGAGTTGAGAAG; Reverse: 
GTGATGCATCCCAGAACTAGAC) and 18S (Forward: 
CTTCCACAGGAGGCCTACAC; Reverse: CTTCGGCCCACACCCTTAAT) were 
designed using Primer-Blast (www.ncbi.nlm.nih.gov) and purchased from Invitrogen 
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(Carlsbad, CA). IDO1 gene expression was calculated with respect to untreated MSCs and 
normalized to 18S expression using the ΔΔCT method. 
 
To assess MSC suppression of T-cell proliferation, PBMCs were isolated from whole blood 
obtained with IRB approval from healthy volunteers via Ficoll (Sigma-Aldrich) density 
gradient separation. Isolated PBMCs were cultured at 400,000 cells per well in 24-well 
plates with adherent (1:9, 1:6, and 1:3 MSC-to-PBMC ratios) and spheroid MSCs (1:3, 1:1, 
and 3:1 MSCs-to-PBMC ratios) stimulated with 20 ng/mL IFN-γ for 24 hours prior to co-
culture. In a subset of cultures, PBMCs were added to the upper well of a 0.4 μm pore 
polycarbonate transwell (Corning) and co-cultured with IFN-γ pre-treated adherent and 
spheroid MSCs. At the start of co-cultures, 0.2 μg/mL of anti-human CD3 and CD28 
antibodies were added to the co-cultures to induce T-cell proliferation and activation. For 
all PBMC co-cultures, T-cell proliferation was assessed 4 days later by flow cytometry 
analysis of CD3 (FITC-conjugated mouse anti-CD3 IgG; BD Biosciences, East Rutherford, 
NJ) and Ki67 (PE-conjugated mouse anti-Ki67 IgG; BD Biosciences) double positive 
stained cells. T-cell activation was also assessed after 4 days by measuring the amount of 
IFN-γ in spent media supernatants by ELISA (R&D). 
 
3.2.7 Statistical Analysis and Hierarchical Clustering 
Statistical analyses were performed using Systat (Systat Software, Chicago, IL). Data are 
presented as mean ± standard error (n=6). Comparisons between multiple experimental 
groups were conducted using analysis of variance (ANOVA) and Box-Cox transformation 
followed by Tukey post hoc analysis to determine statistically significant differences (p < 
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0.05). The Genesis software package was used to produce heat maps of cell growth, 
immunomodulatory factor expression, and suppression of activated macrophage TNF-α 
secretion and to calculate and visualize two-dimensional hierarchical clustering between 
measured parameters and culture format, medium, and cytokine treatment groups, based 




Figure 3.1. MSC spheroid formation and suspension culture. (A) MSC spheroids of distinct 
sizes were aggregated in agarose microwells overnight and subsequently cultured on a rotary orbital 
shaker (65 rpm) in either FBS or MesenCult™ medium. (B) After 4 days, spheroids cultured in 
MesenCult™ medium were larger than their initial size whereas spheroids in FBS medium 
maintained their original size. (C) Spheroid cultures in MesenCult™ medium exhibited a greater 
fold change in cell number over 4 days of culture compared to spheroids cultured in FBS medium 







3.3.1 Impact of Spheroid Culture on MSC Phenotype 
MSC spheroids with approximately 200, 500, or 1000 cells were formed via forced 
aggregation in 400 µm microwells by modulating the number of cells seeded into each 
well. After overnight incubation in the microwells, MSCs aggregated into relatively 
uniform spheroids of distinct sizes (Figure 3.1A) and were transferred to suspension 
culture to prevent surface attachment and agglomeration of individual aggregates. To 
determine if media composition altered the immunomodulatory secretion of MSCs, culture 
in traditional MEMα media supplemented with 16% FBS as well as serum-free, defined 
MesenCult medium, both of which support proliferation of monolayer MSC cultures was 
investigated. Spheroids cultured in MesenCult medium appeared larger after four days of 
culture compared to those cultured in FBS media, suggesting enhanced growth in these 
conditions. Morphometric analysis of spheroid projected area and quantification of cell 
numbers was performed to quantify aggregate size. After 4 days of culture, 200-, 500-, and 
1000-cell spheroids cultured in MesenCult medium had significantly greater mean areas 
(1.8-, 2.6-, and 2.4- fold increase respectively, p < 0.001) compared to spheroids of the 
same initial cell number cultured in FBS medium (Figure 3.1B). In FBS media, no change 
in the total number of cells in spheroid cultures occurred after 4 days, indicating no 
significant expansion in MSCs over the culture period. However, a 1.9-, 2.0-, and 2.9-fold 
change in the total number of cells was observed in 200-, 500-, and 1000-cell spheroid 
cultures, respectively, in MesenCult media after 4 days (Figure 3.1C). H&E staining of 
200, 500, and 1000 cell spheroids after microwell formation and after four days of culture 
in FBS or MesenCult medium revealed distinct differences in spheroid structure (Figure 
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3.2). Spheroids cultured in FBS media were consistently smaller than those cultured in 
MesenCult medium. The distribution of cells within the aggregates was more uniform in 
spheroids cultured in FBS whereas, with the exception of 1000 cell spheroids, MSCs 
clustered at the outer edges of spheroids cultured in MesenCult medium. Together, these 
results indicate that MSCs cultured as spheroids in MesenCult medium continue to grow 
whereas cell spheroids in FBS-supplemented medium fail to do so over the same period of 
time.  
 
3.3.2 Spheroid Culture Increases Immunomodulatory Factor Secretion  
To determine the impact of spheroid culture and medium on the secretion of 
immunomodulatory paracrine factors, conditioned media was collected and analyzed to 
determine MSC secretion of the immunomodulatory factors PGE2, TGF-β1, and IL-6. 
When cultured as spheroids, MSCs in FBS medium secreted greater amounts of PGE2, 
TGF-β1, and IL-6 (Figure 3.3A-C) compared to those cultured in MesenCult medium. In 
comparison to adherent monolayer cultures, MSCs cultured as 500-cell spheroids in FBS 
medium secreted a 4-fold greater amount of PGE2 (p < 0.001), similar to previously 
described results [174], as well as a 1.7- and 3.2-fold increase in TGF-β1 and IL-6 secretion 
(p = 0.041 and 0.001, respectively). However, in MesenCult medium, no difference in 
PGE2 was observed between adherent monolayer and spheroid cultures, and spheroid 
cultures actually secreted less TGF-β1 (p < 0.001). Only IL-6 secretion was observed to be 
increased in spheroid cultures in MesenCult medium compared to adherent monolayers, 
which did not secrete detectable levels of IL-6. Overall, there was little difference in the 
secretion of immunomodulatory paracrine factors between spheroids of different sizes, but 
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the most abundant paracrine factor secretion was consistently observed in 500-cell 
spheroids, thus 500-cell spheroids were chosen for further analysis of immunomodulatory 
paracrine factor secretion. 
 
 
Figure 3.2. Histological analysis of MSC spheroids of varied size and culture medium. MSCs 
initially aggregated overnight to form compact spheroid structures with approximately 200, 500, 
and 1000 cells (top row). After 4 days, MSCs cultured as spheroids in MesenCult™ medium 
appeared more compact than spheroids cultured in FBS medium (middle row). MSCs cultured as 
200- and 500-cell spheroids in MesenCult™ media appeared to be distributed primarily towards 
the exterior of spheroids whereas MSCs were distributed more uniformly throughout 1000-cell 




Figure 3.3. Immunomodulatory factor expression of MSCs. Differential secretion of the 
immunomodulatory factors (A) PGE2, (B) TGF-β1, and (C) IL-6 was observed after 4 days of MSC 
culture in monolayer and spheroid formats, as well as in different culture media. Spheroids with 
approximately 500 cells in FBS supplemented medium exhibited the greatest secretion of these 
three immunomodulatory factors while comparable numbers of MSCs in MesenCult medium 
tended to secrete less of each factor. (D) IDO activity, measured by the amount of kynurenine, was 
greater in cells cultured in FBS medium but was not impacted by culture format. * indicates p < 
0.05 by groups denoted by bar; $ indicates p < 0.05 (FBS) compared to adherent monolayer culture; 
# indicates p < 0.05 (MesenCult) compared to adherent monolayer culture; + indicates p < 0.05 
(FBS) compared to 200-cell spheroid culture; ND = not detectable. 
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3.3.3 Cytokine Conditioning of MSCs is Dependent on Culture Medium 
To investigate the effects of cytokine treatment of MSC spheroids, 500-cell spheroids were 
cultured in FBS and MesenCult mediums supplemented with 10 ng/mL IFN-γ, 10 ng/mL 
TNF-α, or 5 ng/mL of each cytokine, for 4 days in suspension culture. Although MSCs 
cultured in MesenCult medium secreted lower levels of immunomodulatory factors, 
treatment with pro-inflammatory cytokines was hypothesized to stimulate MSC 
immunomodulatory activity even in MesenCult medium. Whereas the size of spheroids 
cultured in FBS medium did not vary when treated with different cytokines, the size of 
spheroids cultured in MesenCult medium was modulated by cytokine treatment (Figure 
3.4A). Spheroids treated with TNF-α alone were larger, while spheroids exposed to IFN-γ 
(alone or in combination with TNF-α) yielded smaller spheroids after 4 days compared to 
untreated controls (Figure 3.4B). However, an increase in cell number after 4 days of 
culture was observed in spheroid cultures in MesenCult medium compared to FBS medium 
and cell expansion was not inhibited by IFN-γ or TNF-α treatment alone (Figure 3.4C), 
suggesting that differences in spheroid size reflected differences in spheroid structure or 
individual cell size. Additionally, no difference in cell numbers was observed between 
spheroids treated with both IFN-γ and TNF-α in either FBS or MesenCult medium, 
suggesting that this cytokine combination inhibits the cell growth observed in spheroids 
cultured in MesenCult medium alone.  
 
Histological analysis of spheroids cultured in FBS and MesenCult medium with pro-
inflammatory cytokine treatment revealed similar spheroid structures and cell distributions 
as untreated controls (Figure 3.5A). Histological analysis to determine the cellular and 
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extracellular composition of spheroids after 4 days of culture indicated little matrix 
deposition within the cores of the spheroid structures as assessed by Toluidine blue, 
Safranin O, and Masson's Trichrome staining (Figure 3.5B-C). Furthermore, viability of 
cells within spheroids did not appear to be significantly affected by cytokine treatment 
(Figure 3.6). However, MSC spheroids cultured in MesenCult medium and treated with 
IFN-γ alone or in combination with TNF-α displayed more uniformly distributed cells 
throughout the spheroid structure that were less densely packed, similar to the multicellular 






Figure 3.4. IFN-γ and TNF-α conditioning of 500-cell MSC spheroids. (A) MSC spheroids were 
cultured in FBS and MesenCult medium supplemented with 10 ng/mL IFN-γ, 10 ng/mL TNF-α, or 
5 ng/mL of both cytokines for 4 days. Scale bar = 500 μm. (B) Differences in aggregate size were 
observed after the 4 day culture period and IFN-γ treatment (alone or in combination with TNF-α) 
appeared to inhibit the increase in spheroid size observed in spheroids cultured in MesenCult 
medium. (C) Treatment with both IFN-γ and TNF-α inhibited the expansion of cell numbers in 
MesenCult medium and resulted in a comparable cell number similar to spheroids cultured in FBS 
medium. * indidcates p < 0.05 compared between FBS and MesenCult medium; $ indicates p < 
0.05 (MesenCult) compared to all cytokine treatment groups; # indicates p < 0.05 (FBS) compared 






Figure 3.5. Histological analysis of MSC spheroids treated with IFN-γ and TNF-α. (A) 
Spheroids (500 cells initially) cultured for 4 days of culture in FBS medium (top row) supplemented 
with IFN-γ alone (10 ng mL-1) or in combination with TNF-α (5 ng mL-1 of each cytokine) appeared 
similar in structure to untreated controls whereas spheroids treated with TNF-α alone (10 ng mL-1) 
appeared to be less densely packed. Spheroids cultured in MesenCult medium (bottom row) 
supplemented with IFN-γ and TNF-α alone had similar structures to untreated controls. However, 
spheroids treated with both IFN-γ and TNF-α appeared smaller in size with less cellularity. 
Spheroids in both FBS and MesenCult displayed very little GAG (B) or collagen (C) deposition 
over 4 days suggesting that MSC spheroids lack significant amounts of extracellular matrix after 
short culture periods. While the spheroid cellular structure was modulated by cytokine treatment, 
IFN-γ and TNF-α treatment did not alter GAG or collagen matrix deposition over 4 days of culture 





Figure 3.6. Cell viability analysis of MSC spheroids treated with IFN-γ and TNF-α. Spheroids 
cultured in FBS or MesenCult media with or without supplementation with 10 ng mL-1 IFN-γ or 
TNF-α were stained with calcein AM and ethidium homodimer to evaluate the ratio and distribution 
of live and dead cells. MSCs were predominately stained with calcein AM with only a few dead 
cells distributed throughout the spheroid. Additionally, cell viability did not appear to be affected 





Analysis of immunomodulatory paracrine factors produced in response to treatment with 
pro-inflammatory cytokines revealed cytokine-specific variation in individual 
immunomodulatory paracrine factor secretion dependent on the culture medium. PGE2 
secretion was found to be greater in spheroids cultured in FBS medium compared to 
spheroids cultured in MesenCult (Figure 3.7A). Treatment with TNF-α alone (10 ng/mL) 
in FBS resulted in a 2.8-fold increase in PGE2 secretion compared to untreated spheroid 
controls. Furthermore, TNF-α treatment of spheroids in FBS resulted in a 4.2-fold increase 
in PGE2 secretion compared to TNF-α treated monolayer cultures in FBS. However, 
spheroids treated with both TNF-α and IFN-γ (5 ng/mL each) did not exhibit significantly 
different PGE2 secretion compared to either non-treated controls or IFN-γ treated 
spheroids. IFN-γ treatment alone or with TNF-α did not impact MSC TGF-β1 secretion in 
FBS medium, while TNF-α treatment alone suppressed secretion of TGF-β1 (Figure 
3.7B). IL-6 secretion by MSC monolayers and spheroids was increased by individual 
cytokine treatment in both FBS and MesenCult medium. Furthermore, treatment with IFN-
γ and TNF-α together appeared to synergistically increase IL-6 secretion by MSC spheroids 
as the greatest IL-6 secretion (23.2-fold increase compared to untreated spheroid controls) 
was observed in spheroids treated with the combination of both cytokines (Figure 3.7C). 
Cytokine treatment in MesenCult medium stimulated secretion of PGE2 only in monolayer 
culture when treated with both cytokines. Additionally, IL-6 secretion was increased in 
both monolayer and spheroid cultures with treatment of both IFN-γ and TNF-α. Finally, 
TGF-β1 secretion was suppressed in all spheroid treatment groups compared to untreated 
spheroid controls. These results demonstrate that treatment with pro-inflammatory 
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cytokines can enhance immunomodulatory paracrine factor secretion of MSC spheroids 





Figure 3.7. Immunomodulatory factor expression of IFN-γ and TNF-α conditioned MSC 
monolayer and spheroid cultures. Increased secretion of (A) PGE2 was observed in spheroids 
treated with TNF-α and cultured in FBS media whereas (B) TGF-β1 secretion of spheroids 
decreased with TNF-α treatment. (C) IL-6 secretion was greatest in 500-cell spheroids treated with 
both IFN-γ and TNF-α in FBS media. * = p < 0.05 compared between groups denoted by bars; & 
= p < 0.05 compared to untreated of same culture format and medium; + = p < 0.05 compared to 
spheroid culture in FBS media with the same cytokine treatment; % = p < 0.05 compared to 
spheroid cultures in MesenCult media with the same cytokine treatment; # = p < 0.05 compared to 
all cytokine treatment groups in FBS medium; $ = p < 0.05 compared to all cytokine treatment 
groups in MesenCult medium; N.D. = not detectable.  
 
3.3.4 Pre-conditioning MSC Spheroids to Enhance Immunomodulation 
Having demonstrated that culture environment parameters alter the secretion of 
immunomodulatory paracrine factors, pre-conditioned MSC spheroid suppression of the 
inflammatory response of activated macrophages (aMΦ) was next determined. Since PGE2 
secretion was greatest with TNF-α treatment alone, and IL-6 secretion was greatest with 
both IFN-γ and TNF-α treatment, the ability of pre-treatment with TNF-α ± IFN-γ to 
enhance MSC immunomodulation in macrophage co-cultures was determined. In co-
culture studies, adherent monolayers of MSCs suppressed macrophage TNF-α secretion 
less than comparable numbers of MSCs as spheroids (Figure 3.8A). Pre-conditioning 
spheroids with both IFN-γ and TNF-α, but not TNF-α alone, further increased suppression 
of macrophage TNF-α secretion compared to untreated spheroids. Since MSCs cultured in 
MesenCult medium secreted lower levels of immunomodulatory factors, whether this 
culture medium impaired the immunomodulatory capabilities of MSCs in an in vitro model 
of an inflammatory environment (i.e. co-culture with activated macrophages) was 
examined. However, no difference in suppression of macrophage TNF-α secretion was 
observed between MSC spheroids cultured in FBS or MesenCult medium after being 
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transferred to macrophage co-culture. However, pre-conditioning spheroids with IFN-γ 
and TNF-α in MesenCult medium was unable to further reduce macrophage TNF-α 
expression. Altogether, these results demonstrate that pre-conditioning MSCs by 
manipulation of culture parameters can enhance immunomodulatory secretion to suppress 
inflammatory responses of activated macrophages that is dependent on the composition of 
the culture medium. 
 
3.3.5 Effects of Aggregation of MSCs on Suppression of T-cell Proliferation 
To further investigate the effects of aggregation and cytokine treatment on MSC 
immunomodulation, the ability of MSC spheroids to suppress T-cell proliferation was 
determined in co-cultures with CD3/CD28 activated PBMCs. Since expression of IDO in 
response to IFN-γ stimulation is critical for the suppression of T-cell proliferation, MSC 
expression of IDO from two different sources of MSCs (Texas A&M and RoosterBio 
MSCs) first evaluated in adherent and spheroid cultures. When treated with 20 ng/mL IFN-
γ, gene expression of IDO1 was massively upregulated (>104 fold induction of IDO) in 
both adherent and spheroid MSCs from both commercial sources (Figure 3.9). 
Additionally, MSC spheroids expressed greater levels of IDO1 when stimulated with IFN-
γ compared to adherent MSCs. In Texas A&M MSCs, gene expression of IDO1 was 1.5-
fold greater (p = 0.019) in spheroids stimulated with IFN-γ compared to adherent MSCs 
stimulated with IFN-γ. Similarly, in RoosterBio MSCs, gene expression of IDO1 was 4-






Figure 3.8. MSC suppression of THP-1 TNF-α secretion. MSCs cultured as monolayers and 
spheroids in FBS medium suppressed aMΦ secretion of TNF-α, however, TNF-α secretion was 
significantly reduced more by co-culture with spheroids compared to monolayer cells. 
However, spheroids cultured in MesenCult prior to co-culture did not differ in suppression of 
aMΦ TNF-α secretion compared to spheroid cultures in FBS culture medium. Pre-treating 
spheroids with 5 ng/mL of both IFN-γ and TNF-α, but not 10 ng/mL of TNF-α alone, in FBS 
medium further enhanced suppression of aMΦ TNF-α secretion. However, addition of IFN-γ 
and TNF-α to MesenCult medium did not enhance the subsequent immunosuppressive effects 





Figure 3.9. IDO expression in IFN-γ stimulated adherent and spheroid MSCs. (A) IDO1 
expression by Texas A&M MSCs was significantly upregulated in response to IFN-γ stimulation 
in both adherent and spheroid cultures. (B) Likewise, IDO1 expression was similarly upregulated 
in RoosterBio MSCs in response to IFN-γ treatment. * indicates p < 0.05 between groups denoted 
by bars.  
 
Despite MSCs from both commercial sources expressing IDO in response to IFN-γ, only 
IFN-γ stimulated MSCs from RoosterBio were capable of inhibiting T-cell proliferation in 
co-culture with CD3/CD28 activated PBMCs (Figure 3.10A). When co-cultured at a 1:3 
MSC:PBMC ratio, adherent RoosterBio MSCs significantly reduced the number of Ki67+ 
T-cells (~23% Ki67+) compared to activated PBMCs alone (~87% Ki67+; p < 0.001). 
However, in co-cultures with Texas A&M MSCs at a 1:3 MSC:PBMC ratio, no significant 
difference was found in the percentage of Ki67+ T-cells compared to PBMCs alone (68% 
Ki67+; p = 0.331). A similar trend in PBMC expression of IFN-γ was observed in co-
cultures; RoosterBio MSCs had significantly greater suppression of IFN-γ expression 
compared to Texas A&M MSCs at an equivalent MSC:PBMC ratio (Figure 3.10B). 
However, it is important to note that the Texas A&M MSCs used were expanded and 
cryopreserved several years prior to experiments, whereas RoosterBio MSCs were ordered 
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new and expanded prior to the start of these experiments. Cryopreservation has previously 
been demonstrated to interfere with the immunomodulatory capability of MSCs [199, 200]. 
Since only RoosterBio MSCs were found to suppress T-cell proliferation, these cells were 
used for all further experiments. 
 
To compare suppression of T-cell proliferation by adherent and spheroid MSCs, varying 
ratios of MSCs-to-PBMCs were investigated. Surprisingly, a greater dose of MSCs were 
needed to suppress T-cell proliferation when MSCs were aggregated despite MSC 
spheroids expressing greater amounts of IDO. Co-culture of PBMCs with adherent MSCs 
at a 1:3 MSC:PBMC ratio significantly reduced the percentage of Ki67+ T-cells (Figure 
3.11A; ~32% Ki67+ compared to ~87% in PBMC only cultures, p = 0.014) and T-cell IFN-
γ expression (Figure 3.11B; ~2.4 ng/mL IFN-γ compared to 9.6 ng/mL in PBMC only 
cultures, p < 0.001). However, at an equivalent dose of MSC spheroids (1:3 MSC:PBMC 
ratio) no significant difference in percentage of Ki67+ T-cells (Figure 3.11C) or IFN-γ 
expression (Figure 3.11D) was observed between co-cultures and PBMC only controls. 
Instead, nearly a 10-fold increase in the number of MSCs was necessary to begin to observe 
suppression of T-cell proliferation by MSC spheroids. Co-culture of PBMCs with spheroid 
MSCs at a 3:1 MSC:PBMC ratio significantly reduced the percentage of Ki67+ T-cells 
(Figure 3.11C; ~21% Ki67+ compared to ~65% in PBMC only cultures, p < 0.001) and T-
cell IFN-γ expression (Figure 3.11D; ~1.2 ng/mL IFN-γ compared to ~10.2 ng/mL in 
PBMC only cultures, p < 0.001). Altogether, MSC spheroids were less effective at 
suppressing T-cell proliferation in vitro compared to an equivalent amount of MSCs plated 




Figure 3.10. Suppression of T-cell proliferation and activation by Texas A&M and 
RoosterBio MSCs. (A) Adherent MSCs from RoosterBio but not Texas A&M significantly 
reduced proliferation of T-cells in PBMC co-cultures as determined by Ki67+ T-cells. (B) While 
both MSCs from RoosterBio and Texas A&M decreased T-cell secretion of IFN-γ at a 1:3 
MSC:PBMC ratio, suppression of IFN-γ secretion was significantly greater in co-cultures with 
RoosterBio MSCs. * indicates p < 0.05 compared to “No MSC” group; # indicates p < 0.05 





Figure 3.11. A greater dose of MSCs is needed to suppress T-cell proliferation when MSCs 
are aggregated. (A) Co-culture of CD3/CD28 activated PBMCs with adherent MSCs at multiple 
MSC:PBMC ratios demonstrated that adherent MSCs were effective at suppressing T-cell 
proliferation, as determined by the percentage of Ki67+ T-cells, at a 1:3 MSC:PBMC ratio. (B) 
Similarly, T-cell expression of IFN-γ was significantly reduced by adherent MSCs at a 1:6 and 1:3 
MSC:PBMC ratio. However, when aggregated into spheroids, a 3:1 MSC:PBMC ratio was 
necessary to suppress (C) T-cell proliferation and (D) IFN-γ expression. * indicates p < 0.05 






To investigate why more MSCs were required to suppress T-cell proliferation in spheroid 
culture, cell-contact dependent mechanisms were first examined. Cell-contact dependent 
signaling has been demonstrated to aid in adherent MSC suppression of T-cell proliferation 
[142, 201] and MSC spheroids have reduced surface area for cell-cell contacts. We 
hypothesized that MSC spheroids rely solely on paracrine mechanisms, such as IDO 
expression, to suppress T-cell proliferation and not direct cell contact and therefore, more 
cells are required to suppress T-cell proliferation. To investigate the role of direct cell 
contact, MSCs and PBMCs were cultured using a transwell co-culture system. Adherent 
and spheroid MSCs were co-cultured with PBMCs at MSC:PBMC ratios found to inhibit 
T-cell proliferation (1:3 MSC:PBMC for adherent MSCs, 3:1 MSC:PBMC for spheroid 
MSCs). As expected, physical separation of adherent MSCs and PBMCs significantly 
reduced the ability of MSCs to suppress T-cell proliferation (Figure 3.12A; ~11% Ki67+ 
T-cells in direct co-culture compared to ~35% Ki67+ T-cells in transwell co-cultures, p = 
0.002) and suppress IFN-γ expression (Figure 3.12B; ~1.6 ng/mL IFN-γ in direct co-culture 
compared to ~7.0 ng/mL IFN-γ in transwell co-culture, p < 0.001). Similarly, transwell co-
culture also reduced the ability of MSC spheroids to suppress T-cell proliferation (~35% 
Ki67+ T-cells in direct co-culture compared to ~75% Ki67+ T-cells in transwell co-cultures, 
p = 0.022) and IFN-γ expression (~1.7 ng/mL IFN-γ in direct co-culture compared to ~5.5 
ng/mL IFN-γ in transwell co-culture, p < 0.001). Altogether, direct cell-contact plays a role 
in both adherent and spheroid MSC suppression of T-cell proliferation yet both adherent 






Figure 3.12. Transwell co-culture reduces the ability of both adherent and spheroid MSCs to 
suppress T-cell proliferation. (A) Co-culture of CD3/CD28 activated PBMCs with adherent and 
spheroid MSCs in transwell co-culture reduced the ability of MSCs to suppress T-cell proliferation 
as determined by percentage of Ki67+ T-cells. (B). Similarly, transwell co-culture reduced the 
ability of MSCs to suppress T-cell expression of the effector cytokine IFN-γ. * indicates p < 0.05 




These results demonstrate that 3D aggregation of MSCs increases endogenous 
immunomodulatory factor secretion that is dependent on medium composition and pro-
inflammatory cytokine treatments. Furthermore, pre-conditioning MSCs via culture 
conditions can enhance inherent secretory properties and improve the suppression of pro-
inflammatory macrophages. In medium supplemented with FBS, MSCs cultured as 500-
cell spheroids secreted greater levels of the immunomodulatory factors PGE2, TGF-β1 and 
IL-6 compared to monolayer cultures. Interestingly, 200- and 1000-cell spheroids did not 
yield significantly increased secretion of TGF-β1 and IL-6 compared to monolayer 
cultures, which may be due to differences in the number or distribution of cell-cell contacts 
58 
 
in 200-cell spheroids or 1000-cell spheroids. However, striking differences in cell 
phenotypes of MSCs cultured as spheroids were observed in FBS (no cell growth, high 
paracrine secretion) and MesenCult (significant cell growth, low paracrine secretion) 
culture mediums (Figure 3.13). PGE2 and IL-6 secretion as well as IDO activity were 
increased by cytokine treatment in FBS medium, whereas only IL-6 secretion was induced 
by cytokine treatment in MesenCult medium. Upon transferring MSC spheroids to 
activated macrophage co-cultures, both FBS and MesenCult culture media altered the 
immunomodulatory capacity of MSCs pre-conditioned with the pro-inflammatory 
cytokines IFN-γ and TNF-α, but did not affect the immunomodulatory capacity of 
untreated spheroids. Pre-treatment of MSCs with both cytokines in FBS medium increased 
suppression of macrophage TNF-α secretion compared to monolayer and untreated 
spheroid cultures while pre-treatment of MSCs in MesenCult did not increase suppression 
of macrophage TNF-α secretion compared to untreated spheroids. Altogether, these results 
suggest that environmental parameters, including spheroid culture, media composition, and 
cytokine conditioning, can modulate the secretion of anti-inflammatory molecules by 
MSCs.  
 
Three dimensional aggregation of MSCs enhanced secretion of immunomodulatory factors 
and suppression of activated macrophage TNF-α secretion, similar to previously published 
results [174]. However, previous studies reported enhanced secretion of the 
immunomodulatory factors PGE2 and TSG-6, from much larger MSC aggregates 
comprised of approximately 25,000 cells per aggregate [174]. Since oxygen gradients arise 
in cell aggregates above a critical size threshold (~300 µm diameter) [182], oxygen 
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availability to cells within spheroids may differ significantly between aggregates grown 
above and below this size threshold. Furthermore, adipose derived stromal cells (ADSCs) 
cultured as spheroids with diameters greater than 100 µm expressed more hypoxia induced 
survival factors such as hypoxia-inducible factor (HIF)-1α and paracrine factors, such as 
HGF and vascular endothelial growth factor (VEGF), compared to monolayer cultures 
[169]. Additionally, hypoxic culture of ADSCs enhanced the suppression of CD4+ and 
CD8+ T cell proliferation but did not affect the expression of IDO [193]. Therefore, oxygen 
transport limitations may play a role in the regulation of MSC immunomodulatory factor 
secretion in spheroid cultures. In large MSC aggregates, enhanced immunomodulation was 
attributed to MSCs responding to signals released from stressed and apoptotic cells induced 
by aggregation [174]. The authors demonstrated that caspase, NFκB, and IL1 signaling, 
which are involved in mediating the cellular stress response, were involved in PGE2 
secretion from MSC aggregates [174, 175]. However, MSC spheroids examined in this 
current study contained approximately 1,000 or fewer cells per aggregate and thus the 
largest sized aggregates remained below the threshold for limited oxygen transport. 
Furthermore, formation of necrotic regions in the interior of cell aggregates was not 
observed in any of the histological analyses performed in this study. Therefore, the increase 
in immunomodulatory factor expression observed in MSC spheroids with fewer than 1,000 
cells per spheroid may be due to another mechanism other than hypoxia induced stress. For 
example, increased MSC immunomodulatory activity may be due to increased cell contact 
dependent signaling and intercellular adhesions, which have been implicated in the 
enhanced paracrine activity of MSC aggregates. Contact-dependent Notch signaling has 
also been demonstrated to play a role in mediating MSC secretion of PGE2, as well as 
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suppression of macrophage TNF-α secretion [175]. Additionally, 3D aggregation of MSCs 
was found to upregulate E-cadherin expression, which in turn was responsible for enhanced 
vascular endothelial growth factor (VEGF) secretion via the ERK/AKT signaling pathway 
[159]. Thus, although the mechanism(s) responsible for increased immunomodulatory 
factor expression by MSCs cultured as 3D spheroids remains unclear, aggregation of MSCs 
represents a rather simple, yet effective means of enhancing the immunomodulatory 
potential of MSCs prior to transplantation.  
 
 
Figure 3.13. Heatmap visualization of MSC growth, cytokine secretion, and activated mΦ 
suppression. Hierarchical clustering illustrated the differences in MSC phenotype between cells 
cultured as monolayers or spheroids in either FBS or MesenCult media. Spheroids cultured in 
FBS medium displayed greater immunomodulatory factor expression and activated mΦ 
suppression but decreased cell growth. Alternatively, spheroids cultured in MesenCult media 
and monolayers cultured in FBS clustered together and displayed lower immunomodulatory 
factor expression and activated mΦ suppression but increased cell growth. Finally, cytokine 
treatment tended to enhance immunomodulatory factor expression and macrophage suppression 
while decreasing cell growth. NT = no treatment; T = 10 ng/mL TNF-α treatment; I + T = 5 
ng/mL IFN-γ and 5 ng/mL TNF-α treatment. 
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The development of culture media with defined components and/or xenogen-free 
supplements, such as human platelet lysate (HPL), are desired for MSC therapies in order 
to reduce the inherent batch-to-batch variability of FBS and address safety concerns about 
the potential transfer of animal-derived proteins as well as zoonotic agents [202]. However, 
few studies to date have examined the effects of media composition on subsequent MSC 
immunomodulation. In this dissertation, culture media was found to drastically influence 
immunomodulatory paracrine factor secretion. Culture in MEMα supplemented with FBS 
induced paracrine factor secretion but limited MSC growth in spheroids, whereas culture 
in MesenCult medium suppressed immunomodulatory paracrine factor secretion but 
promoted MSC growth in spheroids. Compared to MSC spheroids cultured with FBS-
containing media, addition of pro-inflammatory cytokines to MesenCult medium did not 
pre-condition spheroids to secrete increased PGE2 or increase IDO activity and did not 
enhance the suppression of TNF-α secretion by activated macrophages. Similar to our 
results, MSCs expanded as adherent monolayers in medium supplemented with HPL 
displayed enhanced proliferation and expansion potential, yet decreased PGE2 production 
and impaired inhibition of T-cell proliferation [203]. In addition, although MSCs cultured 
in FBS or HPL media inhibited T-cell proliferation comparably in mixed lymphocyte 
reactions, inhibition of B cell proliferation was greater when co-cultured with MSCs 
expanded with FBS instead of HPL [204]. Furthermore, differences in the cytokine 
secretion of lymphocytes were noted in co-cultures with MSCs expanded in either FBS- or 
HPL-containing media. Altogether, these studies demonstrate that the soluble components 
of MSC culture medium can significantly impact immunomodulatory function. Therefore, 
a systematic determination of appropriate culture media that enhances the paracrine 
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secretion capabilities of MSCs may be critical for stimulating immunomodulatory 
phenotypes in MSC cultures for translational applications. Recently, several groups have 
taken this approach to begin to systematically determine chemically-defined xeno-free 
culture medium to culture MSC spheroids and stimulate immunomodulatory factor 
expression [205, 206].  
 
The addition of the pro-inflammatory cytokines IFN-γ and TNF-α to FBS culture media 
further enhanced immunomodulatory paracrine factor secretion and suppression of 
activated macrophages by MSC spheroids, demonstrating that 3D aggregation and 
cytokine treatment can work synergistically to enhance MSC immunomodulation. IFN-γ 
and TNF-α are critical components of the inflammatory milieu, capable of stimulating 
MSC immunomodulatory paracrine factor secretion. PGE2 secretion by adherent mouse 
MSCs can be induced by IFN-γ and TNF-α treatment [32, 35]. PGE2 aids in suppression 
of T-cell activation and proliferation [60, 119], modulates CD4+ T-cell differentiation [81], 
and regulates macrophage phenotypes by suppression of M1 and induction of M2 
phenotypes [70, 79]. PGE2 secretion from MSC spheroids appears to be more responsive 
to TNF-α treatment since treatment with 10 ng/mL TNF-α alone resulted in greater PGE2 
secretion compared to untreated and IFN-γ-treated spheroids, whereas treatment with 5 
ng/mL of both IFN-γ and TNF-α did not significantly alter PGE2 secretion compared to 
untreated or TNF-α-treated spheroids. IFN-γ induces human MSC expression of IDO [67, 
82, 83], which inhibits proliferation of T- and natural killer (NK) cell proliferation through 
tryptophan depletion [77, 116], induces naive CD4+CD25- T-cell maturation into 
CD4+CD25+FOXP3+ Tregs [138], and can aid in the induction of immune tolerance [139]. 
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Additionally, IDO-derived tryptophan metabolites, including kynurenine, can suppress T-
cell proliferation [117]. MSC spheroids were responsive to IFN-γ and had greater IDO 
expression compared to adherent cultures. In MSC spheroid cultures, stimulation with IFN-
γ and TNF-α in FBS culture media resulted in the greatest secretion of IL-6. Secretion of 
IL-6 has been implicated in regulating maturation of dendritic cell (DC) populations by 
suppressing monocyte differentiation [62]. Additionally, mouse MSC suppression of 
inflammation in an arthritis model was primarily mediated by IL-6 dependent secretion of 
PGE2, suggesting that increased IL-6 secretion may be a mechanism by which MSCs are 
self-activated to secrete PGE2 that can impart other immunomodulatory effects [135]. In 
contrast to the increases of PGE2, IDO, and IL-6, secretion of TGFβ1, which has been 
demonstrated to be involved in inducing Treg phenotypes [61, 140, 141], was not enhanced 
by cytokine treatment of spheroid cultures in either FBS or MesenCult media. Taken 
together, while MSC spheroid formation increased the secretion of several 
immunomodulatory factors, pro-inflammatory cytokine treatment could further augment 
secretion of several paracrine factors responsible for MSC immunomodulation.  
 
Several in vitro pre-conditioning strategies have been explored as a means to stimulate 
MSCs to elicit a desired response when transplanted in vivo. For example, hypoxic 
conditioning of MSCs has frequently been used to stimulate angiogenic paracrine factor 
production for MSC-based treatments for ischemia [207–209]. Additionally, there is some 
evidence that pre-conditioning MSCs with activating signals can enhance MSC 
immunomodulation as pre-treatment of adherent MSCs with IFN-γ and TNF-α [131] or 
TLR3 and TLR4 ligands [34,35] can regulate MSC immunomodulation in vitro. In our 
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study, aggregation of MSCs and pre-treatment with IFN-γ and TNF-α in FBS medium, but 
not MesenCult medium, enhanced the suppression of macrophage TNF-α secretion. Pre-
conditioning may therefore provide a potential means of enhancing MSC immunotherapies 
by priming the cells to secrete immunomodulatory paracrine factors immediately upon 
transplantation. However, the success of this strategy to enhance MSC immunomodulatory 
paracrine factor secretion may be dependent on specific culture parameters, such as media 
composition and cell culture format (i.e. spheroid culture).  
 
Interestingly, despite the increased expression of several immunomodulatory factors 
known to be involved in MSC-mediated suppression of T-cells, IFN-γ pre-treated MSC 
spheroids displayed a reduced ability to suppress T-cell proliferation and activation 
compared to an equivalent amount of adherent MSCs. While previous studies have found 
a strong correlation between MSC expression of IDO and the ability to inhibit T-cell 
proliferation [78], this correlation was not consistent with MSC spheroid cultures. The 
difference in surface area between and adherent and spheroid cultures was initially 
hypothesized to reduce the efficacy of MSC suppression of T-cells due to reduced contact 
with immunosuppressive membrane-bound ligands such as PDL1, PDL2, or FasL [142, 
201]. However, physical separation of MSCs from PBMCs using a transwell co-culture 
significantly reduced, but did not eliminate MSC suppression of T-cell proliferation of both 
adherent and spheroid cultures. Therefore, other mechanisms independent from direct cell-
cell contact are likely responsible for the observed differences in MSC suppression of T-
cells when MSCs are cultured as adherent monolayers or aggregated spheroids. 
Interestingly, other groups have found that aggregated MSCs self-activate caspase-
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dependent IL-1 signaling [175]. The expression of IL-1α and IL-1β by MSCs in response 
to aggregation resulted in downstream autocrine signaling that stimulated MSC expression 
of the anti-inflammatory factors PGE2 and TSG-6. While the authors found the 
concentrations of IL-1α and IL-1β to be relatively low (4-10 pg/mL in hanging drops), 
expression of IL-1 or other inflammatory cytokines by MSCs in response to aggregation 
could potentially reduce the effectiveness of MSC suppression of T-cell proliferation in 
vitro. However, despite the reduced capacity of MSC spheroids to suppress T-cells in vitro, 
aggregation of MSCs after intravenous or intraperitoneal injection does not impair the 
immunomodulatory capabilities of transplanted MSCs [173, 174, 210]. Ultimately, a 
broader understanding of the anti- and pro-inflammatory factors expressed by MSCs 
through transcriptomic or proteomic analysis may provide better insight into the response 
MSCs have to not only aggregation but cytokine treatment as well. These broader analyses 
could aid in elucidating the mechanisms regulating MSC immunomodulatory function in 
vitro to better inform therapeutic strategies aimed at using MSCs to modulate immune 
responses in vivo. 
 
3.5 CONCLUSION 
MSCs offer a promising approach for cell-based therapies of inflammatory and immune 
diseases due to their inherent ability to modulate responses of cell populations involved in 
both innate and adaptive immunity. While MSC-based treatments in animal models and 
clinical trials of inflammatory and immune diseases have yielded variable results, the 
development of robust translatable strategies to enhance MSC immunomodulation may 
provide a simple means of improving such therapies and enable translation to the clinical 
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setting. The results of this study demonstrate that 3D aggregation enhances MSC 
immunomodulatory factor secretion and that the biochemical medium composition, 
including the presence of pro-inflammatory cytokines, can additionally increase 
endogenous MSC immunomodulatory properties. More broadly, pre-conditioning MSCs 
via environmental parameters can enhance inherent secretory properties that may improve 
the potency and efficacy of MSC-based therapies for the treatment of inflammatory 










OSTEOPROTEGERIN IS DIFFERENTIALLY EXPRESSED BETWEEN ADHERENT 




Current mesenchymal stem/stromal cell (MSC) therapeutic strategies aim to use MSC-
secreted soluble paracrine factors to modulate immune responses and promote tissue repair. 
As previously discussed, the quantity of paracrine factors secreted by MSCs, such as PGE2, 
TGF-β1, and IL-6, can be enhanced by aggregation of MSCs into 3D spheroids [211]. 
However, the profile of paracrine factors expressed by MSCs is also altered in spheroid 
culture; expression of specific factors can be entirely induced or inhibited by aggregation 
of MSCs. For example, osteoprotegerin (OPG) is a secreted soluble factor that is highly 
differentially expressed between adherent and spheroid cultured MSCs (see Figure 4.1). 
OPG has been studied extensively in bone biology and plays a critical role in bone 
homeostasis by inhibiting osteoclast differentiation and maturation, thereby maintaining 
the balance of bone matrix deposition and resorption [212]. However, OPG has not been 
extensively explored in the context of the immune system, and the close relationship 
between osteoclasts and macrophages suggests that MSC-expressed OPG may also play a 
role in modulation of monocyte/macrophage populations and thereby contribute to the 




OPG (also known as TNFRSF11B) is a secreted 60 kDa protein and is a member of the 
tumor necrosis factor (TNF) receptor superfamily [213]. OPG acts as a soluble decoy 
receptor for the Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL). Binding 
of OPG to RANKL inhibits the interaction between RANKL and its receptor, RANK, 
thereby inhibiting downstream activation of NF-κB and other transcription factors [214]. 
In bone, osteoclast generation from myeloid hematopoietic precursor cells is dependent on 
RANKL as well as the growth factor M-CSF [215, 216]. M-CSF stimulates osteoclast 
precursor survival and induces osteoclast precursor expression of RANK. Subsequent 
stimulation of osteoclast precursors with RANKL, typically by osteocytes and bone 
marrow stromal cells under homeostatic conditions [217, 218], results in expression of the 
transcription factors c-fos [219] and NFATc1/NFAT2 [220] and induces expression of 
genes necessary for osteoclast function including tartrate-resistant acid phosphatase 
(TRAP), cathepsin-K, calcitonin receptor, and c-myc [221]. Thus, OPG production, 
primarily by bone marrow stromal cells, regulates the generation of osteoclasts by binding 
to RANKL and inhibiting the RANK/RANKL interaction. Knockout of OPG in mice 
models results in the development of osteoporosis [222], illustrating the critical role of 
OPG in regulating the balance of osteoclast resorptive activity.  
 
Outside its role as a critical mediator of bone homeostasis, the RANK/RANKL/OPG 
signaling axis has also been demonstrated to play a role in the immune system. RANKL is 
expressed by T-cells, B-cells, and γδT-cells while RANK is expressed by DCs, 
macrophages, and monocytes [223]. Additionally, OPG expression can be induced in B 
cells and DCs in response to CD40L [224]. RANKL expressed by T-cells promotes the 
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survival and function of DCs during immune responses [225–227] and stimulation of DCs 
with RANKL in vitro enhances cell survival, cytokine production, and antigen presentation 
[228]. Furthermore, dendritic cells in OPG-null mice are more effective in stimulating 
allogeneic T-cells [229] demonstrating an important two-way communication between T-
cell and DCs through RANK/RANKL/OPG signaling. In addition to interactions with DCs, 
RANKL expression on T-cells can also induce differentiation of osteoclasts from 
monocytes [230]. Under inflammatory conditions, the cytokines IL-1, TNF-α, and IL-6 
upregulate expression of RANKL in T-cells resulting in increased differentiation of 
osteoclasts and ultimately osteoporosis [231]. Altogether, interactions between RANKL 
expressed by lymphoid cells (i.e. T-cells) and RANK expressed by myeloid cells (i.e. 
DCs/monocytes) increase the immune response of these cell populations. Interestingly, 
MSC expression of OPG has not previously been investigated in relation to 
RANK/RANKL signaling between T-cells and myeloid cell populations and could 
potentially be a mechanism by which MSCs suppress immune responses. 
 
Because of the multiple roles OPG plays in both maintaining bone homeostasis by 
regulating osteoclast differentiation and regulating immune responses, we sought to 
evaluate the functional role OPG expression plays in MSC suppression of T-cell 
proliferation and osteoclast differentiation in vitro. Previous studies have demonstrated that 
OPG expressed by adherent cultures of MSCs can inhibit osteoclast differentiation and 
maturation in vitro but no work has investigated the effect of aggregated MSCs on 
osteoclast differentiation [232]. Furthermore, the mechanisms governing OPG expression 
by MSCs in adherent and spheroid cultures is unclear. In osteoblasts, OPG expression is 
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regulated by a wide array of signaling molecules. For example, TGF-β, IL-1, IL-6, TNF-
α, estrogen, and Wnt ligands all upregulate OPG expression while PGE2 and 
glucocorticoids downregulate expression [233]. Wnt signaling, in particular, appears to 
play a critical role in mediating OPG expression by osteoblasts and osteoclast activity in 
vivo [234]. Activation of the canonical Wnt pathway results in dephosphorylation of β-
catenin and subsequent nuclear translocation where β-catenin, along with T-cell factor 
(Tcf) and lymphoid-enhancing factor (Lef), can regulate transcription of target genes. 
However, β-catenin localization is also mediated by cell-cell cadherin interactions where 
it can be sequestered at adherens junctions. Since cadherins play a critical role in mediating 
self-aggregation of MSC spheroids [158, 159], we hypothesized that β-catenin is 
sequestered to adherens junctions at the cell membrane in spheroid cultures thereby 
inhibiting nuclear translocation of β-catenin and downstream transcription of OPG. 
Altogether, a better understanding of the functional role of MSC paracrine factors, such as 
OPG, and the mechanisms that regulate their expression may provide insight into new 
applications for MSC paracrine-based therapies and approaches to engineer systems to 
modulate MSC paracrine activity.   
 
4.2 METHODS AND MATERIALS 
4.2.1 MSC Expansion and Culture 
Human bone marrow-derived MSCs were obtained from both Texas A&M Institute for 
Regenerative Medicine and RoosterBio Inc., and expanded according to the manufacturer’s 
protocols as previously described (See Chapter 3). MSCs were expanded from 3 donors (1 
Texas A&M Institute for Regenerative Medicine, 2 RoosterBio) and were passaged with 
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0.25% Trypsin and 1 mM EDTA upon reaching 80% confluency. To generate adherent and 
spheroid MSC cultures, MSCs were either plated overnight on tissue culture treated plastic 
or aggregated into 500-cell spheroids by addition of MSCs to 400 µm agarose microwells, 
as described previously (See Chapter 3).  
 
4.2.2 Antibody Cytokine Arrays and Analysis 
In order to more broadly examine MSC cytokine expression, 80 target cytokine antibody 
arrays were purchased from AbCam (ab133998; Abcam, Cambridge, UK) (species listed 
in Table 4.1). To generate conditioned medium for cytokine analysis, 300,000 adherent or 
spheroid MSCs were cultured for four days in 10 mL of RPMI-1640 medium supplemented 
with 10% FBS, 1% L-Glutamine, and 1% Penicillin/Streptomycin. Samples of conditioned 
medium were stored at -20 ºC prior to cytokine detection with antibody arrays. Arrays were 
developed according to the manufacturer's protocol using undiluted media samples and 
subsequently imaged using a Li-Cor Odyssey Fc imager equipped with a CCD camera. 
Semi-quantitative cytokine expression levels were determined by densitometry analysis 
using ImageJ software.  
 
OPG and RANKL expression was also analyzed directly through qRT-PCR and ELISA 
analysis to quantify gene and protein expression, respectively. Adherent and spheroid 
MSCs were lysed 24 hours after plating and aggregation and RNA was collected for qRT-
PCR, as previously described. Forward and reverse primers for OPG (Forward: 
GCTAACCTCACCTTCGAGCA; Reverse: TCAGGATCTGGTCACTGGGT), RANKL 
(Forward: CCAGGTTGTCTGCAGCGT; Reverse: TGACTCTCCAGAGTTGTGTCT), 
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and 18S (Forward: CTTCCACAGGAGGCCTACAC; Reverse: 
CTTCGGCCCACACCCTTAAT) were designed using Primer-Blast 
(www.ncbi.nlm.nih.gov) and purchased from Invitrogen (Carlsbad, CA). OPG and RANKL 
gene expression was calculated with respect to untreated MSCs and normalized to 18S 
expression using the ΔΔCT method. Additionally, the amount of secreted OPG and soluble 
RANKL was examined in adherent and spheroid conditioned medium after 4 days of 
culture via ELISA (R&D), according to the manufacturer’s protocol. Finally, to examine 
the dynamics of OPG expression, MSCs were cultured as adherent monolayers, spheroids 
in suspension culture, spheroids dissociated to a single cell suspension with 0.25% Trypsin 
and 1mM EDTA and plated on tissue culture plastic, or spheroids plated directly onto tissue 
culture plastic. Medium was sampled every day for four days and secreted OPG was 
quantified using an ELISA.  
 





4.2.3 Peripheral Blood Mononuclear Cell Co-culture Assays  
PBMCs were isolated from whole blood obtained with IRB approval from healthy 
volunteers via Ficoll (Sigma-Aldrich) density gradient separation. Isolated PBMCs were 
cultured at 400,000 cells per well in 24-well plates with adherent and spheroid MSCs 
spheroids at a 3:1 MSCs-to-PBMC ratios. At the start of co-culture, 0.2 μg/mL of anti-
human CD3 and CD28 antibodies were added to the co-cultures to induce T-cell 
proliferation and activation. Additionally, a range of concentrations (0.1-2.5 µg/mL) of an 
OPG blocking antibody (R&D) was added to a subset of co-cultures with adherent MSCs. 
Furthermore, a range of soluble recombinant OPG (20-500 ng/mL OPG; R&D) was added 
to a subset of spheroid cultures. For all PBMC co-cultures, T-cell proliferation was 
assessed 4 days later by flow cytometry analysis of CD3 (FITC-conjugated mouse anti-
CD3 IgG; BD Biosciences) and Ki67 (PE-conjugated mouse anti-Ki67 IgG; BD 
Biosciences) double positive stained cells. T-cell activation was also assessed after 4 days 
by measuring the amount of IFN-γ in co-culture spent media supernatants by ELISA 
(R&D).  
 
4.2.4 Osteoclast Differentiation and Analysis 
Osteoclasts were differentiated according to previously published protocols. Briefly, 5x105 
PBMCs per well were plated in 96-well plates in MEMα medium supplemented in 10% 
FBS with 1% Pen/Strep and 1% L-Glutamine. After 1.5 hours to allow for attachment of 
monocytes, wells were washed three times with PBS to remove non-adherent cells. Fresh 
MEMα medium or conditioned medium collected from adherent or spheroid MSC cultures 
was then added to monocytes. For all osteoclast differentiations, recombinant human M-
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CSF (25 ng/mL; R&D) and RANKL (50 ng/mL; Santa Cruz Biotech) were supplemented 
into basal MEMα medium, adherent conditioned medium, and spheroid conditioned 
medium. Additionally, where indicated, 100 ng/mL of recombinant human OPG (R&D) 
was added to either basal MEM medium or spheroid conditioned medium. Monocytes were 
cultured for two weeks to allow for osteoclast differentiation with medium exchanged 
every 3 days with fresh M-CSF, RANKL, and OPG. 
 
To evaluate OPG differentiation, cells were fixed with 4% paraformaldehyde after 14 days 
of differentiation. A subset of fixed cells were stained with 1 µM DAPI and 1 µM 
phalloidin for 30 minutes to examine cell morphology and quantify the number of 
multinucleated cells. Fluorescent imaging of DAPI and phalloidin stained osteoclasts were 
acquired using an inverted Axio Observer Zeiss microscope. Additionally, a subset of fixed 
osteoclasts were stained for TRAP expression using a TRAP staining kit (Sigma) according 
to the manufacturer's instructions. Briefly, fixed cells were incubated with a solution of 
Naphthol AS-Bl phosphates, Fast Garnet GBC, and L-tartrate. Naphthol AS-Bl is released 
by acid phosphates resistant to tartrate and combine with Fast Garnet GBC to form 
insoluble maroon dye deposits where TRAP is expressed. TRAP stained cells were also 
counterstained for 2 minutes with Gill's Hematoxylin solution (Newcomer Supply, 
Middleton, WI). TRAP and hematoxylin stained cells were imaged with an upright Axio 
Imager A2 Zeiss microscope. 
 
In order to evaluate functional activity of osteoclasts differentiated in the presence of MSC 
soluble factors, bone resorption activity was measured by differentiating osteoclasts on 
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fluoresceinated calcium phosphate-coated plates (CosmoBio, Tokyo, Japan). Seven days 
after initial plating of cells, medium from plates was sampled every other day and the 
fluorescent intensity at 488nm was measured using a SpectraMax i3 plate reader to 
determine the amount of fluorescein released from the calcium-phosphate coating by 
osteoclast resorptive activity. Fluorescence intensity at each day was normalized to 
medium samples from control wells with no cells. After 14 days of differentiation, cells 
were removed from the plates using a 5% bleach solution. Phase contrast images of the 
remaining calcium-phosphate coating were obtained using an upright Axio Imager A2 
Zeiss microscope. Resorption pit area was quantified using ImageJ software.  
 
4.2.5 Evaluation of β-catenin Localization in Adherent and Spheroid MSC Cultures 
For determination of β-catenin localization, MSCs were plated at 10,000 cells/cm2 
(equivalent to density used in monolayer cultures) or aggregated into 500-cell spheroids. 
After 18 hours to allow for cell attachment to plates or aggregation of spheroids, MSCs 
were fixed with 4% paraformaldehyde. Cells were stained with a mouse anti-human β-
catenin primary antibody (BD Bioscience) and donkey anti-mouse IgG Alex Fluor 488 
conjugated secondary antibody (Life Technologies). Cells were subsequently stained with 
Hoechst (1:100 dilution) and CellMask (1:1000 dilution) to label nuclei and cell 
membranes, respectively. For adherent MSCs, fluorescent microscopy images were 
acquired with an inverted Zeiss Axio Observer microscope. For spheroid MSCs, 3D 
fluorescent images were acquired using a Zeiss light sheet microscope. 
 
4.2.6 Statistical Analysis 
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Statistical analyses were performed using GraphPad Prism 6 software (Graphpad 
Software). Data are presented as mean ± standard error of the mean. Comparisons between 
multiple experimental groups were conducted using analysis of variance (ANOVA) after 
Box-Cox transformation to ensure normal distribution. Tukey post hoc analysis was then 
used to determine statistically significant differences between experimental groups, with a 
p-value < 0.05 indicating significance.  
 
Figure 4.1. Cytokine array analysis of adherent and spheroid MSC paracrine factors reveals 
differential expression of OPG. (A) Conditioned medium from adherent and spheroid MSCs from 
three different donors displayed similar levels of cytokine expression with the exception of OPG 
(denoted by red circles). (B) The average OPG expression across all donors was the only cytokine 
significantly different in adherent and spheroid MSC medium, as determined by densitometry 




4.3.1 Osteoprotegerin is downregulated upon aggregation of MSCs  
To examine the differences in paracrine factor expression between MSCs cultured as 
adherent monolayers and spheroids, an antibody array with 80 cytokine targets was used 
to broadly assess MSC cytokine expression. Conditioned medium from MSCs from 3 
different donors cultured as adherent monolayers and as spheroids was collected and 
analyzed on the cytokine arrays (Figure 4.1A). Qualitatively, MSC cytokine expression 
was similar between adherent and spheroid cultures between all three donors. After 
densitometry quantification of spot intensity which is proportional to protein concentration, 
three cytokines were found to differ greater than 2-fold between adherent and spheroid 
conditioned medium (2.9-fold increase in CXCL-1, 2.3-fold increase in GCP-2, and 9.2-
fold decrease in OPG; Figure 4.1B). However, osteoprotegerin (OPG) was the only 
cytokine found to exhibit statistically significant different expression in spheroid culture 
compared to adherent culture (p = 0.004). Furthermore, OPG was the most highly 
expressed cytokine in adherent conditioned medium but almost undetectable in spheroid 
conditioned medium. Because of the striking difference in OPG expression between 
adherent and spheroid cultures, we focused on understanding the functional effects of OPG 
in MSC conditioned medium and the mechanisms that regulate its differential expression 
in adherent and spheroid cultures.  
 
To confirm and more precisely quantify the difference in OPG expression between 
adherent and spheroid MSC cultures, qRT-PCR and ELISAs were used to quantify gene 
and protein expression of OPG, respectively. A 16-fold decrease in OPG gene expression 
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(p < 0.001) was found in spheroid MSC cultures compared to adherent cultures 24 hours 
after plating and aggregation (Figure 4.2A). Since OPG acts as a soluble decoy receptor 
for Receptor Activator of NF-κB Ligand (RANKL) and expression of these two proteins 
are inversely correlated, we also examined expression of RANKL. As expected, RANKL 
gene expression was increased 40-fold in MSC spheroid cultures (p < 0.001). At the protein 
level, aggregation of MSCs resulted in a 200-fold decrease in the OPG concentration in 
MSC spheroid conditioned medium compared to adherent medium (Figure 4.2B). 
However, no soluble RANKL protein could be detected within the conditioned medium, 
suggesting that RANKL remains membrane bound. Finally, the temporal kinetics of OPG 
expression was evaluated in MSC cultures to assess whether OPG expression can be 
recovered in aggregated MSCs after dissociation to single cells and subsequent plating as 
adherent monolayers (Figure 4.2C). Very low levels of OPG were secreted by MSC 
spheroids in suspension culture and OPG was only detectable after 3 days of medium 
conditioning. However, no statistical difference was observed in OPG expression of MSCs 
plated directly from adherent culture or MSCs dissociated from spheroids and plated as 
adherent monolayers, suggesting that loss of OPG expression after aggregation is 
reversible. Furthermore, MSC spheroids that were directly plated as aggregates initially 
had reduced OPG expression compared to adherent MSCs but began to recover OPG 
expression as cells began to spread out from MSC aggregates. Taken together, MSC 
expression of OPG is highly dependent on the physical environment (i.e. 2D or 3D) in 




Figure 4.2. MSCs reversibly lose OPG expression upon aggregation. (A) MSC spheroids have 
significantly decreased OPG gene expression but increased RANKL gene expression after 18 hours 
of aggregation. (B) Similarly, a 200-fold increase in OPG protein could be detected by ELISA in 
adherent conditioned medium compared to spheroid conditioned medium, while no soluble 
RANKL could be detected in the culture medium of adherent or spheroid cultures. (C)  The amount 
of OPG secreted by MSCs plated directly as adherent monolayers or plated from dissociated 
spheroids was not significantly different over 4 days of culture, demonstrating the reversibility of 
MSC OPG expression. * indicates p < 0.05 compared to adherent and spheroid cultures. # indicates 




4.3.2 Osteoprotegerin is not responsible for difference in immunomodulatory activity 
between adherent and spheroid MSCs 
Since spheroid MSCs do not express high levels of OPG and require a greater number of 
cells to suppress T-cell proliferation, we sought to determine if MSC expression of OPG 
was involved in inhibition of T-cell proliferation and activation. To perturb OPG inhibition 
of RANK/RANKL signaling in co-cultures with adherent MSCs, a range of concentrations 
of an OPG-blocking antibody (0.1-2.5 µg/mL; IC50 = 0.15-0.3 µg/mL for neutralization of 
100 ng/mL OPG according to manufacturer) was added to MSC-PBMC co-cultures (1:3 
MSC:PBMC ratio). However, supplementation of the OPG-blocking antibody into culture 
did not inhibit the ability of adherent MSCs to suppress T-cell proliferation at any of the 
concentrations tested (Figure 4.3A; ~20% Ki67+ T-cells at each concentration of Ab). 
Additionally, T-cell IFN-γ expression was not significantly different between adherent 
MSC co-cultures with any concentration of blocking antibody (Figure 4.3B). 
Supplementation of a range of concentrations of recombinant OPG (20-500 ng/mL) into 
medium of MS-PBMC co-cultures (1:3 MSC:PBMC ratio) also did not restore the ability 
of MSCs to suppress T-cell proliferation at this ratio of MSCs-to-PBMCs (Figure 4.3C; 
~65% Ki67+ T-cells at each concentration of supplemented OPG). Likewise, no difference 
in T-cell expression of IFN-γ was observed in MSC spheroid co-cultures supplemented 
with any concentration of OPG (Figure 4.3D). Altogether, despite a significant difference 
in the expression of OPG by adherent and spheroid MSC cultures, OPG does not appear to 






Figure 4.3. OPG does not play a role in MSC suppression of T-cell proliferation and 
activation in PBMC co-cultures. (A) Addition of an OPG-blocking antibody into co-cultures of 
PBMCs and adherent MSCs (1:3 MSC-to-PBMC ratio) did not significantly impair MSC 
suppression of T-cell proliferation. (B) Furthermore, MSC suppression of T-cell IFN-γ expression 
was not significantly impacted by addition of the OPG blocking antibody. (C) Supplementation of 
recombinant soluble OPG to co-cultures of PBMCs with spheroid MSCs (1:3 MSC-to-PBMC ratio) 
also did not recover the ability of MSCs to suppress T-cell proliferation at this MSC-to-PBMC 
ratio. (D) Similarly, IFN-γ expression was not significantly different with supplementation of OPG 




4.3.3 Adherent and spheroid MSC paracrine factors differentially regulate osteoclast-
precursor differentiation  
Since RANKL signaling is critical for the differentiation and maturation of osteoclasts 
from osteoclast-precursors and OPG inhibits this process, we next examined the effect of 
MSC paracrine factors from adherent and spheroid cultures on osteoclast differentiation. 
The adherent fraction of PBMCs was cultured in the presence of RANKL and M-CSF in 
either base medium, adherent MSC conditioned medium, or spheroid MSC conditioned 
medium to stimulate osteoclast differentiation. After 15 days of culture, cells were 
analyzed by morphology and colorimetric staining for the expression of the osteoclast 
marker TRAP. After a week of culture, large multinucleated cells could be observed within 
cultures containing little or no OPG (spheroid MSC conditioned medium and base medium, 
respectively) (Figure 4.4B). However, these large multinucleated cells were not observed 
in adherent MSC conditioned medium containing approximately 100 ng/mL OPG. 
Furthermore, a significantly greater number of multinucleated cells was found within 
cultures with spheroid MSC conditioned medium compared to those in basal medium 
(Figure 4.4C; 8-fold increase in multinucleated cells, p = 0.002). Similarly, striking 
differences in TRAP staining were observed between spheroid MSC conditioned medium 
and adherent MSC conditioned medium (Figure 4.4D). Both basal medium and spheroid 
MSC conditioned medium induced TRAP+ cells (~15 and ~260 TRAP+ cells per well, 
respectively) whereas few TRAP+ cells could be observed in cultures in adherent MSC 
medium (Figure 4.4E). Thus, spheroid MSC conditioned medium is permissive for or 
enhances osteoclast differentiation whereas adherent MSC conditioned medium is 




Figure 4.4. Adherent MSCs suppress whereas spheroid MSCs enhance osteoclast 
differentiation. (A) Large cells, morphologically resembling osteoclasts, could be seen in basal 
medium and MSC spheroid conditioned medium supplemented with M-CSF and RANKL after 15 
days of culture. * indicates osteoclast-like cells. Scale bar = 100 µm (B) Furthermore, these 
osteoclast-like cells were found to be multinucleated after staining of nuclei and actin filaments. 
Scale bar = 200 µm (C) A significantly greater number of multinucleated cells were found in 
cultures with spheroid conditioned medium compared to basal medium while no multinucleated 
cells were observed in cultures with adherent conditioned medium (D) Finally, the large 
multinucleated cells in basal and spheroid conditioned medium stained positively for TRAP.  Scale 
bar = 2 mm (E) Again, a significantly greater number of TRAP+ cells was observed in spheroid 
conditioned medium compared to basal medium or adherent conditioned medium. * indicates p < 
0.05 between groups denoted by bar. 
 
 
In order to evaluate functional activity of osteoclasts differentiated in the presence of 
adherent or spheroid MSC conditioned medium, the adherent fraction of PBMCs was 
cultured on fluoresceinated calcium phosphate coated plates for 15 days. Over the course 
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of differentiation, medium samples were taken to evaluate fluorescence intensity in order 
to determine resorption activity of differentiated osteoclasts. An increase in fluorescence 
intensity over baseline in spent media from osteoclast differentiation cultures could first be 
detected after 11 days in cultures in spheroid conditioned medium and basal medium, and 
continued to increase over the 15 days of culture (Figure 4.5A). Furthermore, the 
fluorescence intensity of culture medium was 1.6-, and 1.5- greater in cultures with MSC 
spheroid conditioned medium compared to basal medium on days 13 and 15, indicating 
more resorption activity of osteoclasts differentiated in the presence of MSC spheroid 
paracrine factors (p = 0.01 and 0.002, respectively). Finally, fluorescence intensity did not 
increase over baseline in cultures with adherent MSC conditioned medium indicating the 
lack of functioning osteoclasts in these cultures. Similarly, resorption pits were evident in 
cultures in basal medium and spheroid MSC conditioned medium after 15 days of culture 
whereas no resorption pits were observed in cultures with adherent MSC conditioned 
medium (Figure 4.5B). Furthermore, differentiation of osteoclasts in spheroid MSC 
conditioned medium or basal medium resulted in significantly greater resorption pit area 
compared to culture in adherent MSC conditioned media (Figure 4.5C; 35% and 20% 
resorption pit area, respectively, compared to 0% in adherent MSC conditioned medium). 
Altogether, M-CSF- and RANKL-induced osteoclast differentiation and maturation was 
enhanced in spheroid MSC conditioned medium whereas culture in adherent MSC 




Figure 4.5. MSC spheroids promote osteoclast differentiation and resorption activity. (A) A 
greater amount of calcium phosphate resorption was observed in cultures differentiated in spheroid 
conditioned medium compared to basal medium, as indicated by an increase in fluorescein in 
culture medium released from calcium phosphate coatings by mature osteoclasts. (B) Resorption 
pits in the calcium phosphate coating could be observed from cells differentiated in basal medium 
or spheroid conditioned medium whereas no pits were observed in adherent conditioned medium 
cultures. (C) However, no significant difference was observed in resorption pit area between basal 
and spheroid conditioned medium. * indicates p < 0.05 compared to adherent conditioned medium 









4.3.4 Differential expression of OPG mediates osteoclast-precursor response to MSC 
paracrine factors 
Since OPG expression is drastically decreased in MSC spheroid medium, we sought to 
determine if restoration of OPG levels in MSC conditioned medium inhibited the ability of 
MSC spheroid conditioned medium to enhance osteoclast differentiation. Supplementation 
of OPG at an equivalent level found in adherent conditioned medium (~100ng/mL soluble 
OPG) effectively eliminated the capability of osteoprogenitor populations to differentiate 
to TRAP+ osteoclasts in both basal medium and spheroid MSC conditioned medium 
(Figure 4.6A). Differentiation of osteoclasts in spheroid MSC conditioned media again 
induced approximately 120 TRAP+ cells per well (Figure 4.6B). However, when OPG 
was supplemented into spheroid MSC conditioned medium little to no TRAP+ cells per 
well were observed, similarly to the number observed when osteoclasts are differentiated 
in adherent MSC conditioned medium. While other MSC-expressed soluble factors may 
be involved in supporting osteoclast differentiation, these results suggest that aggregation 
switches MSCs from an osteoclast-inhibitory cell population to an osteoclast supporting 





Figure 4.6. OPG inhibits osteoclasto-genesis in MSC spheroid conditioned medium. (A) 
Supplementation of 100 ng/mL of recombinant OPG into basal or MSC spheroid conditioned 
medium supplemented with M-CSF and RANKL inhibited osteoclast differentiation as determined 
by TRAP staining. Scale bar = 2 mm. (B) Quantification of the number of TRAP+ cells per well 
demonstrated that supplementation of OPG into the culture medium inhibited the differentiation of 
osteoclasts (184-fold decrease in TRAP+ cells in basal medium and 84-fold decrease in spheroid 
conditioned medium). * indicates p < 0.05 between groups denoted by bar. 
 
4.3.5 Increased β-Catenin Localization at the Cell Membrane in Spheroid Cultures 
Due to the striking functional effects the presence or absence of OPG plays in the paracrine 
activity of MSCs, we began to investigate the mechanisms involved in regulating OPG 
expression in adherent and spheroid MSC cultures. Because MSC expression of OPG can 
be rapidly modulated within 24 hours (see Figure 4.2), we focused our efforts on the initial 
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signaling events that mediate aggregation of MSCs, in particular cadherin mediated β-
catenin signaling. Additionally, β-catenin dependent signaling has been shown to be a 
critical mediator of OPG expression [235]. Therefore, we hypothesized that aggregation of 
MSCs induces increased cell-cell contacts and sequestration of β-catenin at the cell 
membrane, resulting in decreased transcription of β-catenin regulated genes, such as OPG. 
To investigate β-catenin signaling, MSCs were plated as adherent monolayers or 
aggregated into spheroids and stained for β-catenin 18 hours after plating and aggregate 
formation. In adherent cultures, the majority of β-catenin staining was diffuse throughout 
the cell, especially in cells with no contact with neighboring cells (Figure 4.7A). However, 
strong bands of localized β-catenin could be observed at the boundary between two 
contacting adjacent cells. In contrast, β-catenin was highly localized to the entire cell 
membrane in MSC spheroids and can be observed as a web-like pattern in 3D imaging of 
the aggregates (Figure 4.7B). Together, these results demonstrate a difference in β-catenin 
localization between adherent and spheroid MSC cultures, which may significantly 
influence downstream signaling in MSCs. However, whether sequestration of β-catenin at 







Figure 4.7. β-catenin is localized to the cell membrane in MSC spheroids. (A) In adherent MSC 
cultures, β-catenin staining was observed to be diffuse throughout the cell and was only strongly 
localized at the boundary of two adjacent and contacting cells (white arrows). (B) In contrast, β-
catenin was observed to be localized to the entire cell membrane of MSCs in spheroid cultures 
likely due to contact with surrounding cells in all three dimensions. 
 
4.4 DISCUSSION 
In this study, we began to investigate the role MSC culture format (i.e. adherent vs. 
spheroid culture) plays on expression of the secreted soluble factor OPG and the functional 
role this difference plays in modulating immune responses and regulating osteoclast 
differentiation. The fact that MSCs can abundantly express OPG is not entirely 
unsurprising, given the role the stromal fraction of bone marrow plays in maintaining bone 
homeostasis in vivo through the expression of OPG [236]. However, few studies have 
rigorously investigated OPG expression by MSCs. Expression of OPG is commonly used 
as an indicator of osteogenic differentiation of MSCs, however, our results indicate that 
undifferentiated MSCs can rapidly and reversibly turn on or off (<24 hours) the expression 
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of OPG, depending on their environmental context. Therefore, expression of OPG is not 
necessarily dependent on differentiation. In this chapter we demonstrate that MSCs lose 
expression of OPG rapidly following aggregation. Furthermore, dissociation of aggregates 
to adherent monolayers restores OPG expression to levels comparable to adherent cultures 
of MSCs within 24 hours, demonstrating the ability of MSCs to rapidly regulate OPG 
expression in response to culture format. Altogether, MSCs dynamically express OPG, a 
critical factor in maintenance of bone tissue, in a manner that is highly regulated by the 
MSC environment. Furthermore, the dynamic expression of OPG highlights the plasticity 
of MSC paracrine activity that has the potential to be fine-tuned by engineering strategies, 
such as through aggregation, based on therapeutic need. 
 
Since little work has investigated the functional role OPG expression plays in MSC 
paracrine activity, we sought to investigate its effects on modulating both T-cells and 
osteoclasts in vitro. Expression of OPG has not previously been linked to the 
immunomodulatory function of MSCs. Only one group has previously examined MSC 
expression of OPG in the context of inhibiting lymphocyte proliferation. The authors found 
that inhibiting OPG with a neutralizing antibody did not reduce the ability of MSCs to 
suppress proliferation and CD25 expression of PHA-stimulated lymphocytes in co-cultures 
[237]. However, since we found a striking difference in OPG expression and the ability to 
suppress T-cell proliferation between adherent and spheroid MSCs, we sought to 
interrogate this pathway directly in the CD3/CD28 activated PBMC co-culture assay. 
Consistent with the previously published work, inhibition of OPG in adherent MSC 
cultures did not reduce the ability of MSCs to suppress T-cell proliferation or activation. 
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Furthermore, supplementation of OPG within MSC spheroid co-cultures did not restore the 
suppression of T-cell proliferation to the extent observed in adherent MSC cultures. 
Together, these results indicate that MSC OPG expression does not play a significant role 
in MSC-mediated suppression of T-cell proliferation in vitro. Interestingly, IFN-γ inhibits 
RANK/RANKL signaling by promoting proteasomal degradation of tumor necrosis factor 
receptor-associated factor 6 (TRAF6), which is necessary for activating p38, JNK, and 
canonical NF-κB pathways downstream of RANK [238]. Since high levels of IFN-γ are 
detected within PBMC co-cultures (>5 ng/mL), the presence or absence of OPG may not 
have a large functional effect as downstream RANK signaling may already be inhibited by 
IFN-γ expression. Alternatively, future work focusing on MSC modulation of macrophage 
or dendritic cell populations in environments without a strong immune response (i.e. high 
levels of IFN-γ or other effector T-cell cytokines) may be beneficial for determining if 
MSC-expressed OPG plays a role in MSC anti-inflammatory function due to the similarity 
between macrophages, dendritic cells, and osteoclasts, which are all derived from a 
common progenitor.  
 
Consistent with previously published reports, paracrine factors from adherent monolayer 
cultures of MSCs inhibited M-CSF- and RANKL-induced differentiation of osteoclasts 
from the adherent fraction of PBMCs. The inhibition of osteoclast differentiation by 
adherent MSCs has been attributed to both OPG expression [232] and CD200 expression 
[239]. However, as conditioned medium was used in this study, CD200 is unlikely to be 
involved in this system, as it requires direct cell-cell contact for signaling. Furthermore, it 
is unsurprising that osteoclasts differentiated in spheroid MSC conditioned medium 
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supplemented with soluble M-CSF and RANKL, which does not contain significant 
amounts of OPG. However, differentiation in spheroid conditioned medium increased the 
number of TRAP+ and multinucleated cells and increased resorption of calcium phosphate 
coatings compared to osteoclasts differentiated in basal medium. Furthermore, addition of 
recombinant soluble OPG into MSC spheroid conditioned medium completely ablated the 
ability of spheroid conditioned medium to promote differentiation of osteoclasts. These 
results suggest that, in the absence of OPG, MSC paracrine factors stimulate and enhance 
osteoclastogenesis. Furthermore, osteoclastogeneiss may be enhanced in the presence of 
paracrine factors from MSC spheroids, since MSC aggregates upregulate expression of IL-
6 (See Chapter 3) and IL-1 [175], which are both known osteoclastogenic cytokines [240]. 
Additionally, increased expression of PGE2 by MSC spheroids could further suppress OPG 
expression and induce RANKL thereby aiding osteoclastogenesis [241]. Altogether, MSCs 
can highly express a critical factor in maintenance of bone homeostasis, which may be a 
critical consideration in strategies aimed at using paracrine-based MSC therapies to aid in 
bone healing and regeneration. 
 
To determine the mechanisms governing OPG expression in adherent and spheroid MSCs, 
we began to explore β-catenin signaling within MSCs. Canonical Wnt signaling and 
downstream translocation of β-catenin to the nucleus has been shown to be critical for 
osteoblast expression of OPG [242]. Overexpression of β-catenin in osteoblasts resulted in 
high bone mass, while deletion of β-catenin expression in osteoblasts resulted in osteopenia 
[242]. Furthermore, the authors found that changes in bone mass were a result of 
dysregulated osteoclast bone resorption and that OPG is a direct target of β-catenin [242, 
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243]. Similarly, conditional deletion of APC in osteoblasts, a necessary component of the 
GSK-3 complex which marks β-catenin for degradation, results in constitutive activation 
of β-catenin, increased serum OPG levels, an absence of osteoclasts, and increased bone 
deposition [244]. Furthermore, deletion of β-catenin in osteoblasts results in decreased 
OPG levels and osteoporosis. While these studies focused on osteoblasts, they suggest that 
β-catenin dependent signaling may also be regulating OPG expression in MSCs. In vitro, 
β-catenin localization was found to be highly dependent on culture format. Diffuse staining 
of β-catenin was observed in adherent monolayer cultures except for at the boundary 
between two neighboring cells. In contrast, due to the aggregate structure of tightly packed 
cells with little to no surrounding matrix, β-catenin staining could be found localized to the 
entire cell membrane, potentially sequestering the majority of β-catenin and inhibiting 
downstream transcription. However, further studies will be necessary to confirm whether 
β-catenin signaling is mediating OPG expression in adherent and spheroid MSC cultures. 
Ultimately, a better characterization of signaling pathways regulated by aggregation may 
provide insight into the mechanisms governing the enhanced immunomodulatory, 
angiogenic, and trophic paracrine activity of MSC spheroids. 
 
4.5 CONCLUSIONS 
Overall, the results of this study demonstrate that aggregation of MSCs into spheroids 
regulates the composition of paracrine factors secreted by MSCs, in particular the RANKL 
decoy receptor OPG. Expression of OPG was found to be reversible after dissociation of 
spheroids, highlighting the critical importance of the MSC microenvironment on regulating 
MSC paracrine factor expression. Additionally, the differential expression of OPG by 
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adherent and spheroid MSCs resulted in functional differences in osteoclast differentiation 
in the presence of MSC paracrine factors. While adherent MSCs inhibit osteoclast 
differentiation by expressing OPG, MSC spheroids promote osteoclast differentiation 
through soluble paracrine factors while downregulating OPG expression. However, 
decreased OPG expression by MSC spheroids was not linked to the decreased ability to 
suppress T-cell proliferation compared to adherent MSCs in co-cultures with CD3/CD28 
activated PBMCs. While the mechanisms mediating OPG expression in adherent and 
spheroid cultures is still unclear, the localization of β-catenin to the cell membrane in MSC 
spheroids suggests that cell-cell adhesions and the β-catenin pathway may be a critical 
mediator of MSC OPG expression and a compelling target for future studies determining 










Due to the dependency of MSC immunomodulation on the local cytokine milieu, the 
efficacy of MSC-based cellular therapies is highly dependent on the in vivo environment 
they are exposed to after injection. The environment may be highly variable based on the 
individual and disease being treated, the stage of inflammation, and the site of MSC 
transplantation. For example, high concentrations of inflammatory cytokines that often 
accompany acute inflammatory responses stimulate MSC immunomodulation[85]. 
However, the low levels of cytokines observed in chronic inflammation may not be 
sufficient to induce MSC immunomodulatory activity, thereby limiting the ability of MSCs 
to regulate inflammation of certain disease states and therefore contributing to variability 
in MSC treatment efficacy. Additionally, MSCs are typically infused intravenously and the 
majority of cells are entrapped within the capillary beds of the lung tissue, distant from 
sites of inflammation[245]. Entrapped MSCs are then rapidly cleared from the body within 
several days, limiting their residency time and effective window for immunomodulatory 
activity. Interestingly, the physical entrapment of MSCs in the lung causes the formation 
of aggregates of MSCs within the lung tissue, which results in upregulation of 
immunomodulatory factors such as PGE2 and TSG-6, even in the absence of any cytokine 
priming[173, 174, 210]. While I.V. infused MSCs are capable of modulating immune 
responses in numerous disease models and human patients, presumably through systemic 
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effects of MSCs entrapped within the lung, the limited retention time and lack of exposure 
to local inflammatory cues may limit the overall immunomodulatory efficacy of 
transplanted MSCs.  
 
To overcome these limitations, local transplantation of MSCs as pre-formed aggregates 
may improve retention of the cells at the site of interest, expose MSCs to the local 
inflammatory environment, and promote increased expression of immunomodulatory 
factors. Delivery of MSCs as aggregates is thought to preserve cell-cell and cell-matrix 
contacts within the aggregate structures, thereby preventing cell loss due to anoikis and 
resulting in better engraftment in host tissue[159, 169]. While systemic infusion of 
aggregates would not be possible due to the likelihood of occluding blood vessels, local 
transplantation through a larger bore needle is feasible and may be beneficial in 
concentrating MSC factors at sites of inflammation as well as exposing MSCs to the local 
inflammatory cytokine milieu. As a potentially complimentary strategy to enhance 
immunomodulation, MSCs are commonly pre-treated with inflammatory cytokines, such 
as IFN-γ, prior to intravenous infusion in order to augment their immunomodulatory 
activity during their minimal residence time after transplantation. IFN-γ pre-treated MSCs 
have exhibited improved resolution of inflammation in models of colitis[246] and graft-
versus-host disease[247] compared to non-treated MSCs. Furthermore, pre-treatment of 
MSC aggregates with IFN-γ and TNF-α further increases the immunomodulatory activity 
of MSC spheroids[211]. However, despite the enhancement of MSC immunomodulation, 
the transient effects of pre-treatment of MSCs may limit the potential of MSC spheroids to 
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modulate immune responses for more than a few days in environments that do not expose 
the cells to high concentrations of IFN-γ, such as in chronic inflammatory states.  
 
To address the transient effects of pre-treatment, we hypothesized that biomaterial-based 
presentation of cytokines within spheroidal MSC aggregates may provide a means of 
locally concentrating and sustaining presentation of bioactive IFN-γ to potentiate MSC 
immunomodulatory activity. Previous work from our group has demonstrated the use of 
microparticles to deliver growth factors and small molecules throughout stem cell 
aggregates[248–251]. Our first approach was to immobilize biotinylated IFN-γ to 
streptavidin-coated polystyrene microparticles in order to deliver IFN-γ within MSC 
spheroids. Additionally, microparticles consisting of cross-linked heparin have previously 
been fabricated and are capable of binding a large amount of heparin binding growth factors 
that remain bioactive when immobilized to the particles [252]. Since heparin has a high 
affinity for IFN-γ (KD= 1-5 nM) [253, 254], can prevent proteolytic degradation of IFN-
γ[255], and can enhance IFN-γ signaling[256], heparin microparticles were also used to 
deliver IFN-γ within MSC spheroids in these studies. The ability of microparticle delivered 
IFN-γ to induce sustained immunomodulatory activity was evaluated by measuring IDO 
expression of MSCs in response to microparticles and soluble pre-treatment and by 
assessing suppression of T-cell activation and proliferation in peripheral blood 
mononuclear cell (PBMC) co-cultures. Altogether, this strategy offers a translatable means 
of controlling MSC paracrine activity post-transplantation and therefore, improve the 




5.2 METHODS AND MATERIALS 
5.2.1 Heparin microparticle synthesis 
Heparin methacrylamide microparticles were fabricated as previously described[252]. 
Briefly, heparin methacrylamide was synthesized from heparin ammonium salt derived 
from porcine intestinal mucosa (17-19 kDa; Sigma-Aldrich, St. Louis, MO) and N-(3-
aminopropyl) methacrylamide (APMAm; Polysciences, Warrington, PA) using 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC; Thermo Scientific, Rockford, IL) and N-
hydroxysulfosuccinimide (Sulfo-NHS; Thermo Scientific) [257]. Heparin ammonium salt 
(325 mg) was dissolved in distilled water (200 mL) with a 10-fold molar excess of EDC, 
sulfo-NHS, and APMAm in relation to the heparin carboxyl groups. The reaction was 
allowed to proceed for 5 hours at room temperature and pH 6.5, before being dialyzed 
against 2 L of water using 3.5 kDa molecular weight cutoff dialysis tubing (Spectrum 
Laboratories, Rancho Dominguez, CA) for 48 hours to remove excess reactants; dialysis 
water was exchanged ever 12 hours. The remaining heparin solution was then lyophilized 
for 4 days and stored at -20 ºC.  
 
To fabricate heparin microparticles, a water-in-oil emulsion technique was used to generate 
small droplets of heparin solution that were subsequently stabilized by thermal cross-
linking of the methacrylamide groups on the heparin species. 55.6 mg of lyophilized 
heparin methacrylamide was dissolved in 400 µL of phosphate buffered saline (PBS; 
Corning, Manassas, VA) supplemented with 18 mM of the free radical initiators 
ammonium persulfate (APS, Sigma Aldrich) and tetramethylethylenediamine (TEMED, 
Sigma Aldrich). The heparin solution was added dropwise to 60 mL of corn oil and 1 mL 
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of polysorbate-20 (Promega, Madison, WI). To form an emulsion, the entire solution was 
homogenized on ice at 3000 rpm for 5 min using a Polytron PT31000 homogenizer 
(Kinematica, Switzerland). After homogenization, free radical polymerization of the 
methacrylamide groups was initiated by submerging the emulsion in a hot water bath (55 
oC) with gentle agitation under nitrogen purging for 30 minutes. The solution was then 
centrifuged at 3000 rpm for 10 minutes at 4 °C to obtain a pellet of microparticles. 
Microparticles were washed once in acetone followed by three water washes to remove 
residual oil and loosely cross-linked particles. The microparticles were then disinfected in 
a 70% ethanol solution for 30 minutes followed by additional washes with sterile water, 
lyophilized for two days, and stored at 4 ºC prior to use. 
 
5.2.2 Heparin microparticle characterization 
To determine the extent of IFN-γ binding to both streptavidin-coated polystyrene (3.0-3.4 
µm diameter; SpheroTech, Lake Forest, IL) and heparin methacrylamide microparticles, 
approximately 1 x 106 particles were incubated at room temperature in 50 µL of PBS with 
0.1% BSA and a range of IFN-γ (10-1000ng, R&D Systems, Minneapolis, MN) that is 
typically used to stimulate MSC IDO expression [258]. For all experiments with 
polystyrene particles, IFN-γ was first biotinylated using an EZ-Link Sulfo-NHS-Biotin 
biotinylation kit (ThermoFisher) according to the manufacturer’s protocol. After 18 hours, 
the microparticles were centrifuged at 200x g for 5 minutes and the supernatant collected 
to determine the amount of free IFN-γ remaining in the solution. The amount of unbound 
IFN-γ was quantified using a human IFN-γ ELISA kit (R&D) and compared to an 
equivalent amount of IFN-γ incubated for 18 hours without microparticles in order to 
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generate a loading curve for IFN-γ binding to heparin microparticles. After the supernatant 
was collected to determine the amount of bound IFN-γ, microparticles were incubated in 1 
mL of RPMI-1640 media with 10% FBS and incubated at 37°C for 7 days in a humidified 
5% CO2 incubator. 100 µL of the medium was sampled and replaced with an equivalent 
volume each day to determine the amount of IFN-γ released from the particles over time.  
 
5.2.3 MSC expansion and culture 
Human bone marrow-derived MSCs were obtained from RoosterBio Inc. (Frederick, MD). 
RoosterBio MSCs were demonstrated to undergo adipogenic and osteogenic differentiation 
and express the accepted panel of surface markers (CD45-, CD34-, CD73+, CD90+, 
CD105+) by the manufacturer prior to use. Adipogenic and osteogenic differentiation 
potential was evaluated by Oil Red O and Alizarin Red staining respectively after 3 weeks 
of culture in the respective Life Technologies differentiation kits. Additionally, MSCs were 
0% CD45+, 0.1% CD34+, 98.9% CD73+, 99.5% CD90+, and 95.9% CD105+ as evaluated 
by flow cytometry. MSCs were expanded according to the manufacturer’s protocols. 
Briefly, 1 x 107 cryopreserved MSCs were plated in twelve T225 flasks in 42 mL of 
RoosterBio High Performance Media and incubated at 37°C for 7 days in a humidified 5% 
CO2 incubator. Media was exchanged after 4 days of culture. Cultures were passaged at 
80% confluency by washing with 10 mL PBS followed by incubation with 10 mL of 
TrypLE at 37 oC. An equal volume of RoosterBio High Performance Media was added to 
quench TrypLE activity. Dissociated cells were then collected and centrifuged at 200x g. 
Cells were frozen in CryoStor CS5 cell cryopreservation media (STEMCELL 
Technologies, Vancouver, BC, Canada) prior to expansion for experiments. MSCs were 
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expanded for one or two passages from frozen stocks by plating 0.5x106 cells in RoosterBio 
High Performance Media in 15 cm tissue culture treated dishes (manufacture details). 
Media was exchanged every three days and cells were passaged at 80% confluency. For all 
subsequent experiments, cell culture was conducted in RPMI-1640 medium (Corning 
Mediatech, Manassas, VA) supplemented with 10% FBS (Hyclone, Logan, UT), 1% L-
Glutamine (Corning Mediatech), and 1% Penicillin/Streptomycin (Corning Mediatech). 
 
5.2.4 IFN-γ loaded microparticle bioactivity 
To evaluate the bioactivity of IFN-γ bound to polystyrene and heparin microparticles, 
adherent monolayer MSCs were cultured with microparticles loaded with 0 or 333 ng of 
IFN-γ per 1 x 106 particles. Particles were loaded with each IFN-γ concentration either 1, 
2, 4, or 7 days prior to addition of particles to adherent MSC cultures to assess the activity 
of microparticle-bound IFN-γ over time. After 18 hours of loading, particles were washed 
to remove excess IFN-γ and incubated in RPMI-1640 medium supplemented with 10% 
FBS at 37oC until addition of particles to adherent MSC cultures. MSCs were plated in 24-
well plates at a density of 50,000 cells/cm2 and after 18 hours, ~200,000 particles were 
added to MSCs from each experimental group (IFN-γ loading concentration and incubation 
time). After 24 hours of culture, MSCs were lysed and RNA collected for quantitative real-
time PCR (qRT-PCR) to measure IDO gene expression. RNA was extracted using an 
E.Z.N.A. Total RNA kit (OMEGA Bio-Tek, Norcross, GA) kit and cDNA was 
subsequently synthesized (300 ng RNA per sample) using an iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA). Forward and reverse primers for IDO1 (Forward: 
AGCTTCGAGAAAGAGTTGAGAAG; Reverse: GTGATGCATCCCAGAACTAGAC) 
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and 18S (Forward: CTTCCACAGGAGGCCTACAC; Reverse: 
CTTCGGCCCACACCCTTAAT) were designed using Primer-Blast 
(www.ncbi.nlm.nih.gov) and purchased from Invitrogen (Carlsbad, CA). IDO1 gene 
expression was calculated with respect to untreated MSCs and normalized to 18S 
expression using the ΔΔCT method.  
 
5.2.5 MSC spheroid formation 
Three dimensional spheroids were formed by forced aggregation of MSCs into an array of 
400 x 400 μm inverse pyramidal agarose microwells as a high throughput method of 
generating homogenous cell aggregates. For all experiments, 500-cell spheroids were 
formed by adding 6x105 cells to an agarose insert containing 1200 microwells and 
centrifuging at 200x g for 5 minutes. After 18 hours, MSCs self-assembled into spherical 
aggregates. In order to form spheroids with microparticles, a suspension of unloaded 
heparin microparticles or microparticles previously incubated with 33 or 333 ng IFN-γ per 
1 x 106 MPs for 18 hours was mixed with the cell suspension at a 2:1 microparticle-to-
MSC ratio and added to the microwells (Figure 5.1). The incorporation efficiency of 
heparin microparticles within MSCs spheroids was quantified by lysing spheroids after 
initial formation and counting the number of particles retrieved from the spheroids. 
Furthermore, MSC spheroids without particles were also formed, and a subset was pre-
treated with IFN-γ at equivalent doses to IFN-γ microparticle groups (20 ng/mL or 200 
ng/mL concentration, equivalent to 66 ng or 666 ng per 1 x 106 cell, respectively). After 
18 hours of microwell aggregate formation, spheroids were either cultured alone to assess 
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IDO and immunomodulatory factor expression or with peripheral blood mononuclear cells 
(PBMCs) to assess the immunomodulatory activity of MSC spheroids.  
 
 
Figure 5.1. Microparticle delivery of IFN-y within MSC spheroids. To form aggregates, MSCs 
were dissociated from adherent culture and mixed with IFN-γ loaded microparticles. Spheroids 
were subsequently formed via forced-aggregation of cells and particles within microwell arrays to 
entrap cytokine-loaded microparticles within the spheroidal construct in order to provide sustained 





5.2.6 Analysis of MSC immunomodulatory factor expression 
To evaluate MSC IDO expression in response to IFN-γ pre-treatment or microparticle 
delivery, MSC spheroids were cultured for up to 7 days. At days 1, 2, 4, and 7, MSCs were 
collected for qRT-PCR analysis of IDO1 gene expression relative to untreated MSC 
spheroids. Cell lysates of MSC spheroids were also collected at days 1 and 4 for Western 
blotting. Sample protein concentration was first determined using a BCA Protein 
Quantification kit (Pierce Biotechnology, Rockford, IL). SDS/PAGE loading buffer was 
then mixed with 25 µg of protein per sample and incubated at 95oC for 5 min. Protein 
samples were subsequently loaded in 4-15% Mini-PROTEAN TGX gels (Bio-Rad 
Laboratories, Hercules, CA). Vertical electrophoresis was performed using the Mini-
PROTEAN Tetra Cell (Bio-Rad) system with SDS/PAGE running buffer at 200V for 20 
min with a 10-250 kDa protein ladder (Precision Plus Protein Kaleidoscope, Bio-Rad) as a 
molecular weight reference. Protein was then transferred to a nitrocellulose membrane 
(Bio-Rad) via semi-dry transfer (Trans-Blot SD, Bio-Rad) at 25V for 20 min. Membranes 
were blocked with infrared blocking medium (Rockland Immunochemicals, Pottstown, 
PA) for 1h followed by incubation with primary antibodies for IDO (rabbit anti-IDO IgG; 
Abcam, Cambridge, UK) and the loading control GAPDH (monoclonal goat anti-GAPDH; 
Abcam) overnight at 4oC. Secondary IR antibodies (680 donkey anti-rabbit and donkey 
800 anti-goat; Li-Cor Biosciences, Lincoln, NE) were used to detect IDO and GAPDH 





To evaluate spatial expression of IDO in response to IFN-γ pre-treatment or IFN-γ loaded 
microparticles, MSC spheroids were fixed in 10% formalin for 30 minutes for 
immunohistological analysis. After fixation, spheroids were washed three times with PBS, 
paraffin processed, embedded, and sectioned at 5 μm. Histological sections were de-
paraffinized, incubated in a citrate-based Antigen Unmasking Solution (Vector 
Laboratories), and labeled with a primary antibody for human IDO (mouse anti-human 
IDO, Millipore) at a 1:200 dilution. Samples were subsequently incubated with horseradish 
peroxidase-conjugated anti-mouse IgG secondary antibody (ImmPRESS Reagent Kit, 
Vector Laboratories) followed by ImmPACT DAB Peroxidase Substrate (Vector 
Laboratories) to visualize IDO. Slides were counterstained with Alcian Blue (pH = 2.0) 
and Nuclear Fast Red to visualize sulfated glycosaminoglycans (in particular, heparin 
particles) and cell nuclei, respectively. An Axio Imager 2 upright microscope (Zeiss) was 
used to capture brightfield images of samples. 
 
5.2.7 Peripheral blood mononuclear cell co-cultures 
PBMCs were isolated from whole blood obtained with IRB approval from healthy 
volunteers via Ficoll (Sigma-Aldrich) density gradient separation. Isolated PBMCs were 
cultured at 400,000 cells per well in 24-well plates with MSCs spheroids at ratios of 1:3, 
1:1, and 3:1 MSCs-to-PBMCs, based on ratios typically reported[78, 259, 260] and 
preliminary testing. At the start of co-culture, 0.2 μg/mL of anti-human CD3 and CD28 
antibodies were added to the co-cultures to induce T-cell proliferation and activation. To 
evaluate microparticle delivery of IFN-γ within MSC spheroids, four experimental groups 
were evaluated: 1) MSC spheroids without additional treatment, 2) spheroids pre-treated 
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with 200 ng/mL (666 ng per 1 x 106 cells) of soluble IFN-γ, 3) spheroids containing 
unloaded heparin microparticles, and 4) spheroids containing heparin microparticles (2:1 
MP:MSC ratio) loaded with 333 ng IFN-γ per 1 x 106 particles. Where indicated, 1-
methylDL-tryptophan (1-MT, diluted in 0.1 N NaOH; Sigma-Aldrich), an inhibitor of IDO 
activity, or an equivalent volume of a vehicle control (0.1 N NaOH) was added to co-
cultures at a final concentration of 5 mM 1-MT. In a subset of cultures, PBMCs were added 
to the upper well of a 0.4 μm pore polycarbonate transwell (Corning) and co-cultured with 
MSC spheroids pre-treated with 200 ng/mL IFN-γ at a 3:1 MSC-to-PBMC ratio. MSC 
spheroids were added to PBMC co-cultures immediately after aggregate formation, except 
where indicated otherwise. To test the persistence of spheroid immunomodulatory activity 
in culture, spheroids were added to PBMC co-cultures 2 or 4 days after initial aggregate 
formation and IFN-γ pre-treatment. For all PBMC co-cultures, T-cell proliferation was 
assessed 4 days later by flow cytometry analysis of CD3 (FITC-conjugated mouse anti-
CD3 IgG; BD Biosciences, East Rutherford, NJ) and Ki67 (PE-conjugated mouse anti-
Ki67 IgG; BD Biosciences) double positive stained cells. T-cell activation was also 
assessed after 4 days by measuring the amount of IFN-γ in co-culture spent media 
supernatants by ELISA (R&D). Finally, expression of anti-inflammatory cytokines was 
assessed after 4 days by measuring the amount of IL-10 in co-culture spent media 
supernatants by ELISA (R&D).  
 
Monocytes were isolated from PBMCs using an EasySep Human CD14+ Positive Selection 
Kit (STEMCELL Technologies) and cultured at 400,000 cells per well in 24-well plates 
with MSC spheroids from each experimental group as in PBMC co-culture experiments at 
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a 3:1 MSC-to-monocyte ratio with no supplemented cytokines. After 4 days of co-culture, 
phenotype was evaluated by flow cytometry analysis of CD14 (FITC-conjugated mouse 
anti- CD14 IgG) and CD206 (APC-conjugated mouse anti-CD206 IgG) stained cells. 
Additionally, the amount of the anti-inflammatory cytokine, IL-10, in co-culture spent 
media supernatants was measured by ELISA (R&D). 
 
5.2.8 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 6 software (Graphpad Software, 
La Jolla, CA). Data are presented as mean ± standard error of the mean. Comparisons 
between multiple experimental groups were conducted using analysis of variance 
(ANOVA) after Box-Cox transformation to ensure normal distribution. Tukey post hoc 
analysis was then used to determine statistically significant differences between 
experimental groups, with a p-value < 0.05 indicating significance.  
 
5.3 RESULTS 
5.3.1 Biotinylated IFN-γ binds to streptavidin-coated microparticles but does not 
remain bioactive over time 
To determine the capacity of IFN- immobilization on polystyrene particles, streptavidin-
coated polystyrene particles were incubated in solutions of varying concentrations of 
biotinylated IFN-γ (10-1000 ng per 1 x 106 particles) for 18 hours.  When incubated with 
100 ng or less of IFN-γ, polystyrene particles depleted approximately 98% of the initial 
biotinylated IFN-γ from solution (Figure 5.2A). However, polystyrene particles only 
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bound ~91% of IFN-γ from solution containing 333 ng IFN-γ and only 47% from a solution 
containing 1000ng IFN-γ solution, suggesting a maximum binding capacity on the order 
of 500ng per 1 x 106 particles. To determine release of biotinylated IFN-γ, microparticles 
were resuspended in fresh cell culture medium containing 10% FBS and incubated for one 
week. While an initial burst release of approximately 5% of initially loaded IFN-γ was 
released form particles loaded with 100 or 1000 ng IFN-γ, no subsequent release of IFN-γ 
occurred over the following 6 days (Figure 5.2B). Finally, to evaluate the bioactivity of 
biotinylated IFN-γ immobilized on polystyrene particles, adherent MSCs were cultured 
directly with particles loaded with IFN-γ (100 ng per 1 x 106 particles). Particles were 
loaded with IFN-γ 7, 4, and 1 day prior to addition to MSC cultures to assess the bioactivity 
of particle-bound IFN-γ over time. Particles loaded with IFN-γ one day prior to MSC 
culture significantly upregulated MSC IDO expression compared to MSCs receiving no 
treatment or unloaded microparticles (~470-fold increase in IDO expression compared to 
no treatment MSCs, p < 0.001), similar to the response of MSCs to an equivalent dose of 
biotinylated IFN-γ delivered solubly (Figure 5.2C). However, particle-bound IFN-γ 
completely lost the ability to induce MSC IDO expression after 4 and 7 days of culture. 
Altogether, while biotinylated IFN-γ could be immobilized on streptavidin-coated 
polystyrene microparticles, bioactivity of particle-bound IFN-γ significantly decreased 





Figure 5.2. Streptavidin coated microparticles bind but do not maintain bioactivity of 
biotinylated IFN-γ. (A) Polystyrene microparticles bound ~98% of IFN-γ from solution over 10-
100 ng per 1 x 106 particles but saturated at about 500 ng. (B) While an initial burst release of IFN-
γ from the particles was observed, little IFN-γ was subsequently released from the particles over 7 
days. (C) Particle-bound IFN-γ, while initially capable of inducing MSC IDO expression, did not 





5.3.2 IFN-γ binds to heparin microparticles and remains bioactive over one week of 
culture 
To establish an alternative microparticle vehicle for delivery of IFN-γ within MSC 
spheroids, the interaction between heparin microparticles and IFN-γ was investigated. 
Heparin particles have previously been characterized to have a large binding capacity for 
the growth factor BMP-2 (~300 µg per mg of MPs[252]). When heparin particles were 
incubated in solutions of varying concentrations of IFN-γ (10-1000 ng per 1 x 106 particles; 
equivalent to 0.2-20 µg per mg of MPs), more than 97% of the initial IFN-γ was depleted 
from solution after 18 hours for each concentration tested (Figure 5.3A). However, the 
maximum binding capacity of the microparticles for IFN-γ was not reached over the range 
of concentrations tested and the highest concentration of IFN-γ tested (approximately 20 
µg IFN-γ per mg of MPs) was significantly lower than the maximal binding capacity of 
heparin microparticles for BMP-2 (300 µg BMP-2 per mg of MPs). Therefore, if desired, 
even greater amounts of IFN-γ could likely be loaded onto the particles. 
 
After loading particles with different concentrations of IFN-γ, microparticles were 
resuspended in fresh cell culture medium containing 10% FBS and incubated for 1 week 
to examine release of IFN-γ from the particles. At each loading concentration, the majority 
of IFN-γ released from the particles occurred within the first 24 hours, suggesting an initial 
burst release of loosely bound IFN-γ from the particles (Figure 5.3B). The amount of IFN-
γ released during this 24 hour period was dependent on the loading concentration, with 
approximately 1% of loaded IFN-γ at the lowest loading concentration and approximately 
30% of loaded IFN-γ at the highest loading concentration. However, after the initial burst 
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release period, minimal IFN-γ was released from the particles over the next 6 days, 
suggesting that the majority of loaded IFN-γ remained bound to the heparin microparticles 
for at least one week of culture. 
 
Figure 5.3. Heparin microparticles bind and present bioactive IFN-γ and incorporate stably 
within MSC aggregates. (A) Heparin microparticles bound >97% of IFN-γ from solution over the 
ranges tested. (B) While an initial burst release of IFN-γ from the particles was observed, little IFN-
γ was subsequently released from the particles over 7 days. (C) Particle-bound IFN-γ remained 
bioactive and capable of inducing MSC expression of IDO over 7 days. * indicates p < 0.05 
compared to no treatment. 
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The bioactivity of IFN-γ bound to heparin microparticles was evaluated by culturing 
adherent MSCs in direct contact with microparticles loaded with IFN-γ (333 ng per 1 x 106 
MPs). Microparticles were loaded with IFN-γ 1, 2, 4, and 7 days prior to addition to MSC 
cultures to examine whether the bioactivity of microparticle-bound IFN-γ was retained 
over time. The ability of particle-bound IFN-γ to induce IDO expression in MSCs was 
compared to treatment with unloaded microparticles or an equivalent dose of soluble IFN-
γ. As expected, treatment of adherent MSCs with IFN-γ induced IDO expression (>103-
fold increase in IDO gene expression, p <0.001) while the addition of unloaded 
microparticles did not significantly increase MSC IDO expression (Figure 5.3C). When 
an equivalent dose of IFN-γ was delivered via microparticles loaded 1 day prior to culture, 
IDO expression was induced in adherent MSCs to the same extent as soluble treatment, 
demonstrating that microparticle-bound IFN-γ remains bioactive. Furthermore, 
microparticles loaded with IFN-γ 2, 4, and 7 days prior to addition to MSCs maintained 
the ability to significantly induce MSC IDO expression (2000-, 350-, and 150-fold increase 
in IDO expression compared to untreated MSCs, respectively; p < 0.001), although 
microparticles loaded with IFN-γ 4 and 7 days prior to addition to MSCs induced IDO at a 
somewhat lower magnitude compared to freshly loaded microparticles (15- and 30-fold 
decrease in IDO expression, respectively; p <0.001). Since, minimal IFN-γ is released from 
heparin microparticles following the first 24 hours, these results suggest that IFN-γ loaded 
onto microparticles retains its bioactivity and ability to elicit a MSC response while bound 




5.3.3 IFN-γ loaded microparticles induce sustained immunomodulatory factor 
expression  
To evaluate incorporation of heparin microparticles within aggregates, fluorescently 
labeled, unloaded microparticles were incorporated within MSC aggregates at several 
different ratios of microparticles-to-MSCs (1:1, 2:1, 4:1 MP:MSC) and cultured for up to 
7 days to evaluate the incorporation efficiency of particles within aggregates and retention 
of particles within the multicellular constructs. Fluorescently labeled microparticles were 
readily incorporated within MSC spheroids after initial formation and remained stably 
incorporated within spheroids for at least 1 week of culture (Figure 5.4A). Approximately 
85% of the particles initially added during aggregate formation were incorporated within 
spheroids for all three ratios tested (Figure 5.4B). Additionally, only ~1.5% of these 
particles were found to escape from the spheroids into the culture medium over 1 week of 
culture. By determining the incorporation efficiency of microparticles within MSC 
spheroids (~85%) and persistence of particles within spheroids over the course of 7 days, 
we were able to adjust the number of particles added at the time of formation for subsequent 
experiments to ensure equivalent doses of IFN-γ presented via particles compared to 




Figure 5.4. Heparin microparticles incorporate stably within MSC aggregates. (A) 
Fluorescently labeled microparticles were incorporated within MSC aggregates at various doses 
and remained stably incorporated for at least 7 days of culture. Maximal intensity projection, scale 
bar = 50 μm. (B) Approximately 85% of microparticles added during aggregate formation were 
incorporated within MSC spheroids over the range of microparticle-to-cell ratios tested, allowing 
for precise control of microparticle and loaded cytokine dose.   
To investigate whether sustained delivery of IFN-γ directly within the MSC spheroidal 
microenvironment could enhance MSC immunomodulatory factor expression, heparin 
particles were loaded with two doses of IFN-γ (33 ng and 333 ng IFN-γ per 1 x 106 MPs) 
or without any cytokine and incorporated into MSC spheroids. The expression of IDO by 
MSC spheroids with microparticles or pre-treated with IFN-γ was then measured over one 
week of culture. Little change in IDO gene expression was observed in MSC spheroids 
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without IFN-γ pre-treatment or with unloaded microparticles over 1 week (Figure 5.5A). 
Both IFN-γ pre-treatment and incorporation of IFN-γ loaded microparticles initially 
induced IDO gene expression within the first day (approximately 104-fold, p < 0.001). 
However, IDO expression rapidly decreased over time when MSC spheroids were pre-
treated with soluble IFN-γ. In contrast, MSC spheroids with IFN-γ loaded microparticles 
maintained an elevated level of IDO gene expression over an entire week of culture. 
Similarly, protein expression of IDO was detected initially on day 1 where MSC spheroids 
were exposed to IFN-γ by pre-treatment or via microparticles (Figure 5.5B). By day 4, 
only spheroids exposed to the sustained presentation of microparticle-bound IFN-γ 
continued to express elevated levels of IDO. Furthermore, the sustained delivery of IFN-γ 
on heparin microparticles was significantly greater than the IDO expression of MSC 
spheroids stimulated with soluble IFN-γ for 7 days (Figure 5.6). Finally, no IFN-γ was 
detected in the spent cell culture medium by ELISA indicating that little to no 
microparticle-bound IFN-γ escaped from the spheroids  (<0.1% of IFN-γ initially loaded 




Figure 5.5. IFN-γ loaded heparin microparticles induce sustained IDO expression. (A) IDO 
gene expression rapidly decreased after initial pre-treatment of MSC spheroids with IFN-γ whereas 
IDO gene expression was sustained over 7 days when IFN-γ was delivered by microparticles within 
MSC spheroids. * indicates p < 0.05 compared between pre-treatment and microparticle treatment 
on the same day of culture. (B) Similarly, IDO protein expression was induced by IFN-γ but was 
only expressed by MSC spheroids after 4 days when IFN-γ was delivered by microparticles. 
 
 
Figure 5.6. MSC IDO expression is greater when IFN-γ is delivered via microparticles than 
solubly. MSC IDO expression was significantly greater after 4 and 7 days of culture in response to 
333 ng IFN-γ delivered on heparin microparticles compared to an equivalent dose delivered solubly 
in the culture medium for all 7 days of culture. * indicates p < 0.05 compared to the soluble IFN-γ 
delivery at the same day of culture. 
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To evaluate spatial distribution of IDO expression within MSC spheroids in response to 
IFN-γ pre-treatment or IFN-γ loaded microparticles, immunohistochemistry was used to 
examine the localization of IDO to the spheroid exterior or to heparin microparticles 
(Figure 5.7).  In MSC spheroids without any treatment, no IDO expression could be 
observed after one or four days of culture, consistent with qRT-PCR and Western blot 
analysis (Figure 5.7A,B). When pre-treated with IFN-γ, IDO expression could be observed 
throughout the spheroid one day after stimulation, suggesting IFN-γ is able to penetrate 
into the spheroid and does not solely stimulate cells on the exterior of the aggregate (Figure 
5.7C). However, four days after pre-treatment, little positive IDO staining could be 
observed in pre-treated spheroids (Figure 5.7D). Slight DAB staining was observed to be 
localized to heparin microparticles in spheroids incorporated with unloaded particles. 
However, DAB staining appeared to be localized only to particles, based on Alcian blue 
staining and morphology (Figure 5.7E, inset), and not to cells, suggesting a potential 
interaction between DAB and the particles. Finally, in MSC spheroids incorporated with 
IFN-γ microparticles, positive IDO staining and microparticles could be observed 
throughout the spheroids after one day of culture (Figure 5.7G). Furthermore, the intensity 
of IDO staining was greater after four days of culture, indicating that IDO production 
continued to be stimulated throughout the spheroid over four days, consistent with what 




Figure 5.7. Delivery of IFN-γ on microparticles stimulates IDO throughout MSC spheroids. 
Representative images of MSC spheroids stained for IDO expression (DAB, brown) and 
counterstained for heparin particles (Alcian Blue, blue) and nuclei (Nuclear Fast Red, red).  MSC 
spheroids were evaluated after one and four days of culture in (A, B) no treatment, (C, D) IFN-
γ pre-treatment, (E, F) unloaded microparticles, and (G, H) IFN-γ loaded microparticles cultures 
to evaluate spatial localization of IDO expression. Scale bar = 50 µm. 
 
5.3.4 IFN-γ loaded microparticles enhance MSC suppression of T-cell activation and 
proliferation 
Since microparticle delivery of IFN-γ promoted sustained MSC expression of IDO, we 
next sought to determine if the enhanced IDO expression resulted in increased suppression 
of T-cell proliferation and activation. At the highest ratio of MSCs to PBMCs (3:1 
MSC:PBMC), suppression of T-cell proliferation, as measured by decreased Ki67 
expression, was observed in all MSC co-culture groups compared to the activated PBMCs 
alone (Figure 5.8A). However, MSC spheroids pre-treated with IFN-γ or incorporated with 
IFN-γ loaded microparticles induced greater suppression of T-cell proliferation compared 
to untreated MSC spheroids. Furthermore, only MSCs treated with IFN-γ (either through 
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pre-treatment or microparticles) were capable of suppressing T-cell proliferation at a 1:1 
MSC:PBMC ratio. Additionally, the sustained microparticle delivery of IFN-γ within 
spheroids significantly enhanced suppression of T-cell proliferation at both a 3:1 and 1:1 
ratio of MSCs:PBMCs compared to spheroids pre-treated with IFN-γ (Figure 5.8B). At a 
3:1 MSC:PBMC ratio, only 15 ± 1% of T-cells were Ki67+ in co-culture with MSCs with 
IFN-γ loaded microparticles compared to 23 ± 2% in co-cultures with pre-treated MSC 
spheroids (p = 0.029). No suppression of T-cell proliferation was observed when MSCs 
were co-cultured at a 1:3 MSC:PBMC ratio in any of the IFN-γ treatment groups. Finally, 
a similar response was observed in expression of IFN-γ and IL-10 in co-cultures. As no 
IFN-γ or IL-10 could be detected in cultures of only MSC spheroids with or without IFN-
γ loaded microparticles, the IFN-γ and IL-10 detected in MSC-PBMC co-cultures is 
expressed by cells from the PBMC fraction. The greatest suppression of IFN-γ secretion 
was observed in co-cultures with pre-treated MSC spheroids and MSC spheroids with IFN-
γ loaded microparticles (Figure 5.8C). Similarly, IL-10 expression was increased in co-
cultures with MSC spheroids at 3:1 and 1:1 MSC:PBMC ratios and was greatest in MSC 







Figure 5.8. Microparticle delivery of IFN-γ enhances MSC spheroid suppression of T-cell 
activation and proliferation. (A) Representative histograms of Ki67+ T-cells in co-culture with 
MSC spheroids at 1:3, 1:1, and 3:1 MSC:PBMC ratios demonstrate a dose dependent response of 
T-cell proliferation (B) Co-culture of activated PBMCs with IFN-γ loaded microparticle treated 
MSC spheroids resulted in the greatest suppression of T-cell proliferation at a 3:1 MSC:PBMC 
ratio. Only MSCs treated with IFN-γ (via pre-treatment or microparticle) suppressed T-cell 
proliferation at a 1:1 MSC:PBMC ratio. (C) Additionally, MSC spheroids suppressed expression 
of the effector cytokine IFN-γ and the greatest suppression was observed in co-cultures with MSCs 
treated with IFN-γ. (D) Similarly, IL-10 expression was increased in co-cultures with MSC 
spheroids and was greatest when MSCs were treated with IFN-γ via pre-treatment or microparticle 
delivery. * indicates p < 0.05 compared to No MSC cultures. # indicates p < 0.05 compared to IFN-
γ pre-treated MSC spheroids at the same MSC:PBMC ratio. + indicates p < 0.05 compared to No 
Treatment and Unloaded Microparticle MSC spheroid co-cultures. 
 
5.3.5 Microparticle induced suppression of T-cell activation and proliferation is 
dependent on induction of MSC IDO expression and aided by induction of M2-like 
monocytes 
To determine if the IDO expression in response to IFN-γ loaded microparticles was 
responsible for the enhanced ability of MSCs to suppress T-cells, pre-treated and 
microparticle treated MSC spheroids were cultured with activated PBMCs in the presence 
of an IDO inhibitor, 1-methylDL-tryptophan (1-MT). Supplementation of 1-MT into co-
cultures significantly impaired the ability of IFN-γ pre-treated spheroids and spheroids with 
IFN-γ loaded microparticles to suppress T-cell proliferation (Figure 5.9A). In PBMC co-
cultures with IFN-γ pre-treated spheroids, 61 ± 2% of T-cells were Ki67+ when 1-MT was 
added to the culture compared to 31±2% Ki67+ T-cells in co-cultures with the vehicle 
control (p < 0.001). Similarly, 57 ± 2% of T-cells were Ki67+ in co-cultures with MSC 
spheroids with IFN-γ loaded microparticles and 1-MT compared to 24 ± 1% Ki67+ T-cells 
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in co-cultures treated with the vehicle control (p < 0.001). However, even with 
supplementation of 5 µM 1-MT into co-cultures, both pre-treated and microparticle treated 
spheroids were capable of slightly suppressing T-cell proliferation compared to activated 
PBMCs alone (77 ± 2% Ki67+, p < 0.001, respectively). MSC suppression of T-cell IFN-γ 
expression was completely inhibited by treatment with 1-MT in both co-cultures with IFN-
γ pre-treated MSC spheroids and spheroids with IFN-γ loaded microparticles (Figure 
5.9C). However, PBMC expression of IL-10 in response to MSC spheroids was only 
partially inhibited by 1-MT (Figure 5.9D; 133 and 132 pg/mL of IL-10 in pre-treated and 
microparticle groups compared to 83 pg/mL of IL-10 in No MSC- 1-MT control, p = 0.003 
and 0.004, respectively). Although additional immunomodulatory factors may contribute 
to the residual suppressive effects observed of MSC spheroids treated with 1-MT, IDO 
inhibition significantly impairs the ability of MSCs to suppress T-cell proliferation, as 




Figure 5.9. Increased suppression of T-cells by microparticle delivery of IFN-γ is dependent 
on induction of IDO expression. (A) Representative histograms of Ki67+ T-cells in co-culture 
with IFN-γ pre-treated or IFN-γ loaded microparticle treated MSC spheroids with or without the 
IDO inhibitor 1-MT. (B) Addition of 1-MT to MSC-PBMC co-culture (3:1 MSC:PBMC ratio) 
significantly inhibited the ability of IFN-γ primed MSCs to inhibit T-cell proliferation in both pre-
treated and microparticle treated spheroids. Similarly, inhibition of IDO activity with 1-MT (C) 
increased T-cell expression of IFN-γ and (D) reduced the induction of IL-10 expression in PBMC 
co-cultures. * indicates p < 0.05 compared to groups denoted by bar. # indicates p < 0.05 compared 




In addition to IDO activity, MSC suppression of T-cell proliferation and activation in 
PBMC co-culture assays in vitro is also dependent on MSC induction of IL-10 expressing 
M2-like monocytes within these co-cultures.[78, 259, 260] Therefore, we investigated 
whether MSC spheroids containing IFN-γ loaded microparticles could also induce CD206+ 
M2-like monocytes in direct co-cultures with monocytes isolated from PBMCs (Figure 
5.10A). We did not observe a significant increase in the number of CD206+ monocytes in 
co-cultures with non-treated MSC spheroids. Additionally, a modest increase in CD206+ 
monocytes co-cultures was observed with MSC spheroids containing unloaded 
microparticles. However, MSCs spheroids pre-treated with IFN-γ and MSC spheroids with 
IFN-γ loaded microparticles induced the highest percentages of CD206+ monocytes 
compared to the naïve monocyte population (Figure 5.10B, 17% and 18% CD206+ 
monocytes in pre-treated and microparticle treated spheroid co-cultures respectively, p < 
0.001 compared to naïve monocytes). Furthermore, the concentration of the 
immunoregulatory cytokine IL-10 in spent media supernatants was greatest in co-cultures 
with spheroids containing IFN-γ loaded microparticles (Figure 5.10C), suggesting that the 
induction of IL-10 expression by M2-like monocytes may be aiding the suppression of T-




Figure 5.10. Microparticle delivery of IFN-γ increases MSC spheroid polarization of 
monocytes to anti-inflammatory phenotype. (A) Representative histograms of CD206+ 
monocytes in co-culture with MSC spheroids. (B) Anti-inflammatory M2-like monocytes were 
induced by co-culture with IFN-γ pre-treated MSCs and IFN-γ loaded microparticle treated MSCs. 
(C) IL-10 production, an anti-inflammatory cytokine produced by alternatively activated 
macrophages, was greatest in co-cultures with IFN-γ loaded microparticle treated MSCs. Induction 
of M2-like monocytes may aid in the suppression of T-cell proliferation and activation in PBMC 
co-cultures. * indicates p < 0.05 compared to No MSC group. # indicates p < 0.05 compared to 
IFN-γ pre-treated MSC spheroid group.  
 
5.3.6 Microparticle delivery of IFN-γ within MSC spheroids sustains 
immunomodulatory activity compared to soluble pre-treated MSCs 
Since MSC spheroids with IFN-γ loaded microparticles expressed elevated levels of IDO 
for at least 7 days while IDO activity of pre-treated MSC spheroids decreased rapidly over 
4 days, we investigated whether MSC spheroids containing IFN-γ loaded microparticles 
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continued to modulate T-cell responses even 4 days after formation. Therefore, MSC 
spheroids were pre-treated or formed with IFN-γ loaded microparticles and added to co-
cultures with activated PBMCs after 0, 2, or 4 days following initial aggregate formation 
and pre-treatment. Consistently, both spheroids pre-treated with IFN-γ and spheroids with 
IFN-γ loaded microparticles suppressed T-cell proliferation when added to co-cultures 
immediately after spheroid formation (Figure 5.11A). However, when spheroids were 
added 2 days after formation and IFN-γ pre-treatment, the ability of pre-treated spheroids 
to suppress T-cell proliferation was significantly reduced (p = 0.035 pre-treated spheroid 
days 0-4 vs. pre-treated spheroid days 2-6). Conversely, no difference in T cell suppression 
ability was observed between spheroids added immediately after formation or 2 days after 
formation, in those spheroids containing IFN-γ loaded microparticles (p = 0.978 spheroids 
with IFN-γ loaded particles days 0-4 vs. spheroids with IFN-γ loaded particles days 2-4). 
Moreover, the ability of spheroids pre-treated with IFN-γ to suppress T-cell proliferation 
was further decreased when spheroids were added four days after initial formation and pre-
treatment. The extent of T-cell suppression observed in pre-treated spheroids after four 
days was comparable to levels observed previously when non-treated MSC spheroids were 
co-cultured with activated PBMCs, suggesting that the effects of pre-treatment were 
completely abolished within four days. However, MSCs with IFN-γ loaded microparticles 
retained the ability to suppress T-cell proliferation even when added to PBMC co-cultures 
four days after initial formation (Figure 5.11B). Altogether, MSC spheroids incorporated 
with IFN-γ microparticles exhibit a sustained ability to suppress T-cell proliferation over 
at least one week of culture, whereas the immunosuppressive ability of MSC spheroids 




Figure 5.11. Microparticle delivery of IFN-γ enhances MSC suppression of T-cells for over 
one week. (A) Representative histograms of Ki67+ T-cells in co-culture with MSC spheroids 
treated with IFN-γ or IFN-γ loaded microparticles 0, 2, and 4 days prior to addition to PBMC co-
culture. (B) IFN-γ loaded microparticles sustained the enhanced MSC suppression of T-cell 
proliferation in response to IFN-γ for up to 8 days, whereas the effects of pre-treating MSC 
spheroids with IFN-γ were transient and resulted in decreased ability to suppress T-cell 
proliferation over time. * indicates p < 0.05 compared to groups denoted by bars. # indicates p < 




In this study, we designed and evaluated a strategy for locally presenting IFN-γ within 
MSC constructs in order to potentiate sustained MSC immunomodulatory activity. To do 
so, we took advantage of a microparticle-based approach previously developed to spatially 
and temporally control presentation of growth factors within stem cell aggregates[248–
251]. Heparin-based microparticles were chosen to deliver IFN-γ in order to exploit the 
high native affinity of IFN-γ for heparin and the ability of heparin to maintain protein 
bioactivity since immobilization of IFN-γ on polystyrene particles did not maintain IFN-γ 
bioactivity. These heparin particles have previously been demonstrated to stably bind 
positively charged heparin-binding growth factors including BMP-2, vascular endothelial 
growth factor (VEGF), and fibroblast growth factor 2 (FGF-2) [252]. Consistent with 
previous studies, heparin microparticles bound large amounts of IFN-γ (>20 µg per mg 
MPs) and very little IFN-γ was released from the particles after the initial burst release 
period during the first 24 hours post-loading. Despite low IFN-γ release, IFN-γ loaded 
particles were still capable of inducing MSC IDO expression even after 7 days of 
incubation at physiologic conditions prior to addition to MSCs. These results are consistent 
with previous studies investigating the interaction between cell-derived heparan sulfate and 
IFN-γ signaling. Heparan sulfate present within plasma membranes can augment IFN-γ 
signaling by stably presenting IFN-γ at the cell surface in close proximity to cell membrane 
receptors[256]. In contrast, supplementation of soluble heparin into culture medium can 
suppress the activity of IFN-γ, likely due to sequestration of IFN-γ in solution that inhibits 
its interaction with cell surface receptors. Altogether, these results suggest that the ability 
of IFN-γ loaded microparticles to induce MSC IDO expression is dependent on direct 
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contact between particle-bound IFN-γ and MSCs and does not require the release of soluble 
IFN-γ from the particles. Furthermore, these results also corroborate results found in 
previous studies demonstrating that physical separation of cells and growth factor loaded 
heparin microparticles via transwell significantly reduces the activity of particle-bound 
growth factors[252]. Additionally, since heparin-bound IFN-γ bioactivity is mediated 
primarily through solid phase presentation of IFN-γ and not soluble release, there is little 
risk of exogenous IFN-γ escaping MSC spheroids and exacerbating an inflammatory 
response in vivo. Overall, these results demonstrate that heparin microparticles are an 
effective carrier for locally restricting sustained delivery of bioactive cytokines within 
MSCs spheroids.  
 
Pre-treatment of MSCs with inflammatory cytokines is frequently used to enhance the 
immunomodulatory activity of the cells by activating expression of IDO and other 
immunomodulatory factors prior to infusion. However, we have demonstrated herein that 
sustained presentation of IFN-γ to MSCs enhances and extends the duration of 
immunomodulatory activity by MSCs. Using a heparin microparticle-based strategy, 
expression of IDO by MSCs was sustained throughout the spheroid structure for at least 
one week. Furthermore, microparticle delivery of IFN-γ within MSC spheroids increased 
MSC suppression of T-cell proliferation and activation compared to pre-treated spheroids. 
By locally concentrating IFN-γ within the MSC spheroid through particle-mediated 
delivery, MSCs may be exposed to an effectively higher dose of cytokine relative to an 
equal soluble amount, thereby resulting in enhanced immunomodulatory activity. More 
strikingly, incorporation of IFN-γ loaded microparticles within MSC spheroids 
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significantly extends the duration of MSC immunomodulation. While the 
immunomodulatory activity of pre-treated MSC spheroids was significantly reduced after 
2 days, MSC spheroids with IFN-γ loaded microparticles continued to effectively suppress 
T-cells through one week of culture. Not surprisingly based on the targeted strategy we 
employed, immunosuppressive effects of MSCs were mediated by IDO expression since 
the IDO inhibitor 1-MT reduced the ability of MSCs to suppress T-cell proliferation. While 
IDO expression is necessary for MSC immunomodulation, additional MSC secreted 
factors or direct cell contact mediated mechanisms may also play an important role in the 
suppression of T-cell proliferation. In addition to direct modulation of T-cells by MSCs, 
MSC induction of M2-like monocytes within PBMC co-cultures also aids in the 
suppression of T-cells in vitro [78]. Therefore, the increased induction of M2-like 
monocytes by MSC spheroids loaded with IFN-γ microparticles could also augment the 
increased immunosuppressive activity of 3D MSC constructs.  
 
Despite the extensive use of biomaterials with specific biophysical and biochemical 
properties and ability to deliver biochemical stimuli to direct differentiation of MSCs, 
similar approaches have largely been unexplored for directing the immunomodulatory 
paracrine activity and broader trophic effects of MSCs. Numerous studies have 
demonstrated that MSC paracrine factor secretion is modulated in response to 
environmental cues in addition to the local cytokine milieu including matrix composition, 
mechanics, and topography [262, 263], as well as oxygen tension [264]. Furthermore, 
environmental stimuli are highly amenable to manipulation via biomaterials to specifically 
define the microenvironment of stem cells and direct their function [265]. To date, only 
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one biomaterial-based approach has been used to increase MSC expression of IDO in order 
to enhance suppression of T-cell proliferation and activation. Delivery of glucocorticoids 
within MSCs via poly-lactic-co-glycolic acid (PLGA) nanoparticles internalized by MSCs 
enhanced the upregulation of IDO in response to IFN-γ and resulted in increased 
suppression of CD3/CD28-activated PBMCs [266]. However, IDO expression by MSCs 
was still dependent on the presence of soluble IFN-γ and the glucocorticoid budesonide 
was unable to stimulate IDO alone. Therefore, sustained presentation of IFN-γ and 
glucocorticoids may offer complementary approaches for enhancing MSC 
immunomodulatory activity. Ultimately, engineering the local environment of transplanted 
MSCs through biomaterial-based approaches provides an additional level of control over 
the efficacy of MSC therapies to promote maximal activity post-transplantation. 
 
Overall, the approach described in this study provides a novel means of enhancing MSC 
immunomodulatory activity by locally concentrating and sustaining presentation of 
immunomodulatory stimuli, and represents a method of potentiating MSC 
immunomodulation after local injection in vivo. Since MSCs are highly dependent on local 
inflammatory signals to stimulate their immunomodulatory activity, spatially controlled 
presentation of inflammatory cues within MSC aggregates provides a means of stimulating 
these cells even when environmental inflammatory signals may not be present, such as in 
systemic delivery strategies, states of chronic inflammation, or when used in combination 
with traditional anti-inflammatory drugs. For example, although MSCs have been effective 
in treating GvHD when infused at the height of inflammation, they are much less effective 
if delivered prior to the onset of inflammation[33, 267]. Similarly, MSCs are less effective 
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at treating experimental autoimmune encephalomyelitis (EAE) when administered during 
disease remission[134, 268]. In clinical studies, MSC-based therapies have been most 
effective in treating immunosuppressant-refractory acute inflammatory diseases [269, 
270]. At low concentrations of strong inflammatory signals (i.e. IFN-γ or TNF-α) present 
during chronic inflammatory states, MSCs upregulate chemokines that recruit lymphocytes 
[85, 271]. However, low cytokine concentrations are not sufficient to induce substantial 
expression of IDO by MSCs to suppress lymphocyte activation and therefore can actually 
augment inflammation. Such studies highlight the critical importance of attaining minimal 
threshold concentrations of inflammatory stimuli in order to effectively stimulate MSC 
immunomodulation. By presenting a sustained, high concentration of a cytokine, such as 
IFN-γ, through incorporation of microparticles within MSC aggregates, the use of MSCs 
for in vivo immunomodulatory applications could be greatly expanded; for example, MSCs 
could potentially be transplanted concurrently with graft tissue to effectively suppress an 
immune response prior to the development of GvHD and severe inflammation. 
Furthermore, based on evidence that MSCs administered together with steroids or 
cyclosporine to immunosuppressant-responsive patients exhibit no clinical effect[272, 
273], it is speculated that the lack of immunosuppression may be due to the decreased 
availability of inflammatory cytokines needed to stimulate MSC immunomodulation[274]. 
Hence, in such a situation, locally sustained presentation of IFN-γ to MSCs may improve 
outcomes in patients receiving both MSCs and traditional immunosuppressants by 
stimulating IDO expression despite the lack of systemic cytokines present in the host 
environment. Altogether, sustained presentation of IFN-γ within MSC aggregates may 
provide a clinically relevant approach for inducing and enhancing MSC 
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immunomodulatory activity in disease states previously deemed to be unresponsive to 
MSC-based therapies.  
 
5.5 CONCLUSIONS 
The results of this study demonstrate that heparin microparticle delivery of IFN-γ within 
spheroidal MSC aggregates presents bioactive IFN-γ locally within the MSC 
microenvironment that in turn induces a sustained MSC suppression of CD3/CD28-
activated T-cells in vitro. The enhanced T-cell suppression by MSC spheroids containing 
IFN-γ loaded microparticles is mediated, in part, through upregulation of IDO expression 
and induction of M2-like monocytes. Overall, this approach could aid in overcoming the 
limitations of transient pre-treatment strategies by continuously presenting bioactive IFN-
γ within the MSC microenvironment and thereby maximizing the immunomodulatory 
potential of transplanted MSCs. Furthermore, this approach provides a means of inducing 
potent MSC immunomodulation irrespective of unknown and/or ill-defined environmental 
inflammatory milieu, such as in chronic inflammation or when administered with 
immunosuppressants. Altogether, biomaterial-based engineering of the MSC 
microenvironment provides a means of controlling the function of transplanted cells to 
specifically direct their therapeutic activity and may improve the efficacy of MSC-based 









Taken together, the data presented in this dissertation establishes a novel approach for 
utilizing aggregation techniques and biomaterial technologies to engineer the local MSC 
microenvironment in order to enhance the intrinsic immunomodulatory capabilities of 
these cells. In Chapter 3, aggregation of MSCs was found to increase the secretion of PGE2, 
TGF-β1, and IL-6 and that stimulation with the cytokines IFN-γ and TNF-α could further 
enhance spheroid expression of immunomodulatory factors and induce expression of the 
key immunosuppressive factor IDO. Furthermore, MSCs spheroids were capable 
suppressing inflammatory responses of macrophages and inhibiting T-cell proliferation 
and activation in vitro. In Chapter 4, the secretome of MSCs was more broadly examined; 
while, the overall composition of MSC-expressed paracrine factors was strikingly similar, 
the expression of OPG was found to be highly regulated between adherent and spheroid 
MSCs and this difference critically regulates the differentiation of osteoclasts in the 
presence of MSC paracrine factors. Finally, in Chapter 5, sustained delivery of IFN-γ 
within the MSC spheroidal microenvironment was found to enhance and sustain MSC 
suppression of T-cell activation and proliferation through inducing sustained expression of 
IDO. Altogether, the findings of this work motivate further studies to better characterize 
the modulation of MSC paracrine activity in response to aggregation and to evaluate the 
efficacy of engineered MSC constructs as a therapeutic agent for treating disease in animal 
models of inflammatory and immune diseases. 
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6.1 Non-biased screening approaches to evaluate changes in MSC secretome 
While many studies have demonstrated increased paracrine activity of MSCs after 
aggregation, no studies to date have systematically determined the exact changes in the 
composition of paracrine factors expressed by MSCs or the mechanisms and signaling 
pathways mediating these changes in the secretome in response to aggregation. Typically, 
assays targeting individual proteins or transcripts are used to determine expression of 
paracrine factors known to play a role in MSC paracrine activity, such as through ELISA 
or qRT-PCR analysis. Other studies have used relatively small protein or PCR arrays to 
examine expression of a larger number of paracrine factors. However, these are still biased 
approaches, in that specific protein or transcript targets must be chosen a priori and are 
still limited by the number of analytes measured. Therefore, unbiased screening approaches 
to evaluate the secretome or transcriptome of MSCs may be beneficial in fully 
characterizing the cocktail of factors expressed by MSCs and evaluate how the composition 
of this cocktail changes in response to aggregation, cytokine treatment, or other approaches 
aimed at manipulating the secretome of MSCs. Furthermore, identification of changes in 
key components of signaling pathways or in expression patterns of gene groups regulated 
through common pathways may provide insight into the upstream pathways mediating 
paracrine factor signaling in MSC spheroids. Finally, these approaches may be useful in 
identifying novel immunoregulatory factors expressed by MSCs, especially in IFN-γ 
treated cells, as immunomodulatory mechanisms have largely been focused on a set of 
approximately 10 factors. Furthermore, broadly identifying differentially regulated genes 
in response to IFN-γ would represent a more holistic approach to determine how IFN-γ 




Transcriptome analysis and RNA sequencing (RNA-seq) technology, in particular, is 
rapidly becoming a powerful tool for quantifying the entire profile of RNA expressed by 
cells, either at a population or single cell level. However, there has been limited application 
of this technology to studying the MSC transcriptome, especially in terms of cytokine 
priming of MSCs to stimulate immunomodulatory function. The majority of published 
experiments examining the transcriptome of MSCs have primarily focused on the 
transcriptional differences of MSCs isolated from different tissue sources as well as other 
stromal or fibroblast populations. These studies have largely been focused on 
understanding the functional differences (differentiation potential) between MSC-like cells 
from various tissue sources and identifying unique markers of MSC populations. The focus 
of transcriptome studies on cell source and differentiation potential of MSCs has likely 
been due to the focus of MSC research on the application of these cells for the repair of 
skeletal tissues. However, as MSC research transitions to become more focused on the 
trophic and paracrine ability of MSCs, transcriptome analysis of MSCs in response to 
environmental parameters could provide valuable information that is missing within the 
current body of literature. For example, genome-wide array comparison of human bone 
marrow-MSCs to human hematopoietic and embryonic stem cells and fibroblasts 
demonstrated a unique transcriptional profile of MSCs, 4,700 genes were differentially 
regulated between MSCs and HSCs, 3,172 genes between MSCs and hESCs, and 1,991 
genes between MSCs and fibroblasts [275]. Similarly, comparison of MSC-like 
populations from different sources, such as bone marrow, umbilical cord, and even 
pluripotent stem cells, reveals significant source dependent differences in gene expression, 
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however, the number of differentially expressed genes between MSCs of different origins 
tend to be fewer than the number of differentially expressed genes between other stem cell 
populations or fibroblasts [276, 277]. Additionally, heterogeneity amongst MSC 
preparations and lineage priming has been frequently studied using RNA-seq technology. 
A recent RNA-seq experiment examining heterogeneity within MSCs populations 
supported the concept of lineage priming amongst MSCs, in that individual cells are primed 
for differentiation to a specific lineage [9], similarly to previously published studies [278]. 
However, this study also examined expression of a set of 12 immunomodulatory factors 
was evaluated in 16 unprimed mouse MSCs, however, expression of these 16 factors was 
fairly homogenous with the exception of IL-6, which almost solely contributed to the 
variability in the primary principal component. However, the functional relevancy of 
variation in IL-6 was not investigated. Furthermore, categories related to immune response 
regulation were not found in ontological analysis of the entire data set, suggesting little 
variation in immunomodulatory function between cells within their cell preparations. 
Altogether, while these studies demonstrate a unique, yet heterogeneous, transcriptome of 
MSCs from different tissues sources, evaluating the transcriptome of MSCs in response to 
environmental parameters, such as culture format or cytokine treatment, may provide 
further insight into the immunomodulatory mechanisms of MSCs.  
 
6.2 Animal models for evaluating engineered MSC construct immunomodulation  
Animal models of disease are critically important to evaluate the safety and efficacy of 
potential therapeutic treatments before proceeding to clinical studies with human patients. 
In this dissertation, we have proposed a novel therapeutic strategy for enhancing and 
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sustaining MSC immunomodulatory activity by incorporation of IFN-γ laden 
microparticles within transplantable 3D aggregates. Therefore, animal models of 
inflammatory and immune diseases would be a vital tool for evaluating if sustained 
delivery of IFN-γ within MSC spheroids enhances MSC immunomodulation in vivo. The 
efficacy of human MSC immunomodulatory activity has frequently been investigated in 
mouse models of DTH, graft-versus-host disease, inflammatory bowel diseases, multiple 
sclerosis, and other models of inflammatory and immune diseases [41]. However, one of 
the major challenges of examining the immunomodulatory capabilities of human MSCs in 
animal models is the species mismatch. Since immunocompromised animals lack a 
complete, functioning immune system, these models are not completely appropriate for 
investigating MSC immunomodulation. However, human MSCs will ultimately be rejected 
by the immune system in immunocompetent animals, although rejection tends to be 
delayed due to the immunosuppressive ability of MSCs [101]. Furthermore, differences in 
critical mechanisms used by MSCs to regulate immune responses (i.e. IDO expression in 
human MSCs and production of nitric oxide through iNOS expression in rodent MSCs) 
also provide a challenge for interpreting results and evaluating mechanisms used by MSCs 
to modulate immune responses in animal models [279]. Finally, licensing of MSCs by 
inflammatory cytokines, particularly IFN-γ, is reduced when transplanted in mice since 
IFN-γ is not well conserved across species and mouse-derived IFN-γ does not cross-react 
with the human IFN-γ receptor. Altogether, significant challenges limit the ability to 




Despite the limitations of testing human MSC immunomodulation in animal models, 
several different approaches have been attempted to address these challenges. To address 
the species differences, mice with humanized immune systems have been proposed and 
used for testing human MSC immunomodulation in vivo. Generation of humanized mice 
is typically accomplished by transplantation of hematopoietic stem and progenitor cells 
into immunocompromised mice, such as NSG (Nod.Cg-PrkdcscidIl2rgtm1Wjl) mice [280]. 
Additionally, improved models have recently been created that improve development of 
innate immune cells, a population that is largely defective in NOG/NSG mice. These 
transgenic mice were created from a Rag2-/-Il2rg-/- background and human genes for 
cytokines important for myeloid cell development (M-CSF, IL-3, GM-CSF, TPO, and 
SIRPα) were knocked-in to the endogenous mouse loci. These humanized mice, referred 
to as MISTRG mice, develop functional myeloid cell populations and better recapitulate 
the percentage of myeloid cells found in humans [281]. Several groups have used these 
humanized mouse models to study MSC interactions with the components of the human 
immune system in models of GvHD, type 1 diabetes, and wound healing which may better 
elucidate how transplanted human MSCs behave in human patients [282–286]. An 
alternative approach to humanized mice is to use IDO humanized mouse MSCs that are 
deficient in iNOS expression (Nos2-/-) but express human IDO under the iNOS promoter, 
allowing for syngeneic cell treatment [287]. IDO humanized mouse MSCs were shown to 
be responsive to mouse-derived IFN-γ, which induces transcription of human IDO, and 
were capable of inhibiting T-cell proliferation in an IDO-dependent manner. However, 
humanized mouse models also have their limitations. The models are technically 
challenging due to the necessity of engraftment of transplanted human hematopoietic 
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progenitor cells.  Additionally, current humanized mouse models do not precisely 
recapitulate the naturally occurring percentages of myeloid and lymphoid cell populations.  
Despite these limitations, humanized mouse models offer a promising alternative approach 
for examining the response of the immune system to human MSCs while decreasing the 
complications of xenogeneic transplantation of cells and the inability of human MSCs to 
respond to the mouse cytokine milieu. 
 
Since inflammatory bowel diseases (IBD) are a major target for MSC-based therapies 
clinically, animal models of IBD are frequently used for examining MSC 
immunomodulation. Inflammatory bowel diseases represent a significant health burden 
with over 1 million Americans affected, resulting in over $6 billion in treatment costs in 
the United States [288]. Crohn's Disease (CD) and Ulcerative Colitis (UC), the two major 
forms of IBD, are characterized by chronic, uncontrolled inflammation of the intestinal 
mucosa and arise due to a combination of environmental factors, individual immune 
responses, and genetics. In both CD and UC, intestinal microbiota antigens are thought to 
trigger an excessive host immune response [289]; while the exact causes and mechanisms 
of IBDs remain unclear, increased production of inflammatory cytokines in the gut play a 
central role in the pathogenesis of these diseases. In CD, elevated levels of the cytokines 
IFN-γ, TNF-α, and IL-17 in the gut have been attributed to pro-inflammatory T-helper 1 
and 17 (Th1, Th17) responses. In contrast, UC is characterized by a non-conventional Th2 
immune response [289]. However, common drug treatments, such as corticosteroids and 
anti-TNF therapies, for CD and UC are often ineffective and the failure of these treatment 
regimens frequently result in the need for multiple intestinal resection [290]. Thus, novel 
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therapies are needed to combat progression of these diseases and MSC-based therapies are 
a potential alternative treatment due to the innate capacity of MSCs to regulate multiple 
immune cell populations and signaling pathways.  
 
Mouse models of IBD are an important tool in studying the pathogenesis of IBD. While 
there are differences between these mouse models and the human manifestation of the 
disease, important immunological processes of human mucosal inflammation can be 
recapitulated [291]. Mouse models of IBD fall into 3 general categories: 1) chemical-
induced colitis through damage to the intestinal mucosal barrier, 2) spontaneous colitis in 
mice with genetic knockouts of immunoregulatory factors, and 3) adoptive transfer of T-
cells in immunocompromised mice [292]. Chemically induced models are commonly used 
for evaluating MSC immunomodulation due to their ease of use and because they can 
recapitulate many key aspects of human disease. Furthermore, as adoptive T-cell models 
lack a completely functioning immune system due to use of immunocompromised mice, 
these models may be more appropriate for specifically investigating MSC effects on T-cell 
populations. Additionally, in genetic knockout models, knockout of critical 
immunoregulatory factors, such as IL-10, may limit the ability of MSCs to suppress 
inflammation as MSCs induce endogenous immune cell populations to anti-inflammatory 
phenotypes expressing immunoregulatory factors, like IL-10, to aid in suppressing 
inflammation.   
 
The two most common chemically-induced colitis models for evaluating MSC 
immunomodulation include trinitrobenzene sulfonate (TNBS) and dextran sulfate sodium 
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(DSS) induced colitis. In TNBS-induced colitis, TNBS is delivered in ethanol directly 
within the colon through an enema. The ethanol disrupts the mucosal barrier while the 
TNBS haptenizes colonic microbiota proteins, causing the proteins to become 
immunogenic, thereby triggering a host immune response in the intestinal mucosa [293]. 
Both acute and chronic TNBS-induced colitis models have been used to explore different 
aspects of innate and adaptive immune responses in mouse colitis. In the acute model, mice 
display increased myeloperoxidase (MPO) activity and an increased IL-12, IL-17, IFN-γ, 
and MIP-1α cytokine and chemokine profile, suggesting a predominant macrophage-
derived cytokine profile, increased neutrophil response, and Th1/Th17 polarized CD4+ T-
cells [294]. In contrast, chronic TNBS-induced colitis displays significantly greater IL-12 
and IL-17 and decreased MPO activity compared to the acute model, suggesting a 
heightened T-cell (Th1/Th17) response as the disease progresses to a chronic inflammatory 
state. Alternatively, in DSS-induced colitis, DSS is dissolved in the drinking water of mice 
and is toxic to gut epithelial cells resulting in significant damage to the mucosal barrier 
[295]. However, as C.B-17scid and Rag1-/- mice also develop intestinal inflammation in 
response to DSS, the adaptive immune response does not seem to play a significant role in 
the acute phase of inflammation and is therefore useful for studying the contribution of 
innate immune mechanisms of colitis. However, repeated administration of DSS results in 
the development of chronic inflammation, which involves the activation of CD4+ T-cells 
and is therefore dependent on adaptive immune responses. Therefore, the differential 
immune response in acute and chronic TNBS-induced and DSS-induced colitis enables the 
evaluation of MSC immunomodulation of separate components of the mucosal 
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inflammatory response and serves as a means for studying immunomodulatory 
characteristics of engineered MSC constructs.  
 
Through preliminary studies, we have begun working on developing these models and 
determining the baseline immunomodulatory activity of single cell suspensions of MSCs 
(see Appendix A). Ultimately, these animal models could be used to address several 
questions, including: 1) does transplantation of pre-formed aggregates improve cell 
retention compared to single cell suspensions, 2) does transplantation of pre-formed 
aggregates increase immunomodulatory activity compared to single cell suspensions, and 
3) does sustained delivery of IFN-γ within MSC aggregates further enhance the 
immunomodulatory activity of these cells? As spheroids are too large to safely be delivered 
intravenously, due to the likelihood of occlusion of blood vessels, another route of 
administration would be necessary for these studies. Intraperitoneal (I.P.) injection has also 
been commonly used with MSC treatments of chemically induced colitis and pre-formed 
spheroids could be injected into the peritoneal space with a wider-bore needle. 
Interestingly, I.P. injection of single cells suspensions of MSCs actually results in the 
formation of aggregates within the peritoneal cavity [175, 176]. However, as aggregation 
is thought to improve the viability and retention of transplanted MSCs, we may still expect 
greater therapeutic benefit from injection of pre-formed spheroids compared to single cell 
suspensions. Alternatively, intraluminal injection of MSC spheroids directly within the 
colon has also been used to treat colitis in a DSS model and may serve as a more local 
delivery site for MSC immunomodulation [176]. To further address the retention of cells, 
MSCs transduced to express luciferase under the ubiquitin promoter can be used with 
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bioluminescent imaging to evaluate retention of MSCs post-transplantation in order to 
determine whether aggregation improves cell retention post-transplantation [296, 297]. 
Altogether, chemically-induced colitis models provide a clinically relevant test bed for 




The results of this dissertation provide a basis for future exploration of the effects of 
environmental parameters on MSC paracrine activity and engineering approaches to take 
advantage of environmental regulation of MSCs to enhance their therapeutic potential. 
Future studies evaluating the transcriptome of MSCs in response to aggregation and 
cytokine treatment could provide valuable information into the mechanisms used by MSCs 
to regulate immune responses. Furthermore, evaluation of engineered constructs in animal 
models could inform how this approach could ultimately be applied to MSC-based 
therapies to improve treatment efficacy. The microparticle-based approach presented here 
represents a novel application of biomaterials to manipulate the presentation of individual 
cytokines within the local environment of MSCs to promote immunomodulatory activity. 
Furthermore, while we have investigated presentation of IFN-γ within MSC spheroids, this 
approach could be expanded to examine the presentation of other or multiple cytokines 
simultaneously to precisely tune the immunomodulatory response of MSCs. Additionally, 
targeting other functional aspects of MSC paracrine activity, such as the angiogenic factors 
secreted by MSCs, could additionally open up new areas of research aimed at regulating 
MSC paracrine activity by manipulating environmental factors. Ultimately, biomaterial-
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based engineering of the MSC microenvironment provides a means of controlling the 
function of transplanted cells to specifically direct their therapeutic activity and may 










Animal models of inflammatory and immune diseases are critically important for 
evaluating MSC immunomodulation and would be a vital tool for evaluating if sustained 
delivery of IFN-γ within MSC spheroids enhances MSC immunomodulation in vivo. Since 
inflammatory bowel diseases (IBD) are a major target for MSC-based therapies clinically, 
animal models of IBD are frequently used for examining MSC immunomodulation. 
Therefore, the objectives of these studies were to evaluate if MSCs reduce inflammation 
in acute models of TNBS- and DSS-induced colitis in order to establish a working model 
and a baseline response of MSCs for future studies evaluating engineered MSC constructs.  
 
A.2 MATERIALS AND METHODS 
A.2.1 TNBS-Induced Colitis Model 
MSCs were purchased from Texas A&M Institute for Regenerative Medicine and 
expanded according to the manufacturer’s protocol, as described in Chapter 3. Acute TNBS 
induced colitis was induced in BALB/c mice (Jackson Labs) according to previously 
reported protocols [125, 298]. 100 μL of TNBS (Sigma Aldrich) diluted in 50% ethanol 
(30 mg/mL) was intrarectally injected. Control mice received an equal volume of 50% 
ethanol alone. After TNBS instillation, mice were injected intraperitoneally with a PBS 
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sham injection or 1x106 MSCs either as a single cell suspension or as 500-cell spheroids 
(n= 8 per group). Animals were monitored daily for diarrhea, body weight, and survival. 
After 3 days, mice were euthanized, and colons were extracted for histological evaluation 
as well as cytokine and protein extraction. Colons were divided longitudinally for 
histological analysis and protein extraction. Colon samples were fixed and 5 µm paraffin 
embedded sections were stained with hematoxylin and eosin (H&E). Colon inflammation 
and damage was assessed as previously described on a scale of 0-4 [299]. Briefly, 0: no 
signs of inflammation; 1: very low level of inflammation; 2: low level of leukocyte 
infiltration; 3: high level of leukocyte infiltration, high vascular density, thickening of the 
colon wall; 4: transmural infiltrations, goblet cell loss, high vascular density, colon wall 
thickening.  
 
A.2.2 DSS-Induced Colitis Model 
MSCs were purchased from RoosterBio and expanded according to the manufacturer’s 
protocol, as described in Chapters 3, 4, and 5. 8-week-old male C57Bl/6 mice (~25g, 
Jackson Labs) were used for the dextran sodium sulfate (DSS) induced experimental colitis 
model (n=3 for each experimental group). On Day 0, drinking water was switched to a 3% 
DSS (w/v, MP Biomedicals) in autoclaved water solution to induce colitis. Two days after 
switching drinking water to a 3% DSS solution, mice were injected intraperitoneally (I.P.) 
using a 26G needle (450 µm diameter to allow free passage of cells and MSC 
spheroids) with MSCs from each MSC experimental group or PBS as a vehicle control. 
For this initial pilot study, dissociated MSC monolayers were injected I.P. at either 0.2x106 
or 1x106 million MSCs per mouse to evaluate dosing of MSCs. Mice were weighed daily 
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to monitor the progression of the disease. After 6 days of DSS treatment, drinking water 
was switched back to standard drinking water without DSS to allow for recovery. After 10 
days, animals were euthanized. After weight measurement, the colon was removed and its 
length was measured. After colon length measurement, the colon was dissected into 3 
segments: 0.5 cm segments at the proximal and distal ends were flash frozen in liquid 
nitrogen for cytokine analysis while the remainder was fixed in 10% neutral buffered 
formalin for histological analysis. Colon samples were embedded in paraffin and 5µm 
sections were stained with hematoxylin and eosin (H&E). Colon inflammation and damage 
was assessed as previously described on a scale of 0-4 [299]. Briefly, 0: no signs of 
inflammation; 1: very low level of inflammation; 2: low level of leukocyte infiltration; 3: 
high level of leukocyte infiltration, high vascular density, thickening of the colon wall; 4: 
transmural infiltrations, goblet cell loss, high vascular density, colon wall thickening. 
 
A.3 RESULTS 
A.3.1 TNBS-Induced Colitis  
Intrarectal instillation of TNBS (3 mg in 50% ethanol) resulted in significant weight loss 
over 3 days compared to control mice injected with ethanol only (Figure A.1A). Mice 
receiving an injection of a single cell suspension of 1x106 MSCs or a sham injection that 
displayed significantly greater weight loss compared to control mice receiving no TNBS. 
However, mice receiving an injection of 1x106 MSCs as spheroids had less weight loss 
than those treated with a PBS sham injection or single MSC suspension and this weight 
loss was not statistically significant compared to control mice receiving no TNBS. 
Histological analysis of colon inflammation revealed indications of inflammation in mice 
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treated with TNBS, although only mice treated with a single cell suspension of MSCs had 
significantly higher histological scores than the “No TNBS” treatment group (Figure 
A.1B). Overall, the histological scores were not as high as expected for mice receiving 
TNBS and indicated that severe acute colitis was not efficiently induced in these mice. 
Therefore, a higher dose of TNBS or a greater percentage ethanol carrier solution may be 
necessary to increase absorption of TNBS into the colon epithelium and further damage 
the mucosal barrier integrity. Interestingly, injection of single cell MSCs resulted in 
increased histological indications of inflammation whereas MSC spheroids protected 
against body weight loss. However, overall there was a large amount of variability in 
weight loss and histological scores in mice and inflammation was not consistently seen in 
each individual animal. Additionally, Texas A&M cells, which were later shown to not 
have T-cell suppressive capabilities in vitro (See Chapter 3, Figure 3.10), were used for 
these experiments, further complicating interpretation of these results. Future studies 
tuning the dose of ethanol and TNBS may therefore be necessary to ensure consistent 
induction of inflammation. Furthermore, analysis of cytokine levels in tissue may also 
provide further insight into the inflammatory state after induction of colitis and MSC 
treatment. Finally, delivery of MSCs that have demonstrated the ability to suppress T-cell 
proliferation in vitro should be used as a quality control for immunomodulation activity 





Figure A.1: Validation of TNBS-Induced Colitis Model. (A) Measurement of mouse weight loss 
over time demonstrated weight loss in mice receiving TNBS and either a PBS sham injection or an 
injection of single cell suspension of 106 MSCs compared to control mice that did not receive 
TNBS. (B) Histological scoring of H&E stained mouse colon sections demonstrated increased 
histological indications of inflammation in mice receiving TNBS and treated with a single cell 
suspension of MSCs compared to mice that did not receive TNBS. (C) Representative cross-
sectional images of H&E stained colons of mice from each experimental group. * indicates p < 0.5 
compared to “No TNBS” experimental group at the same time point.   
 
 
A.3.2 DSS-Induced Colitis 
As expected, supplementation of 3% DSS in the drinking water of mice resulted in 
significant loss of body weight over time. Significant loss of weight was observed in mice 
receiving a PBS I.P. sham injection five days after switching to DSS drinking water 
(Figure A.2A). Furthermore, weight loss of mice receiving a PBS sham injection plateaued 
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at approximately 83% of initial body weight, with no significant recovery seen after 10 
days. Mice receiving injection of 0.2x106 or 1x106 MSCs showed a similar weight loss 
trajectory over the first eight days. However, by day nine, mice receiving the lower dose 
of MSCs (0.2x106 cells) had significantly lower weight loss compared to the PBS sham 
injection. Furthermore, by day 10, both mice receiving a low or high dose of MSCs had 
significantly greater weight loss compared to the PBS sham injection. The lengths of 
colons, and indication of disease severity, from mice receiving I.P. injections were 
significantly shorter in length compared to control mice receiving no DSS (Figure A.2B). 
Finally, colon sections stained with H&E revealed significant signs of inflammation, 
including infiltration of leukocytes, colon wall thickening, and destruction of crypt 
structure in mice receiving DSS, regardless of sham or MSC treatment group (Figure 
A.2C). Thus, the results of this study demonstrate a working model of DSS-induced colitis. 
While injected MSCs appeared to exacerbate indications of disease, the number of 
replicates was relatively low for these pilot experiments (n=2 for low dose MSC group and 
n=3 for high dose MSC group). Additionally, previous studies have indicated that MSCs 
that do not receive IFN-γ priming may actually aid in the immune response by secretion of 
chemokines that can recruit leukocytes to sites of inflammation without concurrent 
expression of immunosuppressive factors, such as IDO. In this study, MSCs were not pre-
treated with IFN-γ prior to injection, therefore, the cells may not have been sufficiently 




Figure A.2: Validation of DSS-Induced Colitis Model. (A) Measurement of mouse weight loss 
over time demonstrated severe weight loss in mice receiving a 3% DSS drinking water solution 
(regardless of sham or MSC treatment) compared to control mice receiving normal drinking water. 
(B) Mice injected I.P. with either 0.2x106 or 1x106 MSCs had significantly shorter colons after 10 
days compared to mice receiving normal drinking water. (C) H&E stained colon tissue sections 
demonstrate severe signs of inflammation in mice receiving DSS drinking water, regardless of 
treatment group. * indicates p < 0.05 compared to “No DSS” group on the same day. # indicates p 




Altogether, while technical challenges still remain for delivery of immunomodulatory 
MSCs to suppress inflammation in these models, the results of these studies demonstrate 
working models of both TNBS- and DSS- induced colitis in mice that could be used in the 
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